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ABSTRACT
EXPLORING THE ARCHITECTURE OF THE HUMAN GABAA
RECEPTOR LIGAND BINDING POCKET VIA MUTATIONAL,
ELECTROPHYSIOLOGICAL, AND KINETIC ANALYSIS

Kurt Laha, B.S.
Marquette University, 2011

The γ-aminobutyric acid type A (GABAA) receptor is a member of the cys-loop
family of ligand-gated ion channels, and plays a crucial role in normal brain function by
providing inhibitory neurotransmission. The objective of my research is to establish the
mechanisms that underlie the interaction between the GABAA receptor and GABA during
binding, as well as to provide direct information about the architecture of the ligand
binding pocket. To achieve this, a multitude of amino acid residues surrounding the
GABA binding pocket were individually mutated and structure-function relationships
were explored. Changes in EC50-GABA, macroscopic kinetics, GABA binding rates and
GABA unbinding rates were assessed using patch-clamp recording, rapid-ligand
application, and kinetic modeling techniques.
A state-dependent interaction bridging the β/α inter-subunit interface was
identified between α1R120 and β2D163 by characterizing GABA binding and unbinding
rates for alanine mutations at each residue. These results were subjected to doublemutant cycle analysis. Intriguingly, the residues appear to be completely independent
when considering the binding of GABA, but they are coupled when looking at the
unbinding of GABA. These results suggest that β2D163 and α1R120 do not interact in
the unbound state but form an interaction upon binding of GABA.
A role for β2F200 at the GABA binding site was also revealed. Mutation of
β2F200 to alanine caused a dramatic reduction in GABA affinity. This was the result of
both an increase in the rate of GABA unbinding and a decrease in the GABA binding
rate. β2F200 fits the profile of a residue that could directly interact with GABA.
Finally, three mutations of the β2 subunit (Y97A, Y157A, and D163A) have
interesting effects on the functional expression of receptors. Mutation of these residues
allowed the assembly of functional receptors when expressed with α1 and γ2, but not
when expressed with α1 only. The aligned residues on the γ2 subunit were also mutated
and found to have unique expression patterns. Each of the residues appears to be
required for the assembly of the β(+)/β(-) interface, which is only present in αβ receptors;
however, only the residue homologous to β2Y97 (γ2F112) is critical for assembly at the
γ/β interface.
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I. Introduction
This dissertation explores the structure and function of the γ-aminobutyric acid
type A (GABAA) receptor. The primary objective is to advance our understanding of
ligand binding. This dissertation provides new information about the architecture of the
γ-aminobutyric acid (GABA) binding pocket and the interactions that exist between the
ligand and receptor.
The GABAA receptor is a member of the cys-loop family of ligand-gated ion
channels (LGICs), including the nicotinic acetylcholine, serotonin-type 3, and glycine
receptors. It is found on nearly every neuron in the brain (Sieghart and Sperk, 2002) and
it acts as the major inhibitory receptor of the central nervous system (Enna and Mohler,
2007). By providing inhibition of neuronal signaling, the GABAA receptor plays a
crucial role in normal brain processing. Therefore, the GABAA receptor has been a
common target for therapeutic agents treating disorders that result from errant signaling,
such as epilepsy and anxiety.
Despite the important role and prevalence of GABAA receptors and other LGICs
in the central nervous system, a detailed functional description of the structural elements
that are responsible for ligand binding, channel gating, and receptor desensitization
remains unresolved. LGICs are dynamic, allosteric proteins that rely on complex
networks of interactions within and between each subunit in order to carry out their
functions. Fascinating and most puzzling of all is how the binding of a neurotransmitter
is able to provoke conformational changes that lead to the opening of an ion channel.
This is a fundamental question in protein biology, but the structural underpinnings of this
process in cys-loop LGICs have not been identified. A comprehensive understanding of
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the biomolecular function of LGICs requires knowledge of the atomic interactions
between the receptor and its ligand, and the subsequent conformational changes that lead
to channel activation. This understanding begins with an accurate description of the
ligand binding pocket.
The findings presented in this dissertation refine the structural model of the
GABA binding pocket, separate the functional contributions of specific residues in the
GABA binding pocket, and shed light on molecular interactions between the receptor and
ligand. The specific aims were designed to study amino acid residues around the GABA
binding pocket, identifying those that directly interact with GABA and those that mediate
inter/intra-subunit interactions that influence binding. Site-directed mutagenesis and a
variety of electrophysiology experiments were employed to investigate the structurefunction relationships associated with GABA binding pocket residues.

The results

yielded a multitude of new evidence. Thirteen residues believed to line the binding
pocket were characterized for their influence on peak EC50 values, deactivation kinetics,
and desensitization kinetics, allowing specific functional roles to be distinguished
(Chapter III). A residue (α1R120) that indirectly contributes to the structural integrity of
the binding pocket by means of a state-dependent inter-subunit interaction was identified
(Chapters IV and V). Support for the precise location of GABA when bound came from
the identification of a residue (β2F200) central to the binding of GABA, and evidence of
an interaction between this residue and a nearby residue (β2R207) was found (Chapter
VI). Lastly, several residues with a critical role in assembly of the receptor oligomer
were identified (β2Y97, β2Y157, β2D163) (Chapter VII). Incorporation of these results
into the current structural model clarifies the exact positioning of several structural
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elements at the binding pocket and supports a precise orientation for GABA with the
positive amino group located between β2F200 and β2Y97.

The major inhibitory receptor of the central nervous system: GABAA
Gamma-aminobutyric acid (GABA) is the most abundant inhibitory
neurotransmitter in the vertebrate central nervous system where it activates GABAA,
GABAB, and GABAC receptors (Macdonald and Olsen, 1994). The GABAA receptor is a
member of the cys-loop LGICs that includes the nicotinic acetylcholine (nACh),
serotonin type 3 (5-HT3), and glycine receptors; the GABAB receptor is a G-protein
coupled receptor; and the GABAC receptor is a homomeric LGIC found primarily in the
retina (Enz and Cutting, 1998) and is considered part of the GABAA receptor family.
Similar in structure to other cys-loop LGICs, the GABAA receptor is comprised of five
heterologous subunits arranged around a central ion-conducting channel, depicted in
Figure 1.1 (Kash et al., 2004). Each subunit has an amino-terminus half that forms an
extra-cellular domain responsible for ligand binding, and a carboxy-terminus half
containing four trans-membrane domains that form the ion-selective channel.
Figure 1.1 The molecular structure of Cys-loop
ligand-gated ion channels. A) The cys-loop LGICs
possess a large extracellular N-terminal domain
containing the disulfide bond signature of the
superfamily (*), followed by four transmembrane
domains (shown by boxes). Arrows identify the
extracellular (EC) and the intracellular (IC) domains.
B) Receptors are constructed as pentameric ion
channels from the assembly of five subunits
(numbered 1-5) in a ring structure, creating an ion
pore within. This image depicts an extracellular view
from above the membrane, looking down at a
receptor.
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The GABAA receptor plays an important role in brain function, for it is found on
virtually every neuron in the brain and it acts as the major inhibitory receptor of the
central nervous system (Enna and Mohler, 2007). In general, LGICs mediate synaptic
transmission and shape the flow of information in the brain, hence controlling both
behavior and cognitive function (Connolly and Wafford, 2004). They can provide
excitatory or inhibitory potentials that alter the membrane potential of neurons, and
thereby increase or decrease firing of action potentials and propagation of neuronal
signaling. The GABAA receptor contains a chloride channel and when activated, as by its
endogenous ligand GABA, the receptor allows the conductance of chloride ions across
the cell membrane. In fully developed organisms this has an inhibitory effect as the
negatively charged chloride ions flow down their electrochemical gradient and into the
cell, making the inside of the cell more negative and less likely to fire an action potential.
As the major inhibitory channel of the central nervous system, the GABAA
receptor is crucial for proper neuronal signaling. It provides inhibition that is central to
the regulation of neuronal excitability and the timing of synchronous population
oscillations (Whittington et al., 1995; Whittington et al., 2000). Both are critical to
normal cognitive function. The GABAA receptor is essential in reflex responses,
voluntary motor control, and processing of sensory signaling (Enna and Mohler, 2007).
Disruption of inhibitory pathways leads to aberrant brain activity and can result in
epilepsy, loss of muscle control, anxiety, and sleep disorders. Therapeutic agents for all
of these disorders target the GABAA receptor (Johnston, 2005), and several GABAA
receptor mutations predispose humans to idiopathic generalized epilepsy (Macdonald et
al., 2010).

5

Figure 1.2 Agonists, antagonists, and modulators of the GABAA receptor. The schematic
representation of a GABAA receptor illustrates the different sites of action for each molecule.
The agonist, GABA, and the antagonists, bicuculline and SR-95531 bind at both β/α inter-subunit
interfaces. Benzodiazepines bind at the α/γ inter-subunit interface (Sigel and Buhr, 1997; Boileau
et al., 1998). Propofol binds near the extracellular end of the third transmembrane domain on the
β subunit (Bali and Akabas, 2004). Pentobarbitol interacts with parts of the first three
transmembrane domains of β subunits (Amin, 1999; Serafini et al., 2000). Neurosteroids interact
with the transmembrane domains at β/α inter-subunit interfaces and within a cavity of the α
subunit (Hosie et al., 2006; Akk et al., 2008). Volatile anesthetics and alcohols interact with the
receptor at sites in the transmembrane domains (Mihic et al., 1997). Zinc acts from within the
ion pore at non-GABA binding α/β inter-subunit interfaces (Hosie et al., 2003). Picrotoxin is an
open channel blocker, interacting with transmembrane domains from within the ionopore (Xu et
al., 1995).

The relevance of the GABAA receptor in brain function is further illustrated by
the fact that it is modulated by a multitude of compounds including anesthetics, Zn2+,
ethanol, barbiturates, and benzodiazepines (Smith and Olsen, 1995). These compounds
have distinct binding sites located in numerous regions around the receptor. Specific
binding sites have been found at inter-subunit interfaces, in pockets within a subunit, at
transmembrane domains, and inside the ion pore (Figure 1.2). This rich pharmacology
provides the impetus both for the identification of better therapeutic agents with which to

6
modulate receptor function, and also for the use of this protein as a model system to study
complex interactions between ligands and receptors.

GABAA receptor structural progress
A high resolution structure has yet to be determined for the GABAA receptor or
any other cys-loop LGIC, limiting our ability to assess the precise interactions that
underlie ligand binding. Ideally, x-ray diffraction experiments would provide atomicresolution details of this interaction; however, the complexity of the membrane bound
receptors with binding sites at subunit interfaces has made obtaining sufficient amounts
of pure protein, and crystallization of these receptors for such experiments very difficult.
The only crystallized structure of a LGIC is of the extracellular domain of a single
subunit from the nACh receptor (Dellisanti et al., 2007). It represents just a monomer of
the pentameric protein and therefore does not form a functional ligand binding site.
Some insights into the general structure of a complete nACh receptor have been provided
by electron microscopy, but images are limited to a resolution of 4 angstroms (Miyazawa
et al., 2003; Unwin, 2005). Nevertheless, a wealth of structural information has come
from cloning, heterologous expression, electrophysiology, mutagenesis, and homology
modeling. These studies have provided insight, although limited, as to how the structure
of GABAA contributes to receptor function.

Cloning of LGICs
The first LGIC subunit cloned was of the nAChR in 1982 (Noda et al., 1983).
This solidified the existence of such ion channels, and allowed for the expression of the
receptor in oocytes in order to perform electrophysiological experiments on a specific
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channel. In 1987, a cloning study by Eric Barnard and Peter Seeburg yielded the first
GABAA receptor cDNA sequences (Schofield et al., 1987). Cloning has since identified
the amino acid sequences of 19 GABAA receptor subunit isoforms (Simon et al., 2004).
Furthermore, comparison of cDNA sequences from GABAA, glycine, 5-HT3, and nACh
receptor subunits indicates that all of them are structurally related, now known as
members of the cys-loop LGIC superfamily because of two conserved extracellular
cysteines that are capable of forming a disulfide bond and create a loop structure. Figure
1.3 depicts an alignment of the amino acid sequences of the extra-cellular domains of
cys-loop LGIC subunits from each receptor type. Although their primary sequences vary,
they have conserved secondary structures and many absolutely conserved residues that
serve as useful anchor points and allow for alignment. These similarities justify
modeling cys-loop LGICs together.
The cloning of the LGIC sequences has enabled the prediction of their secondary
structure and has guided structural studies aimed at understanding the ligand-receptor
complex. The identification of subunit sequences provided an early indication of the
location of the GABA binding pocket. Sigel et al. (1992) found that a point mutation in
the rat α1 subunit (F64L) caused a strong decrease in agonist and antagonist affinity when
expressed with β2 and γ2 in oocytes. Sequence analysis has also supported the conserved
existence of six loop structures that are believed to mediate ligand binding in all cys-loop
LGICS, as highlighted in Figure 1.3 and shown in Figure 1.4 (Kash et al., 2004).
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Figure 1.3. Cys-loop
loop receptors share conserved secondary structures and can be
modeled after the AChBP. Presented here is the alignment of the extracellular NN
terminal domains of the α1, β2, γ2, and ρ1 subunits of the human GABAA receptor, a
mouse serotonin type 3A receptor subunit, the α1 subunit of the human glycine receptor,
the α1 subunit of the mouse nicotinic acetylcholine receptor, and the Lymnaea stagnalis
acetylcholine binding protein (AChBP). Light blue boxes signify predicted helices and
light green boxes signify predicted β sheets (Brejck et al., 2001; O’Mara et al., 2005;
2
Dellisanti et al., 2007). The cysteine residues, which form the disulfide bond that is
characteristic of all cys-loop
loop receptors, are indicated by asterisks (*). Despite variation in
primary sequences, these secondary structures align very well. The six putative binding
site loops are labeled A-F
F (Kash et al., 2004) and contain a number of residues implicated
in binding. Underlined residues indicate those found to face into the binding pocket.
Blue colored residues denote those previously implicated in GABA binding and which
are the focus of the studies presented in this dissertation.
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Figure 1.4
Six discontinuous loops
support binding at subunit interfaces.
This schematic representation of the GABAA
receptor
demonstrates
the
unique
contributions from the α subunit and β
subunit. Note each subunit is asymmetric
and therefore opposite sides of the α subunit
and β subunit are involved in GABA
binding. The classic binding site loop
nomenclature is used (Kash et al., 2004).

Assembly of the GABAA receptor
Along with the advent of cloning, an understanding of the stoichiometry and
assembly of GABAA receptors developed. Work by Levitan et al. (1988), examining the
structural basis behind variations in receptor behavior, found functional expression of
GABAA receptors required both α and β subunit isoforms, and cDNAs encoding several α
subunits and a β subunit were isolated. This indicated that GABAA receptors are
heterogeneous, being formed by combin
combinations
ations of different isoforms of several subunit
classes. Furthermore, expression studies have confirmed that a heteromeric combination
of both α and β subunits is necessary and sufficient for receptor function (Pritchett et al.,
1989), and eventual biochemical studies revealed that the GABAA receptor has a
pentameric stoichiometry (Chang et al., 1996; Tretter et al., 1997; Farrar et al., 1999). A
pentameric structure is also supported by the crystallized pentameric A
AChBP
ChBP (Brejc et al.,
2001)
01) and electron microscopy images of a pentameric nACh receptor (Miyazawa et al.,
2003).
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The five GABAA receptor subunits are arranged pseudo-symmetrically around a
central ion-conducting channel. Eight different subunit classes with 19 isoforms have
been identified to date (α1-6, β1-3, γ1-3, δ, ε, π, θ, ρ). As shown in Figure 1.1 each subunit
has an extracellular amino-terminus domain and a carboxy-terminus domain containing
four transmembrane domains with an intracellular loop between transmembrane domain
3 and transmembrane domain 4. Subunits are cotranslationally inserted into the
membrane of the endoplasmic reticulum, after which they fold and oligomerize
(Connolly et al., 1996; Griffon et al., 1999). Properly folded and oligomerized GABAA
receptors are transported to the cell surface, whereas misfolded or improperly
oligomerized subunits are retained in the endoplasmic reticulum and degraded
(Klausberger et al., 2001a).
During these folding and oligomerization events, each subunit must recognize its
neighbors via specific high-affinity interactions. Selective discriminations must be made
between different subunits to achieve the correct order of subunits around the pore. The
stoichiometry and arrangement of GABAA receptor subunits has been explored using
biochemical, immunohistochemical, and electrophysiology methods, and is depicted in
Figure 1.5. Early evidence for the requirement of specific subunit combinations in
GABAA receptors came from expression studies that found α and β subunit combinations
or α, β, and γ subunit combinations could produce functional surface expression;
however, expressing α or β alone, or combinations of α and γ or β and γ results in the
accumulation of non-surface receptor combinations retained in the endoplasmic reticulum
(Connolly et al., 1996). Using western blots where the relative reactivity of the
antibodies had been determined, the ratio of subunits in recombinant receptors comprised
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of α1β3 subunits or α1β3γ2 was found to be 22α1:3β3 and 2α1:2β3:1γ2, respectively (Tretter et
al., 1997). Additionally, the maximal fluorescent signal
signal, from c-myc
myc labeled subunits
when expressing α1(c-myc)β2γ2, α1β2(c-myc)γ2, and α1β2γ2(c-myc) receptors,, was twice
as intense with labeled α1(c-myc)
myc) or β2(c-myc) than with labeled γ2(c-myc),
myc), supporting a
2:2:1 stoichiometry (Farrar et al., 1999).

Figure 1.5
GABAA receptor
stoichiometry. Depicted is a GABAA
receptor composed of 2α1, 2β2, and a
fifth subunit that is either γ2 or β2.
These subunits have been shown to
assemble with a clockwise orientation
of α,β,α,β, and γ or β.
The
endogenous agonist, GABA, binds at
the β/α interfaces, indicated by black
triangles.

Furthermore, fluorescence energy transfer experiments with two separate
fluorescently conjugated antibodies performed on α1(c-myc)β2γ2 and α1β2(c-myc)
myc)γ2
receptors resulted in significant energy transfer, but when performed on α1β2γ2(c-myc)
receptors did not result in energy transfer (Farrar et al., 1999). Assuming only labeled
subunits within the same receptor are close enough for energy transfer to oc
occur,
cur, this
result supports multiple α and multiple β subunits in a single receptor, but only a single γ
subunit. Another confirmation of the 2:2:1 stoichiometry was provided using the
expression of α-β and β-α
α concatenated subunits, which could not produce functional
receptors when expressed alone or with α, but when β or γ was included functional
expression occurred (Baumann et al., 2001). The use of a variety of concatenated subunit
combinations also demonstrated that the only subunit arrangement of α, β,, and γ subunits
that successfully led to functional receptors trafficked to the cell surface was β2α1β2α1γ2
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(Baumann et al., 2002) (Figure 1.5). This subunit arrangement is consistent with the
formation of the appropriate inter-subunit interfaces known to bind GABA (β/α
interfaces) and benzodiazepines (γ/β interface) (Cromer et al., 2002).
The key to understanding receptor diversity is the identification of assembly
signals that govern which subunits prefer to be positioned next to each other. A region
required for assembly of all GABAA receptor subunits was identified in the cytoplasmic
loop between transmembrane domains 3 and 4 (Lo et al., 2008); however, the majority of
assembly signals have been found in the N-terminal extracellular domain (Srinivasan et
al., 1999; Klausberger et al., 2000; Taylor et al., 2000; Klausberger et al., 2001b; Sarto et
al., 2002; Ehya et al., 2003; Bollan et al., 2003; Sarto-Jackson et al., 2006; Bracamontes
and Steinbach, 2008). Many of these signals lie at or near predicted subunit interfaces.
The physiological impact of receptor assembly is also evident. Mutations that
alter surface expression of receptors from the cys-loop family of ligand-gated ion
channels have been associated with idiopathic generalized epilepsies (Macdonald et al.,
2010), congenital myasthenic syndrome (Shen et al., 2005), and psychiatric disorders
(Niesler et al., 2001). Unfortunately because the structural and cellular determinants of
receptor biogenesis are poorly understood, development of effective treatment strategies
remains a significant challenge.

Photoaffinity labeling used to locate the GABA binding site
Photoaffinity labeling experiments provided the first direct evidence for the
location of the GABA binding site, and have confirmed the participation of both α and β
subunits in the formation of the GABA binding site. In two separate studies, the β
subunit was identified as the major site of incorporation of the GABA homologue [3H]
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muscimol (Casalotti et al., 1986; Deng et al., 1986). In each, GABAA receptors were
purified from mammalian brain by a benzodiazepine affinity column and photoaffinity
labeled with [3H] muscimol. SDS-PAGE and Western blotting revealed the label
incorporated into a single broad band of 57 kDa corresponding to the β subunit.
However, when higher concentrations of purified receptor protein were analyzed in the
photoaffinity reaction, bands corresponding to both α (52kDa) and β (57kDa) subunits
were labeled by [3H] muscimol. Later, photoaffinity labeling of affinity purified bovine
GABAA receptor with [3H] muscimol, followed by microsequencing of a chymotryptic
fragment identified F65 on the α1 subunit as a residue associated with the ligand (Smith
and Olsen, 1994). This is the corresponding residue identified by Sigel et al. in 1992,
strengthening its presumed involvement in ligand binding.

Mutagenesis at the GABA binding pocket
Mutagenesis studies have identified several amino acid residues that may be
involved in binding, all of which fall on or adjacent to the six discontinuous loops of the
β/α inter-subunit interface. In general, a mutation that resulted in a large rightward shift
of the GABA concentration-response curve indicated the residue has a possible role in
binding. Residues that were sensitive to mutation by this measure are denoted in Figure
1.3 (highlighted blue). Although a variety of expression systems, subunit isoforms, and
side-chain substitutions were utilized in each study, the basic interpretation that a large
effect on EC50 suggests a role in binding remains the same.
Concentration-response curves are determined by microscopic processes of ligand
binding/unbinding, channel opening/closing, and desensitization/resensitization.
However, concentration-response curves do not directly reveal information about these
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individual microscopic processes (Colquhuon, 1998). Wagner et al. (2004) provided the
first study to dissect the biophysical role a binding pocket residue plays in channel
function. They examined a cysteine mutation of β2R207 using rapid-ligand application,
single-channel recording, and kinetic modeling. β2R207C caused a 20-fold increase in the
unbinding rate of GABA, an eightfold decrease in the binding rate of GABA, and had no
effect on any of the rates associated with gating. They concluded β2R207 is important for
stabilizing the ligand-receptor complex, and suggested that a direct interaction between
the GABA molecule and β2R207 may occur.
Each loop domain (shown in Figures 1.3 and 1.4) has also been probed using the
substituted cysteine accessibility method (SCAM) in order to determine secondary
structure and identify specific residues that face the ligand binding pocket (Boileau et al.,
1999; Wagner and Czajkowski, 2001; Boileau et al., 2002; Holden et al., 2002; Newell
and Czajkowski, 2003; Newell et al., 2004; Kloda and Czajkowski, 2007). SCAM
evaluates residues mutated to cysteine for accessibility to reaction with a sulfhydryl
reactive reagent, thereby indicating if the residue is found on the aqueous surface within
or near the GABA binding site. Residues found to be accessible to the sulfhydryl
reactive reagent and hence potentially face the binding pocket are highlighted in Figure
1.3. For many of the residues on the six loops (when mutated to cysteine) no effect was
observed during reaction with a sulfhydryl reagent. The lack of an effect could arise if
the mutated residue was not accessible and did not react with the reagent, or if reaction
with the reagent did not interfere with receptor function.
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As each loop was examined by SCAM, information about their secondary
structure was revealed. The alternating accessibility patterns of consecu
consecutive
tive residues to
reaction with a sulfhydryl reagent observed for loops A and D is consistent with a betabeta
strand (Boileau et al., 1999; Boileau et al., 2002). Loops B, C, F did not demonstrate
accessibility patterns consistent with any regular secondary st
structure,
ructure, such as an alpha
helix or a beta strand, and appear to be water
water-accessible
accessible random coils or turns (Newell et
al., 2004; Wagner et al., 2001; Newell et al., 2003). The accessibility pattern of loop E
was consistent with short beta strands separated by a loop structure (Kloda et al., 2007).

Figure 1.6 Chemical structures of SR
SR-95531 and GABA

Furthermore, SCAM experiments examining the rate of reaction in the presence
of agonist or antagonist can indicate if a given residue lies near the ligand binding site.
GABA and SR-95531
95531 share a structural motif with a carboxy group and an amino group
separated
arated by a three carbon chain
chain, depicted in Figure 1.6. Accessibility was protected by
GABA for a number of these residues, increasing the likelihood of a direct interaction
with GABA (Loop D: α1F65C, α1R67C, and α1S69C; Loop E: α1K117C, α1L118C,
α1E123C, α1L128C, α1T130C, and α1R132; Loop F: α1V178C, α1V180C, and α1D183C;
Loop A: β2Y97C and β2L99C; Loop B: β2T160C and β2D163C; Loop C: β2S204C,
β2Y205C, β2R207, and β2S209). Although reduced accessibility in the presence of a
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ligand can indicate proximity to the ligand binding site, it might also be caused by
allosteric effects induced by ligand binding. All of the aforementioned residues, except
α1S69C, α1K117C, and α1E123C, were also protected by the competitive antagonist SR95531. This supports proximity to the ligand binding site because SR-95531 does not
induce gating or the same conformational changes (if any) as GABA. The residues
α1D63C and α1R120C were only protected from reaction by SR-95531, which is larger
than GABA. These residues must additionally be considered near the binding pocket, but
not in as close proximity to GABA.
The use of unnatural amino acid mutagenesis has also been used extensively to
investigate residues at the binding sites of LGICs. In vivo nonsense suppression methods
allow synthetic amino acids to be incorporated during translation of a protein and provide
a powerful tool to exploit the specific chemical properties of a side-chain. The technique
has been successfully applied in LGICs to explore cation-π interactions, which occur
between a cation and the negative electrostatic potential on the face of an aromatic ring.
Aromatic residues are clustered near the binding pockets of each LGIC receptor. These
residues may provide a hydrophobic region which occludes water from the binding
pocket, as well as be a site of direct interaction with ligands.
At least one aromatic residue in nACh receptors (Zhang et al., 1998), 5-HT3
receptors (Beene et al., 2002), and GABAC receptors (Lummis et al., 2005) has been
shown to participate in cation-π interactions at the binding pocket. For the GABAA
receptor several aromatic residues are close to the binding pocket, including Y97 (loop
A), Y157 (loop B), F200 (loop C), Y205 (loop C), and F65 (loop D). Padgett et al.
(2007) explored the cation-π ability of Y97, Y157, and Y205 using unnatural amino acid
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mutagenesis. They were able to identify cation-π interactions by incorporation of
fluorinated aromatics, which had a spectrum of cation-π binding ability. This is because
fluorine is electron-withdrawing, and each fluorine addition serves to further reduce the
negative electrostatic potential on the face of the aromatic ring. Only Y97 demonstrated
a direct relationship between the decreased cation-π ability and the resulting change in
EC50-GABA. In fact, Y97 shows the steepest correlation of any cation-π residue identified
in LGICs, and has been postulated to interact with the primary amine of GABA.

Homology modeling
The crystallization of a related protein, the acetylcholine binding protein
(AChBP), has provided enormous insight into the structure of the extra-cellular domain
of LGICs.

The AChBP is a soluble protein found in the snail Lymnaea stagnalis. It is a

pentamer of identical subunits, each containing 210 amino acids. It has only 24%
sequence homology with the N-terminus of the human nAChR α1 subunit and lacks
membrane crossing regions, the pore, and the large intra-cellular sequence. Nevertheless,
the binding site region shares a strong similarity to that of the nicotinic receptor, and the
snail protein has been used as a guide to the extra-cellular structure of other cys-loop
receptors. Cys-loop LGICs are modeled together because they have a similar architecture
as depicted in Figure 1.1: an amino-terminus extra-cellular domain, a cys-loop, 4 TMDs,
and a pentameric structure surrounding an ion pore. Although there is limited homology
at the primary structural level, several residues are absolutely conserved in all members.
Furthermore, structural analysis reveals similar secondary and tertiary structure. The
homology model extrapolated from the AChBP crystal structure correctly predicted that
the ligand binding domain is formed at the interfaces between subunits, supporting its use
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as a valid template for the extra-cellular domain of the GABAA receptor (Cromer et al.,
2002). Additionally, the AChBP crystal structure fits well with the monomeric structure
from the crystallized extracellular domain of the nACh receptor α1 subunit (Dellisanti et
al., 2007).
A great extent of the structural information describing cys-loop LGICs was also
contributed by Unwin and his continued work on the nicotinic receptor, achieving an
electron microscopy image of four angstrom resolution. Electron microscopy revealed
some of the general topology of these receptors, such as the positioning of the five
subunits around a central pore and secondary structures such as beta sheets (Unwin 1995,
Miyazawa et al., 2003, Unwin 2005). Electron microscopy of nAChRs isolated from
membranes of the torpedo electric organ has supported the findings from the AChBP and
has been used to guide homology modeling of the GABAA receptor transmembrane
regions as well.
The crystal structure of the AChBP (PDB entry 1I9B) and electron microscopy of
the nAChR (PDB entry 1OED) have provided reasonable templates for the design of an
atomic model for the GABAA receptor (Cromer et al., 2002; O’Mara et al., 2005). Figure
1.7 presents a variety of images derived from these models. The homology model for the
GABAA receptor shows that residues predicted to be involved in ligand binding are
indeed located at subunit interfaces, and indicates the presence of multiple loop structures
surrounding the binding site (Figure 1.7C). The presence of multiple loops has
previously been postulated to be central to ligand binding, and their sequence locations
are depicted in Figure 1.3.
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The specific residues that make contact with AChBP ligands were identified
following crystallization of AChBP with the molecules nicotine or carbamylcholine
bound (Celie et al., 2004) (Table 1.1). The identical interactions are not likely to support
GABA binding, but the aligned residues in the GABAA receptor may still be critical. For
instance, many of the residues that the homology model of the GABAA receptor predicts
to surround the ligand-binding pocket are implicated, as
described above, by mutational evidence, covalent
labeling with reactive ligands, and SCAM.
We can begin to predict the role of these
residues when they are considered in the 3-dimensional
context provided by the homology model. The GABA
binding pocket is surrounded by a box of aromatic
residues (Figure 1.7D, green residues) including β2Y157
in loop B, β2F200 and β2Y205 in loop C, and α1F65 in
loop D, which have the potential of binding the
positively charged amino end of GABA via a cation-π
bond. Multiple positively charged arginine residues
(β2R207 and α1R67) near the bottom of the binding

AChBP
(L. stagnalis)

GABAA
(human)

Complementary face
W53
α1 F65*
R104
α1 R120*
L112
α1 L128*
M114
α1 T130*
Principal face
Y89
β2 L99*
W143
β2 Y157*
Y185
β2 F200
C187
−
C188
−
Y192
β2 Y205*
Table 1.1 Amino acids that have
been found to interact with ligands
bound to AChBP (Celie et al., 2004)
are listed with their aligned
counterparts from the human
GABAA receptor α1 and β2 subunits.
Asterisks mark residues have
previously been demonstrated to be
involved in GABA binding.

pocket have the potential to interact with the carboxy end of GABA (Figure 1.7D light
blue residues). There are also a variety of side-chain interactions that may exist across
the binding pocket and stabilize the global architecture of the pocket. For instance, the
proximity of β2Y157 with α1T130 may allow hydrogen bonding; and positioning of
β2D163 and α1R120 has indicated a potential salt-bridge or hydrogen bond (Cromer et al.,
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2002). The research proposed here will dissect these potential interactions and provide
evidence for the nature of GABA binding.

Figure 1.7 Homology model of the GABAA receptor. Using electron microscopy data for the
nAChR to guide transmembrane domains and the crystal structure of the snail AChBP for the
extra-cellular
cellular domain, O'Mara et al. (2005) have published coordinates for modeling the GABAA
receptor. A) Top down view of the pentameric ring formed by the GABAA receptor subunits
α1β2α1β2γ2. B) Side view of the GABAA receptor. C) Side view of the extra-cellular
cellular domain of
the β/α inter-subunit
subunit interface. The six loops regions are colored pink. D) View of β/α
β interface.
Aromatic residues that may contribute to cation
cation-π bonding are colored green, and arginine
residuess that may interact with the negative carboxy terminus of GABA are colored light blue.
The threonine at position 130 is pink, and the aspartic acid at position 163 is red.
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Study of ligand binding interactions using electrophysiology
The ability to determine how a particular mutation affects the function of the
protein is essential to conducting a mutagenic study. As we probe the functional and
structural relationships of GABAA receptor mutations, we utilize a series of
electrophysiological experiments that allow examination of the microscopic rates of
GABA binding and unbinding. This is not straightforward because macroscopic currents
observed from outside-out patches are the product of complex interactions among
microscopic processes such as ligand binding/unbinding, channel opening/closing, and
desensitization/resensitization. It is imperative that changes in the kinetics of
macroscopic currents of mutant receptors be interpreted correctly. Determining whether
a residue is specifically involved in binding rather than another one of these processes,
such as desensitization, requires that these processes be experimentally distinguished
from each other.
When a solution containing GABA is applied to a patch, the rate of activation is
dictated by both the rate of GABA binding and rate of receptor gating. Chloride ions
flowing through open receptors during GABA application produce the electrical current
response which can be measured (Figure 1.8). From the bound-closed state, receptors
can desensitize, resulting in a prolonged closure even though GABA is bound. When the
GABA application is removed, the rate of deactivation is dictated by transitions from
desensitization, opening and closing of channels, and GABA unbinding.
Figure 1.8 also highlights a simplified kinetic model that represents the
microscopic processes that GABAA receptors undergo. Although a number of additional
states have been proposed, it is most useful to use the simplest model with the fewest free
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parameters that accurately represents receptor responses. The four-state model here
illustrates the minimal number of states that are necessary to explain observed responses.
The macroscopic currents we measure are the summation of these processes and it is
critical we separate them in order to determine binding rates. Without this clarity the
nature of changes caused by specific mutations around the GABA binding pocket cannot
be properly interpreted.
To evaluate the role of individual residues in binding or gating, most traditional
site-directed mutagenesis studies have examined how mutations affect macroscopic
parameters such as the steady-state concentration response relationship (Amin and Weiss,
1993; Schmieden et al., 1993; Westh-Hansen et al., 1997; Westh-Hansen et al., 1999;
Boileau et al., 1999; Hartvig et al., 2000; Wagner and Czajkowski, 2001; Boileau et al.,
2002; Newell and Czajkowski, 2003; Newell et al., 2004; Kloda and Czajkowski, 2007;
Padgett et al., 2007); however, the EC50 does not reflect any individual transition but is
instead an indicator of the total time spent in all bound channel states (Colquhuon, 1998;
Jones et al., 2001). Thus, such studies have not provided a quantitative understanding of
the effects of binding, gating, and unbinding when mutations are made. Using a nonequilibrium approach, these processes can be assessed. Our studies use rapid-ligand
application, capable of switching from a solution of saturating agonist concentration to a
wash out in approximately two hundred microseconds. The abruptness of the application
allows the observation and distinction to be made of both desensitization and agonist
unbinding. Using a series of rapid-solution exchange based electrophysiological
protocols and kinetic modeling it is also possible to directly measure microscopic agonist
binding rates, and provide quality estimates of agonist unbinding rates. This dissertation
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employed these techniques in order to thoroughly characterize the effects of specific
spe
mutations around the GABA binding pocket
pocket.

Figure 1.8 Example of a recording from wild
wild-type
type receptors using a saturating GABA
application for 500 ms. It has three distinct phases. First, when the patch has GABA solution
applied, there is rapid activation
ctivation as chloride ions flow across the membrane through the open
channels. Activation is determined both by binding ([Ag] kon) and gating (β).
). The next phase is
desensitization. While still in GABA, receptors begin to close even though GABA is bound.
When the GABA solution is removed, the last phase, deactivation, occurs. Current dissipates as
channels close and GABA unbinds. This is a complex process, which is determined by
transitions in and out of desensitization (d and r) and gating ((α and β)) until unbinding (k
( off) occurs.
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II. MATERIALS AND METHODS
GABAA receptor subunit plasmids and site-directed mutagenesis
In order to heterologously express the GABAA receptor, plasmids containing the
sequences encoding each subunit (α1, β2, β2-GKER, and γ2S) were utilized. Each of these
subunits was previously cloned into pcDNA3.1 vectors (Invitrogen, Carlsbad, CA) under
the control of a high level expression Human cytomegalovirus (CMV) promoter.
Site-directed mutagenesis was accomplished via a PCR-based system termed
QuikChange (Stratagene, La Jolla, CA). For each mutant, we generated two
complementary oligonucleotides, typically 40 to 60 bp. They covered the codon of
interest and incorporated a particular mismatch that altered the codon. The QuikChange
method relied on an ultra-high fidelity polymerase (Pfu-Ultra). In one reaction, with both
primers, the polymerase amplified the entire plasmid. Following the PCR reaction, DpnI,
which digests methylated DNA, was added in order to eliminate the original template
from this mix.
After DpnI digestion, 2 µl of the mixture was used for transformation into
competent E. coli cells. These cells were plated onto a LB-ampicillin (50 μg/ml) agar
plate. The ampicillin selected for cells that took up the pcDNA3.1 vector, which contains
an ampicillin resistance gene. After 18 hours of incubation several colonies were picked
and used to inoculate 3 mL LB cultures with ampicillin (50 μg/ml). Plasmid DNA from
these cultures was then isolated using Wizard Plus SV mini-preps (Promega, Madison,
WI). This yielded 100 µl of pure plasmid at a concentration between 80 ng/µl to 250
ng/µl. The coding region of each mutant plasmid was sequenced with forward and
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reverse primers to ensure the intended mutation was present and no additional, unwanted
changes occurred.
Cell culture, transfection, and labeling
An immortal mammalian cell line, human embryonic kidney (HEK-293), was
used for heterologous expression of GABAA receptors. Cells were maintained in
Minimum Essential Medium Eagle with Earle’s salts (Mediatech, Manassas, VA)
supplemented with 10% newborn calf serum (Thermo Scientific, Waltham, MA) and
Penicillin-Streptomycin-Glutamine (Mediatech) in a 37o C incubator under a 5% CO2
atmosphere. For experiments, cells were plated onto 35 mm dishes coated with poly-Llysine and were transfected 18 to 24 hours later using Lipofectamine 2000 (Invitrogen).
Lipofectamine consists of cationic lipids, which interacts with the phosphate
backbone of the nucleic acid. This interaction is via the cationic head groups of the lipids
and does not result in the formation of micelles or liposomes surrounding the nucleic
acid. The cationic lipids also mediate the interaction of the nucleic acid with the
negatively charged cell membrane. The complex is thought to enter the cell through
endocytosis.
Receptors consisting of α and β subunits, or α, β, and γ subunits were used
throughout this study. For αβ receptors, the following amounts of cDNA were
transfected: 250ng eGFP, 1.5 µg of α1, 1.5 µg β2. For αβγ receptors the following
amounts of cDNA were transfected: 250ng eGFP, 1 µg of α1, 1 µg β2, and 3 µg of γ2S.
eGFP serves as a marker for cells that are transfected. Although poorly understood, a
high correlation exists between cells that take up and express eGFP and also take up and
express GABAA receptors. Cells were recorded from 48-96 hours post-transfection.
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Electrophysiology
All recordings for this study were collected from outside-out patches excised from
HEK-293 cells (-60 mV). The outside-out configuration is achieved by obtaining a tight
seal with a cell, followed by break-in using negative pressure, and then slowly drawing
back the pipette, stretching the membrane until a portion re-seals over the tip as it
separates from the cell. Recordings were made using borosilicate glass pipettes filled
with (in mM): 140 KCl, 10 EGTA, 2 MgATP, 20 phosphocreatine and 10 HEPES, pH
7.3. GABAA receptor agonists and antagonists were dissolved in the perfusion solution,
which contains (in mM): 145 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, 4 mM
Glucose, pH 7.4. For extracellular solutions that contained >30 mM GABA, the
concentration of NaCl was reduced to 95 mM, and a combination of sucrose and GABA
was added to compensate for the reduced osmolarity. The pipette solution was adjusted
in conjunction, reducing the KCl concentration to 90mM, and adding 50mM K-gluconate
to maintain a constant Cl- driving force. GABA, propofol and SR-95531 were obtained
from Sigma-Aldrich Chemicals, St Louis, Mo. Data were collected at 10-20 kHz using
an Axopatch 200B amplifier (Axon Instruments, Foster City, CA) and an ITC-1600
digitizer (InstruTech, Port Washington, NY), controlled by Axograph X software
(Axograph Scientific, Sydney, AUS). Currents were low-pass filtered at 2-5 kHz with a
four-pole Bessel filter, and digitized at a rate no less than twice the filter frequency.
In vivo, GABA mediated synaptic transmission frequently occurs in less than a
millisecond and the post-synaptic current decays in tens of milliseconds. In order to
study the receptor kinetics during such an event, it is necessary to apply and remove
agonist on a similar time scale. Rapid-solution exchange was accomplished by using a
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Figure 2.1 Rapid-ligand
ligand application. After pulling an outside-out
out patch, the electrode is raised
up to the flow-pipes,
pipes, which are already positioned in the bath solution. While the electrode
remains stationary, the flow-pipes
pipes can be rapidly shifted from side to side in order to expose the
electrode to the solution flowing out of any one of the four barrels.

four-barreled
barreled flowpipe array (Vitrodynamics, Rockaway, NJ) mounte
mounted
d on a piezoelectric
bimorph (Vernitron, Bedford, OH) (Figure 2.1). The four pipes are fused in a linear
arrangement and manually pulled down to 100 to 200 µm
m openings separated by septa of
less than 10 µm.
m. A computer controlled current source stimulates the bimorph to shift the
position of the flowpipes with high precision, and causes enough displacement to expose
a patch to solutions from all four pipes without moving the electrode. The exchange time
(the time it takes to completely clear the liquid ju
junction
nction interface between two pipes) is
measured by examining open tip potentials during a shift. Open tip potentials are the
result of differences in the mobility of sodium and potassium ions, which are at different
concentrations in the internal pipette solution compared to the external solution. In order
to distinguish the agonist solution from the wash solution, a small amount of NaCl is
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added to the agonist solution, raising the Na concentration 5 mM. This is enough to alter
the open tip potential. The 10-90% exchange times are consistently under 200 µs.
Concentration-response experiments
To obtain concentration-response curves, current responses evoked by a series of
GABA concentrations are compared to the current response evoked by a saturating
concentration of GABA. The protocol begins with the electrode and patch in wash
solution, then the pipes shift, exposing the electrode to the solution containing a
saturating concentration of GABA. After 500 ms the pipes shift back and the electrode is
in wash solution for 12 to 15 seconds in order to recover from desensitization. Next, the
flowpipes shift the opposite direction, exposing the electrode to a solution containing a
sub-saturating concentration of GABA. After 500 ms the pipes shift back and the
electrode is in the wash solution for 12 to 15 seconds. This protocol is repeated 5 to 15
times and an ensemble average for the two solutions is taken. During a stable patch the
sub-saturating solution can be changed by switching the solution with open flow directed
through a 4:1 (input:output) manifold preceding the flowpipe. Although three or four
concentrations can sometimes be tested on a single patch, only one concentration was
tested on the majority of patches because of patch stability. Therefore, each
concentration-response curve relies on data from several patches.
For each concentration the peak current was measured in Axograph X and
normalized to the peak current for the saturating concentration on the same patch. For a
given concentration the normalized values for each patch were averaged and were plotted
against the log of the concentration of GABA using Prism 4 software (GraphPad
Software, Inc., San Diego, CA). Non-linear regression of the plot was performed using a
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variable slope sigmoidal curve (Y = Ymin + (Ymax – Ymin) / (1+10^((LogEC50 X)*HillSlope))). This identified the concentration that gives a half-maximal response, termed
EC50.

Analysis of macroscopic kinetics: Desensitization and Deactivation phases
During rapid-ligand application distinct desensitization and deactivation phases of
the current response are observed. The desensitization phase of current responses during
a 500 ms application of a saturating concentration of GABA was used for analysis. The
ensemble average of such responses was taken for a given patch and was used for
analysis. The ensemble average was fit using Axograph X. The time of onset of
desensitization was set to zero, and the region of desensitization was fit with a biexponential equation (Y= A1 x e-t/τ1 + A2 x e-t/τ2 + C), where t is time, Y is the total current
amplitude at a given time, τ1 is the time constant of the fast component of decay, A1 is
the relative amplitude of the fast component, τ2 is the time constant of the slow
component of decay, A2 is the relative amplitude of the slow component, and C is a
constant that accounts for the amplitude of current that remains.
The deactivation phase following a 2-4 ms application of a saturating
concentration of GABA was analyzed. Ensemble averages were used. The time of
GABA removal was set to zero, and the region of deactivation was fit with a biexponential equation (Y= A1 x e-t/τ1 + A2 x e-t/τ2).
A weighted time constant (τw) was also calculated for each analysis. τw = (A1/(A1
+ A2)) x τ1 + (A2/(A1+A2)) x τ2. This value allows for a simplified comparison of major
changes that may occur in macroscopic rates of either phase.
Antagonist unbinding experiments
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During antagonist unbinding experiments, the current that is evoked by GABA
following a pre-equilibration in SR-95531 (a competitive antagonist) is measured.
Outside-out patches containing GABAA receptors were first exposed to a saturating
concentration of GABA in order to establish a control response. After returning to the
wash solution for 12 to 15 seconds, SR-95531 was applied for 750 ms, and then rapidly
switched to a solution containing saturating GABA. This procedure was repeated 5 to 15
times, and ensemble averages were used for analysis. The entire experiment was
repeated several times, pre-equilibrating in different concentrations of SR-95531.
The evoked current following pre-equilibration in SR-95531 (Iant) is shaped by the
convolution of the time course of antagonist unbinding and the waveform of the control
current, Ictrl (evoked with no pre-equilibration in antagonist) (Figure 2.2).
Mathematically Iant is the convolution of Ictrl and the function (a(t)) that describes the rate
at which receptors become available due to the unbinding of SR-95531 (Jones et al.,
1998). Therefore, a(t) can be obtained by deconvolving Ictrl from Iant. The following
relationship expresses this operation, where F(f(x)) is the Fourier transform of f(x):
A(t) = F-1(F(Iant)/F(Ictrl))
Integration of a(t) then gives A(t), the fraction of receptors available for binding GABA
as a function of time. This is the deconvolved curve and reflects the time course of
antagonist unbinding. This curve was fit in Axograph X with the function:
A(t) = [P∞ - (P∞ - P0)exp(-t/τu)]N,
Where P0 and P∞ are the probabilities of being available initially (at t=0) and at steady
state (as t →∞), N is the number of antagonist binding sites per receptor, and τu is the
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time constant of antagonist unbinding (Jones et al., 1998). koff-SR was obtained by taking
the reciprocal of τu.

Figure 2.2 Antagonist unbinding experiment. Current responses to a control pulse of GABA
are overlayed with current responses following pre
pre-equilibration in SR-95531.

The experiment was repeated several times, pre
pre-equilibrating
equilibrating in different
concentrations of SR-95531.
95531. The fraction of receptors av
available
ailable at t=0 was plotted
against the log of the concentration of SR
SR-95531
95531 (Prism 4). This plot was fit with the
normalized Hill equation for an antagonist:
B∞=1/(KD-SR/[SR
/[SR-95531]N + 1).
The best curve fits were always achieved with N=1, indicating tha
that one SR-95531
95531
compound is bound. This provided an accurate estimate of KD-SR. After directly
measuring koff-SR and KD-SR, the kon-SR was calculated.
kon-SR = KD-SR / koff-SR
Measuring the microscopic binding rate of GABA
The microscopic binding rate of GABA (kon-GABA) was measured using an
established method, the race experiment, involving competition of GABA with an
antagonist of known kinetics. GABA was co
co-applied
applied with the competitive antagonist
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SR-95531. SR-95531 binds in the GABA binding pocket but does not induce any
activation. The ratio of channels that bind antagonist to those that bind GABA depends
on the concentrations and relative binding rates of each. The resulting activation is
dependent on the percent of channels that bind GABA and are hence open. The GABA
binding rate was determined using the ratio of the peak current generated in the presence
and absence of antagonist. This ratio is termed Irace, and has the following relationship to
kon-GABA:
kon-GABA= ([SR-95531]kon-SR)/([GABA](1/Irace – 1)).
Alternating pulses of a solution containing only GABA with a solution containing
GABA and SR-95531 were applied in order to observe Irace. Incubation in wash solution
(12 to 15 seconds) separated each application. The only uncontrolled parameters were
Irace (measured here), and the binding rate of SR-95531 (kon-ant), which was measured
separately.
Mutant cycle analysis
Mutant cycle analysis was performed on EC50 values, deactivation rates, and
binding rates. ∆∆G'o was calculated as RT ln (kmutant/kwild-type), where R is the ideal gas
constant (1.987 calories/mole) and T is the absolute temperature (296 K). Although EC50
and deactivation rates do not provide true kinetic rate constants, comparison of
macroscopic parameters have been previously utilized to support side-chain interactions
and establish coupling coefficients (Kash et al., 2003; Price et al., 2007; Gleitsman et al.,
2008). If two mutations have independent effects ∆∆G'o(1,2) = ∆∆G'o(1) + ∆∆G'o(2) . Any
value of the coupling energy [∆∆G'ocoupling = (∆∆G'o(1) + ∆∆G'o(2)) - ∆∆G'o(1,2) )] that
deviates from zero could indicate a dependence between two residues. Due to the
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methodological inability to determine a true standard deviation in the sample population
for several of our measured parameters (i.e. EC50 or KD), we consider a coupling energy
of |0.5| kcal/mol or greater sufficiently indicates two residues are dependent. This value
is consistent with confirmed interaction energies between two side-chains (Hidalgo and
Mackinnon, 1995; Ranganathan et al., 1996; Horovitz, 1996). A significant coupling
energy may not exclusively result from a direct interaction between two residues, but
could result from secondary interactions through a third side-chain, or could be the result
both residues contributing to the same structural element.
Nonstationary variance analysis
Nonstationary variance analysis (Sigworth, 1980) was performed on responses to
repeated 3 ms pulses of saturating GABA. As previously described (Goldschen-Ohm, et
al., 2010; Wagner et al., 2004), mean current (I) and variance (σ2) of the repeated pulses
were calculated at each time point. Mean current was divided into 100 equally sized
bins, and the variances in each bin were averaged. The binned variance was plotted
versus current and fit with the equation: σ2 = iI – I2/N, where i is the single channel
current, and N is the number of channels. Conductance was calculated by dividing i by
the holding potential of -60 mV, which is equivalent to the driving force because the
reversal potential for chloride is 0 mV. The mean current (I) is dependent on N, i, and
the open probability (Po) as follows I = N⋅Po⋅i, allowing Po-max to be calculated from
the maximum I. Variance resulting from slow drift, such as rundown or run-up, was
corrected by local linear fitting of the drift, calculating the variance due to this trend at
each point, and subtracting the drift variance (scaled by the square current amplitude)
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from the total variance before fi
fitting.
tting. This method yields accurate estimates of i and N
when tested on simulated data with drift (Wagner et al., 2004).
Kinetic modeling
Kinetic modeling was performed with home
home-written
written software using the Q-matrix
Q
method (Colquhoun and Hawkes, 1995a,b). We utilized a simplified model of GABAA
receptor behavior
ehavior (Figure 2.3
2.3)) that has previously been described (Jones et al., 1998;
Wagner et al., 2004, Goldschen
Goldschen-Ohm
Ohm et al., 2010). Although we considered more
complex variations of this model, which included aadditional
dditional desensitized and open states,
the simplified model was equally suitable to recapitulate our data. During optimization
the rate constant kon and Po-max
max were constrained to the value obtained from experiments
in this study; all other parameters we
were
re initially set to values reported by Goldschen-Ohm
Goldschen
et al. (2010) and were unconstrained. Current responses from 3 ms and 500 ms pulses of
saturating GABA were simultaneously fit for each patch. Following initial optimization,
only koff, r1, d2, r2, and p were left unconstrained; and fits were repeated. Optimization
used a simplex algorithm to minimize the amplitude
amplitude-weighted
weighted sum of squared errors
between actual and simulated currents.

state markov model
Figure 2.3 Kinetic model. The 7-state
used to simulate GABA responses (U, unbound; B, bound;
O, open; D, desensitized).
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Halotag® constructs and fluorescent microscopy
The sequence for the Halotag® (Promega, Madison, WI) was inserted between
the codons for the fourth and fifth amino acid of the mature β2 subunit and of the mature
γ2 subunit. These constructs were made by amplifying the Halotag® sequence (pFN22A
vector) with two primers that contained flanking ends, one with the restriction site AscI
and one with the restriction site FseI. The corresponding restriction sites were inserted
into the GABAA receptor subunit sequence using the Quikchange site-directed
mutagenesis system. Both the plasmid and amplified Halotag® sequence were digested
with the two restriction enzymes and then purified. Following a ligation reaction,
competent E.coli cells were transformed and plated on LB-Ampicillin (50 μg/ml) plates.
Due to a high percentage of plasmids that re-sealed and produced false-positive colonies,
the desired construct was identified using a PCR-based colony screening method. Each
colony was picked, dipped into 5 ul of water inside a PCR tube, and then streaked onto a
fresh replicate agar plate. A standard PCR mix was added to each PCR tube containing
primers that flanked the insert. After thirty rounds of PCR, appropriate colonies were
identified based on the size of the PCR product as determined by agarose gel
electrophoresis.
Appropriate replicate colonies were picked and used to inoculate 3 mL LB
cultures with ampicillin (50 μg/ml). Plasmid DNA from these cultures was then isolated
using Wizard Plus SV mini-preps (Promega, Madison, WI). The coding region of each
new construct was sequenced with forward and reverse primers to ensure the intended
mutation was present and no additional, unwanted changes occurred.
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For fluorescent imaging experiments HEK-293 cells were plated onto poly-dlysine coated glass coverslips that had been placed in the bottom of 24-well plates. The
next day transfection with lipofectamine was carried out. The media was changed 36
hours post transfection and after an additional 24 hours two-step labeling experiments
were performed.
Sequential labeling of cells expressing Halotag® GABAA receptor subunits was
performed first with Halotag® AlexaFluor 488 ligand (Promega) (1uM in media, 20
min), followed by 3 rinses with warm media and a 25 minute incubation (37degree 5%
CO2). Then cells were labeled with Halotag® TMR ligand (Promega) (5uM in media, 15
min), followed by 3 rinses with warm media and a 25 min incubation (37degree 5%
CO2). The Alexafluor 488 ligand cannot cross the cell membrane and only labels protein
on the surface of the cells. TMR is membrane permeable and labels intracellular protein.
The cells were fixed immediately after labeling using 4% paraformaldehyde, 0.2%
sucrose in 1X PBS (pH 7.5) for 10 minutes room temperature, followed by treatment
with 0.2% Triton X-100 in 1X PBS for 10 minutes room temperature. The coverslips
were placed onto glass slides with Vectashield mounting medium (Vector Laboratories,
Inc., Burlingame, CA).
Imaging was performed using a Nikon A1 confocal microscope (Tokyo, Japan)
with a 40x objective. Halotag® Alexafluor 488 (494 nm excitation, 517 nm emission)
and Halotag® TMR (555 nm excitation, 585 nm emission) images were collected and
analyzed using NIS-Elements Advanced Research software (Nikon). During acquisition
of images the gain for each PMT channel was set between 100 and 105, the laser power
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for both 494 nm and 555 nm lasers was set to 11.5, and the pinhole was 1.1 AU. Images
were collected with a Galvano scanner at a 1/8 scan line speed.
The mean intensity of the Alexafluor 488 label and the TMR label was measured
for individual cells after subtracting background fluorescence. Using a Bezier hollow
tool, a region of interest was established around every cell that appeared to have
intracellular TMR labeling, and hence expression of GABAA receptor subunits. The
percent surface expression was calculated as the mean intensity of Alexafluor 488
divided by the total of Alexafluor 488 and TMR label mean intensities. For statistical
analysis an arcsine transform was performed on the percent surface expression. These
values were used with a Student's t-test, p< 0.05, in order to compare mutant and wildtype receptors (Prism 4).
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III. ALANINE MUTATIONS OF GABA BINDING
POCKET RESIDUES DESTABILIZE THE
LIGAND-RECEPTOR COMPLEX
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Introduction
The overall objective of this study is to improve our understanding of the structure
of the GABA binding pocket. A variety of experiments, described in Chapter I, have
determined that GABA binds at the β/α inter-subunit interface, yet the molecular
interactions that mediate GABA binding remain elusive (Sigel et al., 1992; Amin and
Weiss, 1993; Smith and Olsen, 1994; Boileau et al., 1999; Westh-Hansen et al., 1999;
Wagner and Czajkowski, 2001; Boileau et al., 2002; Newell and Czajkowski, 2003; and
Newell et al., 2004; Kloda and Czajkowski, 2007). A number of studies have utilized
site-directed mutagenesis, photoaffinity labeling, and substituted cysteine accessibility
method (SCAM) to study the structure of the GABA binding pocket. These studies have
identified a multitude of residues from both the β subunit and α subunit that may form the
GABA binding pocket. The residues are listed in Table 3.1. Unfortunately, the precise
location of these residues within the binding pocket is not clear, nor is it understood how
these residues mediate GABA binding. Previous mutagenesis studies failed to
distinguish the nature of the effect that arose when mutating such residues. Relying
mostly on comparisons of whole-cell currents and EC50 data, such studies have not
adequately addressed whether a given residue is functionally involved in binding,
desensitization, or gating.
Although the atomic structure of the GABAA receptor has not been resolved, a
homology model provides some indication of how the GABA binding pocket might look.
Cromer et al. (2002) made use of the crystal structure of AChBP from the snail Lymnaea
Stagnalis to model the extracellular domain of the GABAA receptor. The AChBP shares
significant primary and secondary sequence with the N-terminal domain of nACh
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receptor as well as the other cys-loop LGICs (GABAAR included). The completed model
illustrates the location of the numerous residues that have been implicated experimentally
in ligand binding (Figure 1.6, Chapter I). These residues align with loops A, B, and C of
the β subunit, and loops D and E of the α subunit. With a lack of high-resolution
structural information, the homology model is our best resource for placing the identified
residues and the predicted secondary structure of the critical loops into a threedimensional context. The homology model appears to depict the precise locations of
these structural elements; however, it is only indirect evidence and requires experimental
support to confirm it.
Scanning alanine mutagenesis was performed on the residues believed to form the
GABA binding pocket. The objective was to establish which receptor processes, such as
binding, unbinding, desensitization, or gating, are influenced by each residue. In addition
to determining EC50-GABA values for each alanine mutant, the macroscopic kinetics for
mutated receptors were examined using rapid-ligand application techniques, which allow
distinct desensitization and deactivation phases to be observed during GABA evoked
currents. The effect that a mutation has on these phases has not previously been explored
for most binding pocket residues, and changes in desensitization and deactivation phases
provide an initial indication as to what receptor functions are altered. This systematic
screen of the binding pocket established which residues similarly contribute to a given
receptor function, specifically identifying a number of residues that appear to stabilize the
ligand-receptor complex. The study also identified several mutated residues with
particularly interesting or severely altered profiles. Such residues deserve further
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analysis and are the subject of later chapters exploring microscopic binding rates, kinetic
modeling, and paired mutations.
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Results
The candidate residues investigated in this study are listed in Table 3.1. Although
this list covers many of the predicted binding pocket residues, a handful of residues are
absent, such as α1F65, α1R67, α1R132, and β2R207, which were already being
investigated in our lab. In order to explore the role each residue has in receptor function,
the wild-type side-chain was replaced with the methyl group of alanine. Alanine
replacement serves to remove electrostatic or hydrogen bonding interactions inherent to
the wild type side-chains, and minimizes the potential for introducing new interactions.
Thirteen residues were individually mutated to alanine using PCR-based site-directed
mutagenesis. Double stranded sequencing of the entire coding region was conducted in
order to verify fidelity.

GABA Evoked Current
Expressing Expressing
Mutant Expressing
α1 and β2α1, β2, and
Residue α1 and β2
GKER
γ2
α1L118A

None

√

n.d.

α1R120A

None

√

n.d.

α1I121A

None

None

n.d.

α1L128A

None

√

n.d.

α1T130A

None

√

n.d.

β2Y97A

None

None

√

β2L99A

None

None

None

β2Y157A

None

None

√

β2D163A

None

None

√

β2F200A

None

√

√

β2T202A

None

None

√∗

β2Y205A

None

None

None

β2S209A

None

None

None

Table 3.1 Expression of
GABA binding pocket
mutants.
Currents were
observed during application
of GABA on outside-out
patches pulled from HEK293 cells that had been
transfected with a mutant
subunit along with the
appropriate counterpart(s).
Expression
combination
with observable current are
marked with a √ . (n.d.=
data not determined, * =
only small currents for 100
mM GABA)
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Expression difficulties for alanine mutants
Attributing a particular receptor function to a given residue using mutagenesis
required that a discernible effect be observed after mutation. Furthermore, no such
assessment on receptor function can even take place if the mutant subunit fails to
assemble. Indeed the expression and assembly of functional receptors was impacted by
all of the residues considered in this screen. In every case, HEK-293 cells transfected
with a mutant α1 subunit and wild-type β2 or wild-type α1 and mutant β2 displayed no
GABA (30 - 100 mM) or propofol (100 - 300 uM) evoked current (Tables 3.1 and 3.2).
Like GABA, propofol activates the GABAA receptor; however, it has a different binding
site. Even if GABA binding is disturbed, propofol should elicit current if receptors have
been assembled and inserted into the membrane. Therefore, the absence of propofol
current suggests that all of the mutations negatively affect receptor expression or
assembly in our system.
In order to continue with the study two strategies were employed to rescue
assembly. First, a β2 variant that was developed experimentally, termed β2-GKER, was
used. β2-GKER has four amino acids of β2 replaced with the aligned residues found on the
β3 subunit, D171G, N173K, T179E, and K180R (Taylor et al., 1999; Bollan et al., 2003).
This subunit has been shown to assemble more efficiently (Bollan et al., 2003) and we
have found no differences in kinetics, EC50-GABA, or current amplitude between β2 and β2GKER

containing receptors (unpublished data).
Mutant α1 subunits were expressed with β2-GKER instead of β2. This was sufficient

for expression of α1L118A, α1R120A, α1L128A, and α1T130A. Mutant β2 subunits were
reconstructed on a β2-GKER background and expressed with α1. This was sufficient for
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expression of β2-GKERF200A, but failed to restore functional expression of the other β2
mutants.

Propofol Evoked Current
Expressing Expressing
Mutant Expressing
α1 and β2α1, β2, and
Residue α1 and β2
GKER
γ2
α1L118A

None

√

n.d.

α1R120A

None

√

n.d.

α1I121A

None

None

n.d.

α1L128A

None

√

n.d.

α1T130A

None

√

n.d.

β2Y97A

None

None

√

β2L99A

None

None

None

β2Y157A

None

None

√

β2D163A

None

None

√

β2F200A

None

√

√

β2T202A

None

None

√

β2Y205A

None

None

None

β2S209A

None

None

None

Table 3.2 Binding pocket
mutants disrupt propofol
activation. Currents were
observed during application
of GABA on outside-out
patches pulled from HEK293 cells that had been
transfected with a mutant
subunit along with the
appropriate
counterpart(s).
Expression combination with
observable
current
are
marked with a √ . (n.d.= data
not determined)

For the β2 mutants that were not rescued by β2-GKER a second strategy was
employed, involving the expression of a different combination of GABAA receptor
subunits. Previously, the bulk of work in our lab studied α1β2 receptor types. These two
subunits are necessary to form the GABA binding site and sufficient to produce
functional receptors. GABAA receptors are also capable of incorporating a γ subunit by
forming a pentamer of 2α’s, 2β’s, and a γ, instead of 2α’s and 3β’s (Connolly et al., 1996;
Tretter et al., 1997; Farrar et al., 1999). Co-expression of β2Y97A, β2Y157A, or
β2D163A with α1 and γ2 led to robust GABA evoked currents. Expression of β2T202A
with α1and γ2 led to propofol-activated currents, but demonstrated a limited response to
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GABA. These results indicate that these β2 mutations do not prevent oligomerization of
the β/α inter-subunit interface.
Neither GABA nor propofol currents were observed for α1I121A, β2L99A,
β2Y205A, or β2S209A in any of these attempts. This result suggests that these mutations
interfere with expression, but it is also possible that receptor gating is severely disrupted.

Figure 3.1 Examples of GABA concentration-response experiments for α1β2-GKER and
mutant receptors. Currents evoked by a saturating GABA concentration (black trace) and a
sub-saturating GABA concentration (red trace) to the same patch are overlayed for each
receptor type. A 500 ms pulse of GABA was applied in all cases (black bar). A red arrow
indicates the peak current evoked by 100 µM GABA for L118A, L128A, and T130A. Example
responses are ensemble averages of 10-30 traces.
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Concentration-response curves shifted by alanine mutations
A macroscopic parameter that should appear altered when mutating a residue
involved in binding is the concentration of agonist that gives a half-maximal response,
known as the EC50 value. Most of the residues being explored have previously been
demonstrated to have an effect on EC50-GABA, but such analysis was completed using a
variety of side-chain substitutions, different expression systems, and different application
methods. Concentration-response experiments here allow us to verify that an alanine
mutation in particular alters the EC50-GABA.
They also allow us to determine what
concentration of GABA is saturating, which
is important for later experiments. The peak
current evoked by an application of a series
of GABA concentrations was used to
establish the EC50-GABA value of a given
mutant (Figures 3.1 and 3.2). Table 3.3
includes these values for each receptor type.
The EC50-GABA for α1β2 receptors is 7 µM,
Figure 3.2
Examples of GABA
concentration-response experiments for
α1β2γ2 and mutant receptors. Currents
evoked by a maximum GABA concentration
(black trace) and a sub-saturating GABA
concentration (red trace) to the same patch
are overlayed for each receptor type. A 500
ms pulse of GABA was applied in all cases
(black bar). Example responses are ensemble
averages of 10-30 traces.

and the EC50-GABA for α1β2-GKER is 6 µM.
When α1R120A is expressed with β2-GKER, a
10-fold increase in EC50-GABA occurs. The
expression of β2-GKERF200A with α1 has an
even more dramatic effect, shifting the EC50GABA

over 130-fold. The mutations
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α1L118A, αL128A, and α1T130A have more subtle effects, shifting the EC50-GABA 7.5fold, 5 fold, and 4-fold respectively.
The concentration-response curve for α1β2γ2 yields an EC50-GABA of 70 µM.
β2D163A causes a modest 2.2 fold shift in EC50-GABA, while β2Y97A and β2Y157A
dramatically shift the dose-response curves, 14-fold and greater than 400-fold
respectively.
The expression of α1β2T202Aγ2 yielded minimal responses to GABA (even at 100
mM). The fact that propofol application consistently evoked large currents in patches
pulled from HEK cells expressing this receptor type suggests that the mutation allows
normal receptor assembly, but significantly disrupts the GABA binding site. Propofol
typically activates wild type receptors with a maximum current that is only 60% of the
maximum GABA current evoked (Davies et al., 1997; Hales et al., 2006). For β2T202A,
the currents evoked by propofol were 10-fold larger than the currents evoked by 100 mM
GABA, which was the maximal concentration of GABA tested (Figure 3.3). The greater
propofol activation indicates functional channels are being assembled efficiently, but that
GABA activation is severely disrupted.
Figure 3.3 For β2T202A GABA exhibits
limited potency relative to propofol. For
α1β2T202Aγ2 receptors, current responses were
evoked by a 500 ms application of 100 mM
GABA (black trace, black bar), followed by a
15 second washout and a 500 ms application of
100 µM propofol (red trace, red bar). Example
responses are ensemble averages of 10-30
traces.

48
Macroscopic deactivation kinetics
Another parameter of interest was deactivation. Changes in deactivation can be
the result of altered unbinding rates, closing rates, or desensitization rates. Mutants with
clear changes in deactivation will be of interest for further study. The receptor kinetics
of macroscopic deactivation were characterized following a brief (3ms) pulse of GABA,
similar to that occurring during synaptic transmission (Figure 3.4 and 3.5). Changes in
the rate of deactivation often correlate to a change in the stability of the ligand-receptor
complex.

Figure 3.4 The deactivation phase of α1β2-GKER and mutant receptors. Currents evoked from
a 3 ms pulse of GABA (arrow) exhibit distinct deactivation for many of the mutant receptors.
Example responses are ensemble averages of 10-30 traces.

Initial characterization of deactivation was done by fitting bi-exponential
functions to each trace and calculating the weighted tau (Table 3.3).

α1T130A has little

effect on the deactivation, whereas α1L128A, β2Y97A, and β2D163A show significant
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increases in the rate of deactivation. The most dramatic deactivation effects occur with
α1L118A, α1R120A, β2Y157A, and β2F200A, which reduce the weighted time constant
(τw) by 9-fold, 24-fold, 12-fold, and 19-fold compared to their respective controls.

Figure 3.5 The deactivation phase
of α1β2γ2 and mutant receptors.
Currents evoked from a 3 ms pulse of
GABA (arrow) exhibit distinct
deactivation for many of the mutant
receptors. Example responses are
ensemble averages of 10-30 traces.

Macroscopic desensitization kinetics
The desensitization of macroscopic currents was also assessed in order to explore
the functional affect of each mutant. Long pulses (500 ms) of saturating GABA were
applied to patches (Figures 3.1 and 3.2). The resulting desensitization phase was fit with
a bi-exponential function. Desensitization is composed of several phases, with additional
slower phases being revealed during prolonged exposure to GABA. Typically, two
phases are observed during a 500 ms pulse (generically referred to as fast and slow
desensitization). The rate and extent of desensitization can vary significantly for a given
receptor type. Although the data for the individual components is useful during detailed
analysis, a simplified comparison of the total extent of desensitization and the τw is more
prudent for easy comparison. Most of these residues showed no significant
desensitization effect when mutated to alanine (Table 3.3). Subtle differences created by
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many of the mutants were overshadowed by the generally large variability in
desensitization.
Three mutations did significantly affect desensitization. α1R120A has a significant
reduction in the time constant τw. α1L128A significantly increases the percent remaining,

but not τw. β2Y157A also shows a significant increase in percent remaining; however,
desensitization experiments were carried out with a solution of 100 mM GABA, which
may not have been saturating for this mutant. Desensitization profiles at non-saturating
concentrations are inherently different and could lead to a misleading result.

Figure 3.6 α1β2-GKER exhibited
different desensitization rates
during 2006-2007 and 2008-2010.
For α1β2-GKER receptors, currents
evoked from a 500 ms pulse of 30
mM GABA (bar) in 2006 and 2008
exhibit unique desensitization.
Example responses are ensemble
averages of 10-30 traces.

A complication arose over the course of these experiments, which were conducted
during a span greater than four years. The rate and extent of desensitization for the
control receptor type from 2006-2007 were distinct from data collected from 2008-2010
(Figure 3.6). The variables that influence desensitization are not well understood.
Within our expression system, expression levels of endogenous proteins that modulate
the GABAA receptor may vary. Additional concern exists with an unintended external
modulator that might influence receptor function. Whether this is in our media,
supplements, plastic-ware, or solutions is extremely difficult to deduce. For the sake of
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consistency, all mutants were compared against control data collected during the same
experimental timeframe.
Table 3.3 Macroscopic analysis of amino acid residues lining the GABAA receptor
ligand binding pocket.
Deactivation
(τw)

n

GABA

α1β2

7 µM

103 ± 14 ms

9

α1β2-GKER

6 µM

96 ± 12 ms

9

Construct

Expression
requirements

EC50-

Desensitization
(τw)

Desensitization
(% remaining)

n

67 ± 15 ms
85 ± 10 ms 1;
22 ± 3 ms 2

30 + 13
28 + 12;
19 + 11

20
29
26

α1R120A

β2-GKER

63 µM

4 ± 1 ms *

4

40 ± 4 ms *

31 + 12
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α1L118A

β2-GKER

45 μM

11 ± 2 ms *

2

26 ± 4 ms

22 ± 3

3

α1L128A

β2-GKER

31 μM

35 ± 3 ms *

3

24 ± 7 ms

44 ± 6 *

3

α1T130A

β2-GKER

26 μM

114 ± 12 ms

2

26 ± 5 ms

33 ± 4

3

β2F200A

β2-GKER

800 µM

5 ± 12 ms *

10

23 ± 3 ms

20 + 6

26

37 ± 6 ms

14

124 ± 10 ms

39 + 2

38

12 ± 3 ms *

19

137 ± 20 ms

33 + 8

12

3 ± 1 ms *

3

139 ± 14 ms

61 ± 4 *

4

16 ± 1 ms *

20

85 ± 6 ms

34 + 2

28

-

-

-

β2Y97A

γ2

β2Y157A

γ2

β2D163A

γ2

70 µM
1,000
µM
> 30,000
µM
155 µM

β2T202A

γ2

N.D.

α1I121A

No expression

-

-

-

β2L99A

No expression

-

-

-

β2Y205A

No expression

-

-

-

-

β2S209A

No expression

-

-

-

-

α1β2γ2

Desensitization for α1β2-GKER is broken into two data sets: (1) data collected from 2006-2007, and
(2) data collected from 2008-2010. Values are reported ± SEM and those that are significantly
different from the appropriate control are indicated by an asterisk, determined by ANOVA with
Dunnett’s post-test, p < 0.05. α1R120A was the only mutant compared with the 2006-2007 α1β2GKER desensitization data.
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Discussion
The screening of residues throughout the GABA binding pocket was conducted
with the purpose of exposing which receptor functions are influenced by a given residue,
as well as identify a subset of residues worth exploring in more depth.

As we try to

improve our understanding of the architecture of the ligand binding pocket, it is important
to distinguish residues that are clearly critical for binding or gating, from those that are
not involved. Previous studies have utilized mutagenesis, but have not explored how
each mutation affects the kinetics of receptors. Our screen examined receptor kinetics
systematically, using alanine substitution, and took a closer look at each mutation’s
effect. This study served as a preliminary screen to identify residues that will be further
analyzed for their role in GABA binding.
GABA binding pocket mutations disrupt assembly
Mutations at the interface between two subunits commonly disrupt receptor
assembly (Enna and Mohler, 2007). These residues may play a major role in GABA
binding, but a comparison cannot be made among them unless we have an observable
GABA response. A number of studies conducting serial mutagenesis on residues around
the binding pocket have found particular substitutions that are not well tolerated while
other substitutions maintain full expression/functionality (Amin and Weiss, 1993;
Harrison and Lummis, 2006). All of the mutations studied in this screen hindered
functional expression of GABAA receptors and many are likely to play an important role
in assembly. For residues that could not be explored due to a lack of expression,
alternative side-chain substitutions may need to be utilized. These include L99 to valine,
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which simply shortens the side-chain by one carbon, T202 to serine, which alters the
orientation of the hydroxyl group, as well as S209 to threonine.
Mutation of certain residues located on the β subunit allow the assembly of
functional receptors when expressed with α and γ, but not when expressed with α only.
Activation by GABA requires the proper formation of β/α inter-subunit interfaces (the
location of the GABA binding site). Considering what is known about the subunit
arrangement of the GABAA receptor, the difference between these two potential receptors
is a β/β interface versus a β/γ interface. This suggests these residues are required in
assembly of the β/β interface, critical for GABAA receptors composed of αβαββ subunits,
but not αβαβγ subunits. Chapter VII details a series of experiments designed to confirm
the assembly effect for each mutated residue that only expresses in the presence of γ2.
Several residues stabilize the ligand-receptor complex
As expected, several residues of the GABA binding pocket impacted receptor
function when mutated to alanine. Significant shifts in EC50, and increased deactivation
are strong evidence that a mutation destabilizes the ligand-receptor complex. α1R120A
and β2F200A are two mutations that exemplify destabilization of the ligand-receptor
complex. Both cause significant increase in EC50-GABA and their deactivation rates are
particularly affected. An increase in the rate of deactivation can be caused by several
factors, but often represents an increase in the microscopic unbinding rate. We cannot
directly measure the rate of unbinding because deactivation depends not only on the
unbinding rate, but also on the rates of channel opening and closing, and on the rate of
desensitization. However, if desensitization during a long pulse of saturating GABA is
unchanged, a change in the relative unbinding rates between the mutant and control
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receptor can be identified. This is because the rate and shape of macroscopic
desensitization depend on all of the same transitions that contribute to deactivation,
except for agonist unbinding. For β2F200A, desensitization is unchanged indicating an
increased unbinding rate is causing the accelerated deactivation phase. For α1R120A the
weighted time constant of desensitization was reduced only 2-fold, yet the weighted time
constant of deactivation was reduced 24-fold. Therefore, in addition to any gating
change associated with desensitization, an increased unbinding rate of GABA likely
contributes to the accelerated deactivation phase for α1R120A.
Both of these residues appear to play an important role in stabilizing the ligandreceptor complex. The large shifts in EC50 and deactivation suggest that they influence
GABA affinity. Later chapters detail the analysis of microscopic kinetics related to each
residue, and explore structural interactions for each.
Y97A and Y157A are two other residues that significantly shift the concentration
response curve and speed deactivation. Like R120A and F200A, this suggests that these
residues have large influences over GABA affinity. The significance of these tyrosines
may be associated with their participation in a structural motif, termed an "aromatic box".
Y97 and Y157, as well as F200 and Y205, are clustered closely, form a hydrophobic
region, and are capable of forming cation-π interactions. Homologous residues form an
aromatic box in the nAChR, and are believed to contribute to the binding of the positive
amine group of acetylcholine (Grutter and Changeux, 2001). The actions of these
GABAA receptor side-chains were hypothesized to form cation-π bonds and this question
was addressed by Padgett et al. (2007). They used unnatural amino acid substitution to
introduce fluorinated aromatic side-chains, which had a decreasing potential to form
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cation-π interactions. This decreasing cation-π ability was compared with the effect on
EC50. Only Y97 showed a strong correlation and they postulated that it directly interacts
with the amino group of GABA.
Further investigation, particularly of the microscopic binding rate, of these
aromatics is definitely relevant. However, the extreme disruption caused by Y205A is
problematic, and the EC50-GABA of Y157A may be too shifted to complete full kinetic
analysis. Therefore, more conservative mutants were generated: Y97F, Y157F, and
Y205F. These mutations maintain the aromatic ring and capability of a cation-π bond,
but lose the hydroxyl group, a potential player in hydrogen bonding. All of these
expressed well with γ2. Although this subset of residues could be of great interest, it has
not been investigated any further.
A mutant with no significant changes in deactivation, desensitization, or EC50GABA

is considered silent, and would not be further explored. Of the residues tested, only

T130A lacks a distinguishing effect. This does not exclude all importance of the residue,
but at minimum demonstrates that alanine is sufficient in maintaining normal function for
this position. The result of the threonine mutation suggests that the hydroxyl group,
which could participate in hydrogen bonding, is not critical, or such an interaction is not
required for the parameters we assessed. Mutation of α1T130 to cysteine, on the other
hand, caused a 102-fold increase in EC50-GABA (Kloda and Czajkowski, 2007); therefore
the contribution of this side-chain is not easy to discern.
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IV. α1R120: A DISTINCT ARGININE
RESIDUE IN THE GABA
BINDING POCKET
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Introduction
Hypotheses about the mechanisms involved in the binding of GABA have often
included interactions of the negative carboxy end of GABA with positively charged sidechains, such as arginines. As these types of interactions have been explored, a couple of
plausible candidates have been found, specifically α1R67 and β2R207. Interestingly,
mutations of both of these arginines had qualitatively similar effects on receptor kinetics.
Namely, α1R67A and β2R207A displayed significantly faster deactivation (24-fold and
13-fold increase in the weighted time constant), but macroscopic desensitization was not
different from wild type (Goldschen-Ohm et al., 2011). The implication of this result is
that each arginine plays a role in maintaining the stability of the ligand-receptor complex
by slowing the GABA unbinding rate. In addition, each arginine to alanine mutation
demonstrated approximately equal and opposite shifts in unbinding and binding rates
(Goldeschen-Ohm et al., 2011).
The alanine mutagenesis screen presented in Chapter III identified a third arginine
that may serve a similar capacity. α1R120 is located near the top of the GABA binding
pocket (Figure 4.1), and is highly conserved amongst GABAA receptor subunits. Several
previous studies have implicated α1R120 in GABA binding. Westh-Hansen et al. (1999)
showed α1R120K expressed with β2 and γ2 had a 180-fold rightward shift in the
concentration-response curve, as well as abolished the binding of radiolabeled muscimol
(another GABAA receptor agonist) and radiolabeled SR-95531 (a competitive
antagonist). Further demonstrating the strong impact of this residue, Harrison and
Lummis (2006) made mutations of the corresponding residue in the homomeric GABAC
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receptor (ρ1R158) to lysine, alanine, or glutamine. All of these mutations resulted in nonnon
functional receptors.

Figure 4.1 Homology model depicting three important arginines in the GABA binding
pocket. The model is derived from the AChBP (O’Mara et al., 2005). The extracellular domains
of a β/α inter-subunit
subunit interface are viewed from the side. The residues are colored by CPK type.

With the objective of understanding the role of α1R120 in the context of the
previously identified arginines, a thorough kinetic characterization of the mutant
α1R120A
A was performed. Quantifying the effect on binding kinetics allowed a more
complete interpretation of α1R120
R120’s contribution in receptor function and aided our
understanding of the similarities and differences between tthe
he binding pocket arginines.
The results presented here demonstrate that mutation of the third binding pocket arginine,
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α1R120, to alanine also causes a large increase in the rate of deactivation with no effect
on desensitization, but only causes a small decrease in the GABA binding rate.
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Results
The α1R120A mutation causes significant changes in deactivation and EC50-GABA
GABA
The effects of the α1R120A mutation on GABAA receptor function were
characterized using rapid-ligand
ligand application on outside-out
out patches from HEK-293
HEK
cells
expressing the mutant α1 subunit with a β2-GKER subunit. The peak current response to a
series of GABA concentrations was used to establish an EC50-GABA value for the mutant.
Each response was normalized to the maxi
maximum peak current
ent evoked, in this case using
100 mM GABA. R120A shifted the concentration
concentration-response curve rightward
ghtward 10-fold
10
(Figure 4.2).
). A shift in the concentration
concentration-response
response curve can be caused by decreasing
affinity, as well as by changes in the equilibr
equilibrium
ium constant of the opening and closing
rates of the channel (Colquhoun 1998).

Figure 4.2 R120A shifts the GABA
concentration-response
response curve rightright
ward. Responses to a series of GABA
concentrations were normalized for the
maximum evoked current. The data
da was
fit with a sigmoidal curve: Y = Ymin +
(Ymax – Ymin) / (1 + 10^((LogEC50 – X)
* HillSlope)). α1β2-GKER
GKER (▼)
(
has an
EC50 of 6 µm. R120A (○)) has an EC50 of
63 µm.

Macroscopic desensitization
esensitization and deactivation phases were examined during
GABA evoked currents in order to pinpoint specific parameters (i.e. desensitization,
resensitization, or GABA unbinding) that are altered by the R120A mutation. The
desensitization phase represents a spontaneous and prolonged closing of channels even
though GABA is still bound, and it is dictat
dictated
ed by several gating processes, including the
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rates of channel opening and closing, and the rates of desensitization and resensitization.
The deactivation phase represents the current decay following removal of GABA. Not
only is it influenced by the same gating processes as desensitization, but it is also largely
dictated by the GABA unbinding rate.

Figure 4.3 R120A dramatically accelerates the rate of deactivation, but has only minimal
effect on desensitization. A) Curre
Currents
nts evoked by a 500 ms pulse of GABA (bar) exhibit similar
desensitization. B) Currents evoked by a 3 ms pulse of GABA (arrow) exhibit distinct
deactivation. Example responses are ensemble averages of 10
10-30 traces.

During a 500ms application of GABA, th
the early “fast” component of the
desensitization phase appears unaffected by the α1R120A mutation (Figure 4.3A,
4.
Table
4.1). However, when the desensitization phase is fit with a bi
bi-exponential
exponential equation
changes in the time constant τslow, % τslow, and the weighted time constant τw are evident.
α1R120A also displays greatly accelerated deactivation during a 3 ms application of
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GABA (Figure 4.3B, Table 4.1). Although the subtle change in the desensitization phase
suggests that channel gating is altered by the mutation, it is unlikely to account for the
more than twenty-fold increase in the time-course of the deactivation phase. The
accelerated deactivation time-course could be best explained by an increased GABA
unbinding rate. If faster unbinding occurs, a lower apparent affinity would be expected
because receptors would spend less time in the ligand-bound states. The measured shift
in EC50-GABA is consistent with this interpretation.
Table 4.1 Summary of parameters from exponential fits of deactivation and desensitization
Desensitization (500 ms, 10 mM GABA)
τ (ms)
τ (ms)
Receptor type
fast

αβ

1 2-GKER

R120A

slow

R120A

%τ

slow

%
Remain

τ (ms)

n

w

238 ± 155

49 ± 14

23 ± 9

28 ± 12

87 ± 59

23

15 ± 6

151 ± 113*

55 ± 17

15 ± 9*

31 ± 12

40 ± 27*

46

τ (ms)

n

fast

1 2-GKER

fast

17 ± 5

Deactivation (2-4 ms, 10 mM GABA)
τ (ms)
τ (ms)
Receptor type
αβ

%τ

slow

%τ

fast

%τ

slow

w

23 ± 11

281 ± 92

71 ± 8

29 ± 8

96 ± 36

9

3 ± 1*

34 ± 11*

94 ± 2*

6 ± 2*

4 ± 1*

4

Parameters are from bi-exponential fits to the desensitization and deactivation waveforms evoked
by 3 ms and 500 ms pulses of 10 mM GABA. All data are reported as mean ± standard deviation.
Significant differences between control and mutant parameters were calculated using Student’s ttest (* p < 0.05).

The a1R120A mutation causes 2-fold increases in both SR-95531 affinity and binding rate
The binding kinetics of the competitive antagonist SR-95531were determined
because this molecule binds in the GABA binding pocket, and the SR-95531 binding rate
can be used in subsequent experiments to calculate the GABA binding rate. The
microscopic kinetics of SR-95531 were directly measured with a series of antagonist
unbinding experiments. Outside-out patches were pre-equilibrated in SR-95531 before
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jumping into GABA. Figure 4.4A illustrates the response
esponse to GABA following prepre
equilibration in SR-95531
95531 for α1β2-GKER and R120A.

Figure 4.4 R120A does not alter the unbinding rate of SR
SR-95531. The koff for SR-95531
SR
was
determined for each receptor type by examining the current response to GABA following a prepre
equilibration in SR-95531.
95531. A) Current responses to a control pulse of 10 mM GABA are
overlayed with current responses foll
following pre-equilibration in 1 µM SR. B) Plots show the
deconvolution of GABA-evoked
evoked currents with SR
SR-95531 pre-equilibration
equilibration from those without
pre-equilibration.
equilibration. Curve fits (red lines) reveal the time course of SR
SR-95531
95531 unbinding.

As the waveform of the pre
pre-equilibrated current
nt is the convolution of the GABA
current and the antagonist unbinding time
time-course, the antagonist unbinding time-course
time
was extracted from this data by deconvolving the GABA-only current from the prepre
equilibrated current (Figure 4.
4.4B).
4B). The time course of unbinding was similar for α1β2GKER

and R120A. The microscopic unbinding rate, which is equal to 1/
1/τu, was 7.3 ±

3.0 s-1 for α1β2-GKER and 7.1 ± 3.2 s-1 for R120A.
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Figure 4.5 R120A shifts the SR95531 inhibition curve.
Concentration-response curves for
the
equilibrium
antagonist
occupancy in the absence of
GABA were fit to the normalized
hill equation I/Imax = 1 – 1/[(KDN
+ 1]. α1β2-GKER
SR/[SR-95531])
(, black curve) has a KD of 47
nM. R120A (o, red curve) has a
KD of 30 nM.

The antagonist unbinding experiment was repeated with pre-equilibration at
several different SR-95531 concentrations, and the microscopic affinity constant, KD-SR,
was obtained by plotting the fraction of receptors that were unbound (and therefore
available) at t=0 versus antagonist concentration (Figure 4.5). The y-intercept of the
deconvolved curve provides the fraction of receptors available (Figure 4.4B). This plot
was fit with a normalized Hill equation for antagonist. R120A caused less than a 2-fold
decrease in KD-SR.
The microscopic binding rate was then calculated using the equation kon = koff/KD.
For α1β2-GKER, kon-SR = 1.6 ± 0.6 x108 M-1s-1. For R120A, kon-SR = 2.6 ± 0.9 x 108 M-1s-1,
which was significantly different from control (Student’s t-test, p < 0.05).
The α1R120A mutation decreases the GABA binding rate 2-fold
The effect that the R120A mutation has on EC50-GABA and the rate of deactivation
strongly suggests that this mutation alters GABA affinity. Other arginine residues of the
GABA binding pocket that alter affinity (i.e. R67 and R207) exhibit shifts in GABA
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binding that are proportional to their shift in unbi
unbinding.
nding. The GABA binding rate for
R120A was measured in experiments where the competitive antagonist SR
SR-95531
95531 and
GABA were simultaneously applied. The current response during co
co-application
application
depends on the relative concentration aand binding rate of each compound.. All of these
parameters are known, except for the GABA binding rate
rate,, which can then be calculated.
calculated
When 300 µM SR-95531
95531 and 10 mM GABA were co
co-applied, R120A exhibited a peak
response that was 50% of the peak response to application of 10 mM GAB
GABA
A alone
(Figure 4.6). For α1β2-GKER co
co-application of 300 µM SR-95531
95531 and 10 mM GABA
elicited a peak response that was 80% of the peak response to 10 mM GABA.
GABA This
percentage, termed Irace, is related to the binding rates as follows: kon-GABA = [SR95531]
[SR95531
kon-SR/([GABA](1/Irace -1))
1)) (Jones et al., 1998). The GABA binding rate was computed
for α1β2-GKER as 2.7 ± 0.7 x 107 M-1s-1 and for R120A as kon-GABA = 1.4 ± 0.7 x 107 M-1s-1,
and they were significantly different from each other (Student's t-test, p < 0.05).
0.05)

Figure 4.66 R120A decreases the GABA binding rate 22-fold. Race experiments are depicted
for α1β2-GKER (A) and R120A (B)
(B).. For both receptor types, currents evoked by simultaneous
application of 10 mM GABA and 300 µM SR-95531
95531 were compared with the current evoked by
10 mM GABA alone. The two separate applications are overlayed for each receptor type.
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Discussion
α1R120 stabilizes the ligand-receptor complex
α1R120 plays a significant role in receptor function, as evidenced by changes in
EC50, deactivation, and GABA binding rate. The large increase in the speed of
deactivation, accompanied by a reduction in binding rate explained the shift in EC50 that
was observed in the alanine mutagenesis screen. The lopsided effects on apparent
unbinding versus binding suggest α1R120 contributes more to the stabilization of the
ligand-receptor complex than to its formation. This is unusual in that other arginine
residues at the GABA binding pocket (α1R67 and β2R207) all have equal effects on both
rates (Wagner et al., 2004; Jones et al., 2005).

Distinct roles for arginines at the GABA binding pocket
The parameters affected by the alanine mutation of α1R120 are similar to those of
α1R67A and β2R207A. There were shifts in EC50, deactivation, and binding rates, but
little change in desensitization. However, the degrees of these effects are noticeably
different. α1R67A and β2R207A cause more severe shifts in every one of these
parameters than α1R120A. These quantitative differences indicate a distinct role or
contribution for α1R120 that is less critical for GABA binding.
The distinction of α1R120 from the other arginines, which may directly interact
with GABA, is further supported by the unique actions that GABA and the antagonist
SR-95531 mediated on methane thiol sulfonate (MTS) reactions of these three residues.
For β2R207 and α1R67, GABA and SR-95531 interfere with the MTS reaction (Wagner
and Czajkowski, 2001; Boileau et al., 1999). MTS reaction with α1R120C, on the other

67
hand, is affected by SR-95531 but not GABA (Kloda and Czajkowski, 2007). Although
composed of similar chemical moieties as GABA, SR-95531 is a larger molecule (13.5 Å
in length versus 4.5 Å) (Boileau et al., 2002). This suggests α1R120 is further from the
GABA binding site than α1R67 or β2R207.

α1R120 indirectly contributes to the GABA binding pocket
α1R120 is crucial for normal receptor function and its absence greatly decreases
the potency of GABA. However, when analyzed in the context of the other arginines
located in the GABA binding pocket, it becomes apparent that α1R120 is less influential.
α1R67 or β2R207 may be directly involved in coordinating GABA binding via hydrogen
bonds between their terminal guanidinium groups and the carboxyl group of GABA.
α1R120, however, may play an indirect role in binding. Considering the location of this
residue near the upper perimeter of the binding pocket, α1R120 more likely contributes to
the global architecture of the binding pocket than interacts with GABA directly. This
could occur due to an impact on structural elements at the α1 face of the GABA binding
pocket or by influencing subunit positioning in general.
The charged nature of arginine makes it ideal for electrostatic interactions (i.e.
salt-bridge or hydrogen bond), which could be critical for either function. Current
structural models indicate an aspartic acid residue (β2D163) is positioned in close
proximity to α1R120, and the two may be capable of forming a salt-bridge or hydrogen
bonds. Identifying an inter-subunit interaction between α1R120 and β2D163 would
confirm the role of these residues in the binding pocket architecture and provide distinct
structural evidence to the location of each residue. This topic is explored in the next
chapter.
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V. A STATE-DEPENDENT SALT-BRIDGE INTERACTION
SPANS THE β/α INTER-SUBUNIT INTERFACE
OF THE GABAA RECEPTOR
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Introduction
Homology models (Cromer et al., 2002; Omara et al., 2005) derived from the
crystallized structure of the molluscan acetylcholine binding protein (AChBP) (Brejc et
al., 2001) have been used to generally position the residues in the binding pocket and can
further inform us of the structural role an individual residue plays. However,
interpretations drawn from these models must be experimentally verified. One
interpretation drawn from homology models is that an arginine from the α subunit
(α1R120) forms an inter-subunit salt-bridge with an aspartate from the β subunit
(β2D163), and that this salt bridge is conserved at every subunit interface (Cromer et al.,
2002) (Figure 5.1). These two residues are highly conserved among LGIC subunits and
experimental evidence for a corresponding salt-bridge interaction has been presented for
the γ/β inter-subunit interface of the GABAA receptor (Goldschen-Ohm et al., 2010).
Mutagenesis studies show the GABA concentration-response curve is sensitive to
changes at either α1R120 or β2D163 (Westh-Hansen et al., 1999; Kloda and Czajkowski,
2007; Newell et al., 2004; see Table 3.3). Also, SCAM studies demonstrated both
residues are accessible to modification by sulfhydryl reactive reagents, indicating that
they are present at the aqueous surface (Newell et al., 2004; Kloda and Czajkowski,
2007).
This postulated interaction between α1R120 and β2D163 was explored by
characterizing macroscopic parameters (EC50-GABA, deactivation, and desensitization) and
microscopic parameters (GABA binding and unbinding rates) for alanine mutations at
each residue. These results were then subjected to double-mutant cycle analysis to test
for interactions. Interestingly, mutation of both residues affected the GABA binding rate
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(kon-GABA), independently. However, when analyzing the deactivation time constants or
the GABA unbinding rates, the two residues appear to be coupled. These results suggest
that α1R120 and β2D163 form a state
state-dependent salt-bridge.

Figure 5.1 Homology models of the GABAA receptor depict a putative salt-bridge
bridge between
β2D163 and α1R120. A) View from the extracellular side looking through the channel pore.
β2D163 (red) and α1R120 (blue) are located at the β/α inter-subunit
subunit interfaces. Residues were
mutated
tated at both interfaces. B) Side view of the extracellular domain at a single β/α
β interface.
The nearest charged atoms of α1R120 and β2D163 are 3.6 Å apart. C) Sequences of
representative human GABAA receptor, glycine receptor, 5-HT3A
HT3A receptor, and nicotinic
n
acetylcholine receptor subunits aligned with the acetylcholine binding protein sequence,
demonstrates the conservation of the residues mutated in this study (in bold).
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Results
In homology models β2D163 and α1R120 are juxtaposed across the “top” of the
GABA binding pocket. In order to further explore the roles of these residues in receptor
function, and to determine if they functionally interact, each wild type side-chain was
replaced with the methyl group of alanine. Alanine replacement serves to remove
electrostatic or hydrogen bonding interactions inherent to the wild type side-chains, and
minimizes potentially confounding interactions from the introduced side-chain.
Receptors containing the α1R120A mutation, the β2D163A mutation, or both mutations
were characterized.
β2-GKER rescues α1R120A expression and γ2 rescues β2D163A expression
HEK 293 cells transfected with wild-type β2 and α1R120A display no GABA (100
mM) or propofol (300 uM) evoked current. The propofol binding site is distinct from the
GABA binding site where α1R120 is located. Therefore, it is likely that the α1R120A
mutation negatively affects receptor assembly in HEK-293 cells. In order to rescue
assembly, the β2-GKER construct was utilized. β2-GKER contains four point-mutations
where a given residue is replaced with its counterpart from the β3 subunit. This construct
has been shown to rescue expression of another binding site mutant, α1R67A, (Bollan et
al., 2003) and has subsequently been used in our lab to restore assembly of several other
mutant constructs (unpublished data).
Transfections with wild type α1 and β2D163A also failed to display GABA or
propofol evoked currents. In an attempt to rescue expression, the β2D163A mutation was
recreated in the β2-GKER background, but this construct failed to give current. Ultimately,
co-transfection with the γ2 subunit was necessary to obtain robust GABA-evoked
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currents. To ensure adequate expression and to control for any influence of the γ2
subunit, this study was performed using cells transfected with α1β2-GKERγ2, α1β2GKERD163Aγ2,

α1R120Aβ2-GKERγ2, or α1R120Aβ2-GKERD163Aγ2, which shall be referred

to from here on as wild-type, D163A, R120A, or R120A/D163A respectively.
The sensitivity of this region to mutations was additionally observed during our
attempts to express charge reversal mutants of each residue (D163R and R120D), alone
or in concert as a charge swap. Transfection with either charge reversal or the swap
failed to express functional receptors.
Double-mutant cycle analysis of D163A and R120A using EC50-GABA yields a weak
coupling energy
The primary goal of this study was to determine whether β2D163 and α1R120
participate in an inter-subunit salt-bridge. A tool that can be used to this end is the
method of double-mutant cycle analysis, which quantifies the coupling energy between
two mutated residues and clarifies the likelihood of two residues interacting (Horovitz,
1996). One parameter that has been commonly used for double-mutant cycle analysis in
the study of LGICs is the apparent affinity for ligand, or EC50 (Kash et al., 2003; Price et
al., 2007; Gleitsman et al., 2008). Therefore, the effects of the D163A and R120A
mutations were initially characterized by determining the peak current EC50-GABA value
through concentration-response experiments. The D163A mutation caused a 2.4-fold
increase in EC50-GABA (155 µM) compared to the wild-type (65 µM), whereas the R120A
mutation had a much larger effect on EC50-GABA causing a 14-fold shift to 900 µM.
Receptors containing both mutations displayed a 25-fold increase in EC50-GABA (1600
µM) (Figure 5.2A).
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Figure 5.2 Mutant cycle analysis of EC50-GABA indicates α1R120 and β2D163 are weakly
coupled. A) GABA concentration
concentration-response
response curves for single and double alanine mutations at
α1R120 and β2D163 when measuring peak GABA responses. B) The mutant cycle for these
alanine mutations. Equations for calculating the change in free energy associated with each
mutation and the overall coupling energy are listed in the methods.

EC50 values were input into a mutant cycle to obtain a coupl
coupling
ing energy of 0.2
kcal/mol (Figure 5.2B,
2B, Table 5.2). If β2D163 and α1R120 are functionally independent
with respect to EC50-GABA, we would expect the coupling energy to be 0 kcal/mol. Any
value that significantly deviates from zero may theoretically indicate coupling, but
typically a more stringent criterion ((i.e.. a coupling energy of at least |0.5| kcal/mol) is
utilized to identify directt interactions between two side
side-chains (Horovitz, 1996).
1996)
Although studies of LGICs commonly use EC50 values to derive thermodynamic
energies, these results can be confounded by the complex nature of the EC50 value, which
depends on multiple microscopic processes that underlie both ligand affinity and channel
gating (Colquhoun, 1998; Gleitsman et al., 2008). Therefore, coupling energies
calculated from EC50 values may be skewed, particularly when exploring in
interactions
teractions that
influence multiple parameters or exist only in certain receptor states. The significance of
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the weak coupling energy found here is unclear, and an interaction between β2D163 and
α1R120 cannot be confirmed or excluded with this evidence.
D163A and R120A independently reduce the GABA binding rate
Since analysis of EC50-GABA was indeterminate, the microscopic binding rates for
GABA for each construct were directly measured using race experiments, as previously
described by Jones et al. (2001). Briefly, the first step in this process is to directly
measure the binding rate for a competitive antagonist, in this case SR-95531. Once the
binding rate for SR-95531 (kon-SR) is determined, the binding rate of the agonist, GABA,
can be measured by performing an experiment in which GABA and SR-95531 are coapplied. The resulting current is compared to the current evoked by an application of
GABA alone. The extent to which the peak current is reduced by the presence of
antagonist depends on the relative binding rates of the two compounds. Since the binding
rate of SR-95531 has been determined, the binding rate of GABA (kon-GABA) can be
calculated.
The binding kinetics of the competitive antagonist SR-95531 were characterized
for each receptor type. Antagonist unbinding experiments were employed as previously
described (Jones et al., 2001), and the dissociation constant (KD-SR) and microscopic
unbinding rate (koff-SR) for each receptor type was measured (Figure 5.3). Each mutant
construct causes a small, albeit significant, (≈ 30%) reduction in koff-SR, but there are no
significant changes in KD-SR (Table 5.1). kon-SR, which was determined using the equation
kon-SR = koff-SR/KD-SR, was also not significantly affected by any of the mutations.

75
Figure 5.3 Microscopic kinetics for the
antagonist SR-95531. A) The KD, koff, and kon
for SR-95531
95531 was determined for each
receptor type by examining the current
response to 30 mM GABA following a prepre
incubation in a series of concentrations of SRSR
95531 (1 µM
M shown). B) Deconvolution of
GABA-evoked
evoked currents after SR-95531
SR
preequilibration
n from control currents (no prepre
equilibration) reveals the time course of SRSR
95531 unbinding. Deconvolutions were fit to
the equation A(t) = [P∞ - (P∞ - Po)exp(t/τu)]N,
where A(t) is the fraction of available
receptors (antagonist not bound at any site), P0
and P∞ are the probabilities that a single
binding site is available initially at t=0 and at
steady state as t→∞, τu is the time constant of
antagonist unbinding from each site (k
( off-SR =
1/τu), and N is the number of binding sites
(Jones et al., 2001). C) Dose response curves
for the equilibrium antagonist occupancy in the
absence of GABA A(t=0) were fit to the
normalized hill equation I/Imax = 1 -1/[(KDN
SR/[SR-95531]) + 1].

Table 5.1 Summary of microscopic binding and unbinding rates and macroscopic affinity
for the competitive antagonist SR
SR-95531

Wild-type

KD-SR
140 nM

koff-SR
15.9 ± 0.8 s-1

D163A
R120A
R120A/D163A

110 nM
100 nM
100 nM

10.3 ± 0.7 s-1 *
11.5 ± 0.4 s-1 *
11.1 ± 0.9 s-1 *

kon-SR
1.2 ± 0.1 x 108 M1 -1
9.7 ± 0.6s x 107 M1 -1
1.2 ± 0.1s x 108 M1 -1
1.2 ± 0.1s x 108 M1 -1
s
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Figure 5.4A
4A depicts the results of the race experiment. The ratio of the peak
response of co-application
application to the peak response to a control application of GABA alone is
the result of the relative binding rates and concentrations of GABA and SR
SR-95531.
95531.
Using this ratio, termed Irace, the GABA binding rate can be computed as kon--GABA =
[SR95531] kon-SR/([GABA](1/Irace -1)) (Jones et al., 1998). Application of 3 mM GABA
and 300 µM SR-95531
95531 gave an Irace ratio of 0.41 ± 0.04 for the wild-type
type receptor, while
for the same concentrations Irace was reduced to 0.27 ± 0.01 for D163A, indicating a
slower binding rate for GABA. R120A and R120A/D163A receptors required
require a ten-fold
increase in the concentration of GABA (30 mM) co
co-applied with 300 µM
M SR-95531to
SR
obtain Irace values of 0.37 ± 0.03 and 0.31 ± 0.01 respectively, indicating even greater
reductions in the GABA binding rate than seen for D163A receptors. Indeed,
Indeed when these
Irace values are used to calculate kon-GABA, all of the mutants display significantly reduced
GABA binding rates (wild-type:
type: 7.4 ± 0.4 x 106 M-1s-1; D163A: 4.3 ± 0.5 x 106 M-1s-1;
R120A: 8.3 ± 0.8 x 105 M-1s-11; R120A/D163A: 5.0 ± 0.3 x 105 M-1s-1).

Figure 5.4 GABA binds more slowly to R120A,
D163A, and R120A/D163A. Race experiments of
either single alanine mutation or the double alanine
mutation of α1R120 and β2D163. For wild-type
wild
and
D163A receptors, currents evoked by simultaneous
application
ication of 3 mM GABA and 300 µM
µ SR-95531
(gray traces) were compared with the current evoked
by 3 mM GABA alone (black traces). For R120A and
R120A/D163A receptors, currents evoked by
simultaneous application of 30 mM GABA and 300
µM SR-95531 (gray traces)) were compared with the
current evoked by 30 mM GABA alone (black traces).
The two separate
parate applications are overlaid
overlai for each
receptor type, and the peak current evoked by coco
application is indicated with an arrow.
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When these numbers are subjected to double-mutant cycle analysis the resulting
coupling energy is effectively nil (-0.03 kcal/mol) (Table 5.2). Therefore, the mutations
R120A and D163A demonstrate additive effects on the GABA binding rate, strongly
indicative of an independent relationship. During the binding process, a salt-bridge
between these residues is either irrelevant or non-existent.
D163A and R120A accelerate the deactivation phase and display significant coupling
Each mutation causes significant changes in EC50 and the GABA binding rate;
therefore, it is evident that these residues are important for normal receptor function.
Examination of the macroscopic kinetics associated with GABA-evoked currents allowed
us to further uncover the impact each mutation has on receptor function. The kinetics of
macroscopic deactivation were characterized following a brief (3 ms) pulse of saturating
GABA, similar to that occurring during synaptic transmission (Figure 5.5). When the
deactivation time constants were extracted by fitting bi-exponential functions it was
observed that both single mutations significantly accelerated deactivation (wild-type: τw=
37.4 ± 5.5 ms; D163A: τw =15.6 ± 1.2 ms; R120A: τw = 3.5 ± 0.2 ms). Also, the double
mutant has the same deactivation time constant as R120A (R120A/D163A: τw = 3.5 ± 0.3
ms).
Double-mutant cycle analysis of the deactivation time constant revealed a
significant coupling energy of 0.5 kcal/mol (Table 5.2). This coupling energy suggests
that the contributions of β2D163 and α1R120 to the function of deactivation are not
independent, but rather that they interact during this phase. Deactivation has a very
complex nature and is comprised of numerous microscopic parameters, any of which
could be functionally coupled for β2D163 and α1R120. Changes in the deactivation phase
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are often associated withh changes in the microscopic unbinding rate, but other transitions
such as desensitization and channel closing can influence deactivation (Jones and
Westbrook, 1995). In order to investigate which of these microscopic transitions are
responsible for the coupling
oupling found in the deactivation time constants of β2D163 and
α1R120, I performed kinetic modeling as presented in a later section.

Figure 5.5 Deactivation is faster for R120A, D163A, and R120A/D163A. A) Macroscopic
current responses to a 3 ms pulse of saturating GABA (indicated by arrow). Each mutant
response is overlaid with the normalized wild
wild-type
type response (light gray). B) Summary of
weighted time constants (τw) for deactivation, generated from bi
bi-exponential
exponential fits of the
macroscopic currents. τw is computed as Σai ⋅ τi/Σai where ai and τi are the amplitude and time
constant of component i.

R120A suppresses desensitization
Further assessment of macroscopic data was conducted to explore the functional
effect of D163A and R120A, as well as to provide additional constraint for kinetic
modeling. Macroscopic desensitization was characterized during a long (500ms) pulse of
saturating GABA and the resulting desensitization phase was fit with a bi
bi-exponential
exponential
function from which a weighted ti
time constant was calculated (Figure 5.6).
6). Unlike
D163A, which had little effect on desensitization, R120A and R120A/D163A show a
visible reduction of desensitization
ensitization in raw traces (Figure 5.6A).
6A). Comparison of the
weighted τ values revealed R120A and R120A/D1
R120A/D163A
63A have significantly slower
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desensitization (wild-type: τw= 124 ± 10 ms; D163A: τw= 85 ± 6 ms; R120A: τw= 218 ±
23 ms; R120A/D163A: τw= 242 ± 33 ms) (Figure 5.
5.6B).
6B). The extent of desensitization
displayed by R120A and R120A/D163A is similarly reduced, un
unlike
like that of D163A,
which remains normal (wild--type:
type: 61 ± 2 %; D163A: 66 ± 2%; R120A: 53 ± 2%;
R120A/D163A: 39 ± 3%) (Figure 5.
5.6C).

Figure 5.6 Macroscopic desensitization during a long GABA pulse. A) Macroscopic current
responses to a 500 ms pulse of saturating GABA (indicated by a black bar above trace). Each
mutant response is overlaid with the normalized wild
wild-type
type response (light gray). (B and C)
Macroscopic currents for all receptor types were fit with a bi
bi-exponential
exponential equation, although
several responses for R120A and R120A/D163A only required a mono
mono-exponential
exponential during fits.
B) Summary of weighted time constants for desensitization. C) Summary of the extent of
desensitization after 500 ms.

Microscopic unbinding rates are strongly coupled for D163A and R120A
In order to determine the microscopic basis for the coupling of deactivation
effects causedd by D163A and R120A
R120A, a previously established 7-state
state kinetic model was
employed (Figure 5.8A)
A) (Jones and Westbrook, 1995; Wagner et al., 2004; Barberis
Barbe et
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al., 2007; Goldschen-Ohm
Ohm et al., 2010). This is a simplified model that recapitulates the
dominant features present in our macroscopic αβγ receptor data. It incorporates several
known features of GABAA receptor physiology including two binding ste
steps
ps (Bormann
and Clapham, 1985), multiple open states (Macdonald et al., 1989), and desensitized
states that can occur prior to ope
opening (Burkat et al., 2001). Also, an unlinked unbinding
step was utilized,, as was required by Goldschen
Goldschen-Ohm et al. (2010), which was necessary
to consistently simulate our experimental data.

Figure 5.7 Nonstationary variance analysis demonstrates that these mutations do not affect
the peak open probability (Po-max). Plots are of normalized mean current versus variance for
each
ach receptor type. Data points were fit with a parabola (black line) describing the single channel
conductance, Po-max,
max, and the number of channels present in each patch, none of which differed
between constructs (Student's t--test).

Prior to model optimization
optimization, nonstationary variance analysis was performed
(Figure 5.7)) (Sigworth, 1980). This assessment provides a measure of both the singlesingle
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channel conductance and maximal open probability (Po-max) of each receptor type, which
can be used to further constrain our modeling. None of the mutations altered
conductance (γ) at -60 mV or the Po-max (wild-type: γ = 32 ± 3 pS, Po-max = 0.59 ± 0.05;
D163A: γ = 33 ± 3 pS, Po-max = 0.55 ± 0.03; R120A: γ = 29 ± 3 pS, Po-max = 0.58 ± 0.06;
R120A/D163A: γ = 31 ± 3 pS, Po-max = 0.57 ± 0.04).
Current responses were simultaneously fit to 3 ms and 500 ms pulses of saturating
GABA for each receptor type. Initially, kon and Po-max were fixed to their experimentally
determined rates and the remaining parameters were set at the values previously reported
by Goldschen-Ohm et al. (2010). The model was then optimized under relatively tight
constraints until values for the opening and closing rates (α1, β1, α2, β2), as well as for
entry into D1, were obtained that gave consistently good fits to our data. These values
were identical for all constructs except for the opening rate of the dominant open state
(β2), which varied for each mutant to account for the slower rise times observed for the
mutant constructs during responses to saturating concentrations of GABA (Figure 5.9).
With these values constrained, a second optimization run was performed in which only
the unbinding rates (koff) and the rates for entering and leaving the doubly-bound
desensitized state (D2) were allowed to vary.
Our model quantitatively reproduced both wild-type and mutant data (Figure 5.8B
and C). The models for all three of our mutant constructs display slower binding and
faster unbinding of GABA relative to wild type. The models for R120A and
R120A/D163A also have slower entry and a more rapid exit from the doubly-bound
desensitized state (D2). When double-mutant cycle analysis is applied to the modeled
unbinding rates, coupling energies of 0.63 kcal/mol and 0.34 kcal/mol were calculated for
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koff1 and koff2, respectively (Table 5.2).
2). This indicates that coupled effects on unbinding
are the basis for the coupling seen in deactivation.

Figure 5.8 Kinetic modeling demonstrates that the effects of R120A, D163A, and
R120A/D163A can be similarly explained by faster unbinding rates, while differential
changes in desensitization occur. A) The 7-state
state markov model used to simulate GABA
responses (U, unbound; B, bound; O, open; D, desensitized). B) Rate constants used to
simultaneously simulate responses to short and long pulses of saturating GABA for wild-type,
wild
D163A, R120A, and R120A/D163A. The units are s-1 except for GABA binding steps, which are
M-1s-1. Only koff1, r1, d2, r2, and p are reported as ± standard error because they were allowed to
vary while the model was optimized. C) Current responses (black trace) and simulated responses
(red trace) to both short and long pulses of GABA are displayed for eeach
ach receptor type.
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Figure 5.9 The rise times during activation of GABA responses were measured from 1010
90% (baseline to peak). The activation rates (1/rise time) are plotted against GABA
concentration for each receptor type. A quality fit to the equation (Y = (Rmax * [GABA]) / (KD
+ [GABA]), where Rmax is the maximum activation rate) could only be achieved for wild-type
wild
and D163A.

Table 5.2 Summary of macroscopic and microscopic parameters used for doubledouble
mutant cycle analysis
Wild-type

D163A

R120A

R120A/D163A

|∆∆G
|∆∆ coupling|

EC50-GABA

65 µM

155 µM

920 µM

1600 µM

0.2 kcal/mol

Deactivation
τw

37.4 ms

15.6 ms *

3.5 ms *

3.5 ms *

0.5 kcal/mol

kon

7.4 x 106
M-1s-1

4.3 x 106
M-1s-1 *

8.3 x 105
M-1s-1 *

5.0 x 105
M-1s-1 *

0.03 kcal/mol

koff1

8 s-1 *

21 s-1 *

118 s-1 *

108 s-1 *

0.63 kcal/mol

koff2

271 s-1 *

485 s-1 *

1072 s-1 *

1079 s-1 *

0.34 kcal/mol
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Discussion
In order to build upon our understanding of the structure of the GABA binding
site and the functional significance of specific residues, I experimentally tested for the
existence of an interaction across the β/α interface between β2D163 and α1R120. It has
been demonstrated that mutating either residue alters the GABA concentration-response
curve, but whether either of these residues is involved in binding, gating, or
desensitization has been speculative. Here the residues were mutated to alanine and
double-mutant cycle analysis was applied to a variety of macroscopic and microscopic
parameters. Intriguingly, the residues appear to be completely independent when
considering the binding of GABA, but they are coupled when looking at the unbinding of
GABA. These results suggest that β2D163 and α1R120 do not interact in the unbound
state but form an interaction upon binding of GABA.
Evidence for a salt-bridge between β2D163 and α1R120
The effects on unbinding (koff1) for β2D163A and α1R120A were coupled with an
energy of 0.63 kcal/mol. This energy is slightly lower than, but consistent with energies
reported for confirmed surface salt-bridges in other proteins (0.86 kcal/mol and 0.95
kcal/mol) (Horovitz et al., 1990; Makhatadze et al., 2003). Low coupling energies are
expected because salt-bridges at solvent-exposed surfaces of a protein have significantly
weaker interactions compared to those buried in the hydrophobic interior. In the case of
β2D163 and α1R120, both are exposed to the aqueous environment, as demonstrated by
SCAM studies (Kloda and Czajkowski, 2007; Newell et al., 2004). Additionally, the
strength of a salt-bridge is influenced by the distance between the two residues. In
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homology models of the GABAA receptor, the nearest charged groups of β2D163 and
α1R120 are 3.6 angstroms apart (O’Mara et al., 2005), just within range for a salt-bridge.
Because the coupling energy between pairs of residues decreases with distance, the
weaker coupling energy measured in our experiments may be the consequence of this
distance. Therefore, the coupling energy observed with β2D163A and α1R120A likely
represents the loss of a salt-bridge.
It is also important to acknowledge additional interpretations to a significant
coupling energy. A predicted interaction may not exclusively be direct, but could result
from secondary interactions through a third side-chain, or could be the result of indirect
coupling due to broader structural rearrangements or conformational changes. Although
such possibilities cannot be ruled out, the presumed proximity of these residues suggests
a direct interaction.
A state-dependent interaction
Double-mutant cycle analysis indicates that an interaction between β2D163 and
α1R120 occurs during GABA unbinding, but not binding steps. A state-dependent
interaction is not difficult to envision, where these residues are coupled during the GABA
bound state, but not during the unbound state. In the unbound receptor no interaction is
present; when GABA binds, conformational changes occur that move the residues into
position to interact. Conformational rearrangements in response to GABA binding are
expected and repeatedly observed in studies of the binding pocket (Wagner and
Czajkowski, 2001; Newell et al., 2004; Muroi et al., 2006). β2D163 and other residues on
loop B of the β2 subunit have been shown to undergo rearrangements in response to
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receptor activation (Newell et al., 2004). This movement may underlie the statedependence of the interaction between β2D163 and α1R120.
State-dependent electrostatic interactions have previously been proposed in Cysloop receptors for residues coupled to the open state of the nAchR (Kash et al., 2003;
Gleitsman et al., 2008). Additionally, there is growing evidence in the field of protein
structure supporting the occurrence of salt-bridge switching, especially where networks
of charged residues are involved (Law and Lightstone, 2009). Transient salt-bridges may
underlie a mechanism governing conformational changes and stabilization of specific
receptor states. Regarding the residues studied here, both aspartic acid and arginine are
capable of forming dual interactions. Aspartic acid has two partial negative charges
distributed between the two oxygen atoms of the carboxylic group; and arginine has three
protonated nitrogens in its guanidinium group. No additional interactions for β2D163 and
α1R120 have been identified; however, a number of polar side-chains are found in close
proximity and either residue could also form hydrogen bonds with backbone amides and
carbonyls. The ability of each residue to form multiple electrostatic interactions or easily
switch partners may be crucial for normal receptor function. For example, mutation of
α1R120 to lysine, which only has a single amino group and exists in less flexible
geometries than arginine, causes dramatic shifts in EC50-GABA (Westh-Hansen et al.,
1999).
Discontinuity in functional effects
β2D163 and α1R120 appear to interact in the ligand-bound state; however, the
residues have asymmetric roles in desensitization. α1R120A displays greatly reduced
desensitization, while β2D163A displays desensitization indistinguishable from wild type.
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These residues, as part of a dynamic region, may stabilize the bound-closed receptor
without necessarily influencing the rate-limiting transitions of desensitization. The
additional effect observed for α1R120A may be the byproduct of its involvement in a
complex electrostatic network. It is highly probable that a simple binary interaction is
not occurring between β2D163 and α1R120. Several examples of an arginine residue
simultaneously making multiple interactions have been identified (Horovitz et al., 1990;
Borders et al., 1994). The multifaceted functional group of α1R120 may be participating
in an additional interaction that is separate from β2D163 and is critical to desensitization
transitions. Under these circumstances, an interaction between β2D163 and α1R120 could
exist in all bound receptor states, and still yield asymmetric effects when either is
mutated.
Functional role of β2D163-α1R120 interaction
The interaction between β2D163 and α1R120 appears to be highly conserved, not
just at the β/α interface where a negative and a positive residue are found at these
positions on every isoform of β and α subunits, but also at other inter-subunit interfaces.
Recently, a corresponding interaction at the γ/β interface was identified (Goldschen-Ohm
et al., 2010). This interaction consisted of a triad of charge residues (β2R117, γ2E178,
and γ2R43) forming a salt-bridge network. The additional arginine (γ2R43) is conserved
at the β/α interface (β2R28), but was not investigated in our current study. This
conserved motif may play an important role in establishing the architecture at each
subunit interface.
Goldschen-Ohm et al. (2010) reported that mutation at any of the residues in this
motif slowed deactivation following a GABA response. Not only is this significant
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because it demonstrates that a homologous interaction influences ligand binding at other
subunit interfaces, but it is also significant because disruption of this interaction at the γ/β
interface had the opposite effect of disruption of the corresponding interaction at the β/α
interface. Mutation of either β2D163 or α1R120 significantly increases the rate of
deactivation. This inter-subunit motif is likely involved in subunit positioning. In this
scenario, breaking of the interaction at the β/α interface may increase the distance
between the β and α subunits, speeding unbinding, whereas breaking the interaction at
the γ/β interface may reduce the distance between the β and α subunits at the β/α
interface, slowing unbinding.
The GABA binding site is involved in desensitization
This study is the first to offer in depth characterization of an α1R120 mutation. It
provides results that demonstrate α1R120 has important roles in GABA
binding/unbinding and desensitization. It should not be lost in this discussion that
α1R120 is the first residue at the GABA binding pocket that shows a dramatic influence
in desensitization (particularly the early, fast phase). Most work regarding
desensitization has focused on the transmembrane domains, and previous studies have
demonstrated a significant role for the pre-M1 region in transducing desensitization to the
pore surrounded by the TM2 domain (Bianchi and Macdonald, 2002). The identification
of α1R120 may provide a unique focus for studying how desensitization is transduced
from the GABA binding site.
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VI. β2F200: A NOVEL RESIDUE INVOLVED
IN GABA BINDING
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Introduction
The phenylalanine residue at position 200 on the β2 subunit is located amongst a
number of residues believed to contribute to the ligand binding pocket, and the
participation of aromatics, such as phenylalanine, in the ligand binding site is a conserved
theme for cys-loop receptors. However, there has been little evidence to date that β2F200
plays a significant role in binding. The crystallized structure of AChBP revealed a box of
aromatics surrounding the quaternary ammonium of a HEPES molecule (Brejc et al.,
2001). This motif has also been shown in
nAChR where many of the corresponding
aromatics have been implicated in
binding via site-directed mutagenesis and
photo-affinity labeling experiments
(Grutter and Changeux, 2001). β2F200
aligns with Y190 of the nAChR α
Figure 6.1 Homology model of the GABAA
receptor. A side view of the extracellular
domain at a single β/α inter-subunit interface.
β2F200 is depicted in green.

subunit, which is covalently labeled by
both radioactive agonists and antagonists
(Dennis et al., 1988; Abramson et al.,

1989; Grutter et al., 2000). This indirect evidence suggests β2F200 belongs to a similar
cluster of aromatic residues at the GABA binding site.
β2F200 is located on Loop C, which contributes to the GABA binding pocket
(Figure 6.1). Loop C does not have a regular secondary structure and appears to be an
extended coil or loop (Wagner and Czajkowski, 2001). This loop is believed to extend
over the site of GABA binding, perhaps occluding it. It is a dynamic region and
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movements have been shown to occur during GABA activation, which may cause the
loop to constrict over the bound GABA molecule (Wagner and Czajkowski, 2001).
Cysteine mutation of many Loop C residues, including F200, causes a significant
reduction of GABA affinity (Wagner and Czajkowski, 2001). Although this implicates
F200 in GABA binding, SCAM experiments found that reaction with MTS reagents did
not alter GABA responses for the N-terminal residues of Loop C (V199-T202). The
SCAM result suggested that F200 may not face the binding pocket and has cast doubt
over its role in GABA binding.
Despite the evidence that GABA currents were not affected by MTSEA-biotin
modification of F200C, F200 was investigated here as a potential binding pocket residue.
After mutating F200 to alanine, electrophysiological experiments were performed in
order to assess several macroscopic and microscopic parameters of receptor function.
F200A not only shifted the concentration-response curve to the right and accelerated
deactivation, but also caused a reduction in binding rates of GABA and SR-95531. This
data supports a previously unsuspected role in GABA binding for F200.
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Results
GABAA receptor function is sensitive to mutation at position 200 of the β2 subunit
Characterization of the alanine mutation at position 200 on β2 required expression
on a β2-GKER background. Subsequent concentration
concentration-response
response experiments revealed β2GKERF200A

caused a 130-fold
fold rightw
rightward shift in the curve (Figure 6.2).
). Such a change in

EC50 is often assumed to be the result of a reduction in GABA affinity, although a
reduction in channel gating could also contribute.

Figure 6.2 F200A shifts the GABA
concentration - response curve.
Responses to a series of GABA
concentrations were normalized for
the maximum evoked current. The
data was fit with a sigmoidal curve: Y
= Ymin + (Ymax – Ymin) /
(1+10^((LogEC50 – X)*HillSlope)).
α1β2-GKER (■)) has an EC50 of 6 µm.
F200A (▲) has an EC50 of 800 µm.

Mutational effects onn receptor gating can be investigated by observing the
macroscopic desensitization phase during a long pulse of GABA. The macroscopic
desensitization waveform is the result of the interaction of numerous microscopic
processes, including channel desensitization and resensitization, and channel opening and
closing. If any of these gating processes are altered, m
macroscopic
acroscopic desensitization should
reflect this. During a 500ms pulse of saturating GABA, the desensitization phase for
F200A showed no significant differences from α1β2-GKER for τfast, τslow, τw, or the percent
remaining when fit with a bi--exponential equation (Figure 6.3A, Table 6.1).
1).
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Figure 6.3 F200A drastically accelerates the rate of deactivation, does not alter
desensitization. A) Currents evoked from a 500 ms pulse of 30 mM GABA (bar) exhibit similar
desensitization. B) Currents evoked from a 3 ms pulse of 30 mM GABA (arrow) exhibit distinct
deactivation. Example responses are ensemble averages of 10
10-30 traces.

Examination of the macroscopic deactivation can also reveal changes in receptor
kinetics. The deactivation waveform is influenced by all of the same transitions that
govern the desensitization phase, with the addition of unbinding. In this case, since there
was no change in desensitization, any significant change in deactivation is likely to
represent a change in unbinding. Interestin
Interestingly, F200A accelerated the time-course
course of the
deactivation phase, increasing τw 10-fold (Figure 6.3B, Table 6.1),
1), indicative of an
increased unbinding rate.
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Table 6.1 Summary of parameters from exponential fits of deactivation and desensitization
Desensitization (500 ms, 30 mM GABA)
τ (ms)
τ (ms)
Receptor type
αβ

1 2-GKER

F200A

slow

9±3

87 ± 68

63 ± 17

13 ± 3

85 ± 58

70 ± 11

Deactivation (2-4 ms, 30 mM GABA)
τ (ms)
τ (ms)
Receptor type
fast

αβ

1 2-GKER

F200A

%τ

fast

slow

%τ

fast

fast

%
Remain

τ (ms)

n

18 ± 12

19 ± 11

22 ± 17

26

10 ± 7

20 ± 6

23 ± 14

26

%τ

τ (ms)

n

%τ

slow

slow

w

w

24 ± 10

281 ± 92

71 ± 8

29 ± 8

96 ± 36

9

2 ± 1*

40 ± 27*

94 ± 7*

6 ± 7*

4 ± 1*

10

Parameters are from bi-exponential fits to the desensitization and deactivation waveforms during
3 ms and 500 ms pulses of 30 mM GABA. All data are reported as mean ± standard deviation.
Significant differences between control and mutant parameters were calculated using Student’s ttest (* p < 0.05).

F200A reduces affinity for the competitive antagonist SR-95531
Dozens of compounds have been shown to bind in the GABA binding pocket.
Exploring the effect F200A has on the interaction between any of these compounds and
the GABAA receptor could clarify the role of F200. The microscopic kinetics of the
competitive antagonist SR-95531 were directly measured with a series of antagonist
unbinding experiments. In this protocol, outside-out patches were pre-equilibrated in SR95531 before jumping into a GABA solution that does not contain SR-95531. Figure
6.4A illustrates the response to GABA following pre-equilibration in SR-95531 for α1β2GKER

and F200A. The pre-equilibration alters the GABA response because receptors

bound with SR-95531 during pre-equilibration must first unbind SR-95531 before GABA
can bind and activate the receptor. This produces a slowed rise phase mediated by the
interplay between antagonist unbinding and agonist binding.
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Figure 6.4 F200A causes faster unbinding of SR
SR-95531. The koff for SR-95531
SR
was
determined for each receptor type by examining the current response to GABA following a prepre
equilibration in SR-95531.
95531. A) Current responses to a control pulse of 30 mM GABA (black
traces) are overlaid with current responses following pre
pre-equilibration in 3 µM
M SR-95531
SR
(α1β295531 (F200A) (red traces). B) Plots show the deconvolution of GABAGABA
GKER) or 100 µM SR-95531
evoked currents with SR-95531
95531 pre
pre-equilibration from those without pre-equilibration.
equilibration. Curve fits
(red lines) reveal the time course
se of SR
SR-95531 unbinding.

The current response after pre
pre-equilibration
equilibration relies not only on antagonist
unbinding kinetics, but also on the gating and desensitization kinetics of the GABAA
receptor. In order to extract the microscopic antagonist unbinding w
waveform
aveform from this
data, the GABA only current must be deconvolved from the pre
pre-equilibrated
equilibrated current
(Figure 6.4B).
4B). When these processes are separated by deconvolution, the time course of
unbinding is revealed. The deconvolved curve for unbinding was fit by the equation A(t)
= [P∞ - (P∞ - P0)e-t/τu]N , where P0 and P∞ are the probabilities of being available initially
(at t =0) and at steady state (as t →∞), N is the number of antagonist binding sites, and τu
is the time constant of antagonist unbinding at each site (Jones et al.,1998). The yy
intercept represents the fraction of receptors unbound after pre
pre-equilibration
equilibration and
immediately available for activation by GABA. The microscopic unbinding rate (k
( off-SR)
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is equal to 1/τu. F200A significantly increases the unbinding rate of SR-95531, from 7.3
± 3 s-1 for α1β2-GKER to 116 ± 32 s-1 for F200A.
The microscopic affinity constant (KD-SR) was obtained by plotting the fraction of
receptors unbound at t=0 versus antagonist concentration (Figure 6.5). The antagonist
unbinding experiment was repeated with pre-equilibration at several different SR-95531
concentrations. This plot was fit with a normalized Hill equation for antagonist. F200A
caused a 7-fold increase in KD-SR.
Figure 6.5 F200A shifts the SR95531 inhibition curve rightward.
Dose response curves for the
equilibrium antagonist occupancy in
the absence of GABA were fit to the
normalized hill equation I/Imax = 1 –
1/[(KD-SR/[SR-95531])N + 1]. α1β2-GKER
(■, black curve) has a KD of 47 nM.
F200A (▲, red curve) has a KD of 330
nM.

The microscopic binding rate was directly calculated based on these results using
the equation kon = koff/KD. For α1β2-GKER kon = 1.6 ± 0.6 x108 M-1s-1. For F200A kon = 3.5
± 0.9 x 108 M-1s-1. The microscopic binding rate for SR-95531 was increased 2 fold by
F200A.
F200A decreases the microscopic binding rate of GABA 20-fold
The effect F200A has on EC50-GABA and the rate of deactivation suggests that the
mutation alters GABA affinity. If this is the case, a considerable reduction in the GABA
binding rate is also expected. The GABA binding rate was measured in experiments
where the competitive antagonist SR-95531 and GABA were simultaneously applied.
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The current response was diminished relative to a
control application of GABA, because SR-95531
competes with GABA for receptor binding sites.
This response depends on the relative
concentration and binding rate of each molecule.
All of these parameters are known, except for the
GABA binding rate, which can then be calculated.
F200A elicited a response of 50% when 300µM
Figure 6.6 F200A decreases the
GABA binding rate 20-fold. Race
experiments are depicted for α1β2GKER and F200A. For both receptor
types,
currents
evoked
by
simultaneous application of 30 mM
GABA and 300 µM SR-95531 (red
traces) were compared with the
current evoked by 30 mM GABA
alone (black traces).
The two
separate applications are overlayed
for each receptor type.

SR-95531 and 30 mM GABA were co-applied.
This value is termed Irace and is related to the
binding rates as follows: kon-GABA = [SR95531] konSR/([GABA](1/Irace

-1)) (Jones et al., 1998). The

GABA binding rate was computed for α1β2-GKER as
2.7 ± 0.7 x 107 M-1s-1, while F200A kon-GABA equals
1.3 ± 0.7 x 106 M-1s-1.

Potential interactions of F200 with arginines in the GABA binding pocket
F200A has a very similar profile to receptors containing the mutations α1R67A
and β2R207A, which were previously examined in the Wagner lab. The effects on EC50,
deactivation and GABA binding rates are strikingly similar both qualitatively and
quantitatively. These residues may simultaneously play independent roles in GABA
binding; alternatively, GABA binding may require an interaction between F200 and one
of the arginine residues. The aromatic phenylalanine and the positively charged arginine
are able to interact via a cation-π bond. In order to evaluate if either α1R67 or β2R207
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interacts with β2F200, double mutants for F200A with R67A, and F200A with R207A
were expressed. If there is a specific interaction between the two wild type residues, a
mutation of just one of the residues to alanine eliminates the bond. Mutating the other
residue would have no additional effect since the bond is already eliminated; therefore,
the double mutant should have very similar kinetics to either single mutant. If the
mutations are additive, or completely disruptive, the residues have interactions that are
not solely dependent on one another and are functionally independent.
Figure 6.7 F200A and R67A
have additive effects on the
GABA concentration–response
curve. Responses to a series of
GABA
concentrations
were
normalized for the maximum
evoked current. The data was fit
with a sigmoidal curve: Y = Ymin
+
(Ymax
–
Ymin)
/
(1+10^((LogEC50 -X)*HillSlope)).
α1β2-GKER (■) has an EC50 of 6µm.
F200A (X) has an EC50 of 800 µm.
R67A (□) has an EC50 of 1mM.
The EC50 for F200A/R67A ()
could not be determined.

When β2-gkerF200A was expressed with α1R67A, GABA activation was only
observed for concentrations of GABA greater than 1mM. A complete concentrationresponse curve was not established because the maximum GABA concentration used for
recording did not saturate the GABA response. The partial curve is shown in Figure 6.7.
Although an EC50 value cannot be determined for the double mutant, the curve is clearly
shifted rightward.
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In order to demonstrate that the disruption was specific to the GABA binding site,
GABA responses were compared to responses to propofol, which has a different binding
site. Unlike wild-type
type receptors, in which GABA evoked currents have slightly larger
amplitudes
plitudes than those evoked by propofol, the double mutant exhibited a robust propofol
current and a diminished GABA response (Figure 6.8).
8). The severe disruption of GABA
activation in the double mutant F200A/R67A indicates that these two residues have
additive
tive effects and therefore independently contribute to the stabilization the GABA
interaction.

Figure 6.8 R67/F200A reduces the potency of GABA relative to propofol. For both wildwild
type and R67A/F200A receptors, current responses were evoked by a 750 ms aapplication
pplication of 30
mM GABA (black trace, black bar), followed by a 15 second washout and a 750 ms application
of 300 µM
M propofol (red trace, red bar).

A full concentration-response
response curve was obtained for F200A
F200A/R207A
R207A (Figure
6.9A).
). The double mutant has an EC50-GABA of 1mM. Although this is higher than either
single, the mutations do not appear to be additive. Double mutant cycle analysis of the
EC50 values provided a quantitative assessment of the coupling exhibited by F200 and
R207 (Figure 6.9B). A significant
ificant coupling energy of 11.6 kcal/mol was revealed,
revealed
suggesting they interact.
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Figure 6.9 F200A and R207A display significant coupling. A) Responses to a series of
GABA concentrations were normalized for the maximum evoked current. The data was fit with a
sgmoidal curve: Y = Ymin + (Ymax – Ymin) / (1+10^((LogEC50 – X)*HillSlope)). α1β2-GKER
(■), F200A (X), R207A (□),
), F200A.R207A ((∆).
). B) Double mutant cycle analysis was performed
on the EC50 values. ∆∆G
G = RT ln(mutant EC50/wild-type EC50), ∆∆G1 = -2.0
2.0 kcal/mol; ∆∆G2 = 2.9 kcal/mol; and ∆∆G1,2 = -3.3
3.3 kcal/mol. ∆∆Gcoupling = ∆∆G1,2 – (∆∆G1 + ∆∆G2).
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Discussion
F200, a novel residue critical to the GABA binding pocket
Determining the structural significance of a given residue and its relationship to
receptor function is rarely an easy process, especially without the aid of a high-resolution
three-dimensional structure. However, a detailed kinetic analysis of GABAA receptor
function following a mutation can provide novel information about a particular residue.
In order to clarify the biophysical role of β2F200 this study aimed to distinguish which
processes are affected by its mutation and to quantify those effects. It was previously
shown that mutation of F200 increases EC50, and it is located at a region (Loop C) that is
particularly critical for GABA binding. Presented here is the first evidence of its
influence on macroscopic deactivation of GABA, the microscopic binding rate of GABA,
and the binding kinetics of SR-95531.
When observing macroscopic currents evoked by GABA it became quickly
apparent that the alanine mutation at position 200 had a major effect. The major shift in
EC50-GABA and acceleration of deactivation suggests a large reduction in GABA affinity.
The EC50 parameter is largely influenced by the KD, and will be shifted rightward by
increased GABA unbinding rates or decreased GABA binding rates. Although a
reduction in channel opening could also shift the EC50 it has been shown that a reduction
of 90% would be necessary to cause more than a ten-fold shift (Colquhoun 1998). It is
highly unlikely that this is the case. Maximum currents from each patch have a large
variability, but a reduction of that magnitude would lead to current amplitudes that would
be too small to analyze. In addition, the change in deactivation was accompanied by no
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change in macroscopic desensitization. This suggests there are no gating changes and
that the accelerated deactivation is caused by faster unbinding.
Ultimately, the measurement of the GABA binding rate provides the most direct
evidence to the effect of F200A. Indeed, there was a large reduction in the GABA
binding rate, confirming the importance of this residue in mediating the ligand-receptor
complex. The significant increase in unbinding and decrease in binding rates suggests
that the mutation destabilizes the bound state with GABA, which results in a dramatic
reduction in GABA affinity. F200 fits the profile of a residue that could directly interact
with GABA.
Relating structure to function
The phenylalanine side-chain consists of a short one-carbon chain connected to an
aromatic ring making the side-chain large and hydrophobic. Also, the aromatic ring has
an electronegative potential on its planar surfaces, which is capable of forming
electrostatic interactions via a cation-π bond. Such a bond could potentially stabilize the
amine group of GABA. A cation-π interaction with GABA has previously been proposed
for β2Y97 (Padgett et al., 2007), yet has never been considered for F200.
F200 has not previously been postulated to directly interact with GABA because
SCAM surveys of the region found no detectable effect on GABA responses when
β2F200C or nearby residues were reacted with a MTS reagent (Wagner and Czajkowski,
2001). It was concluded that this region was likely buried in the hydrophobic core of the
subunit, but it was also acknowledged that these residues may react with a MTS reagent
without affecting the GABA response. The evidence here demonstrates that F200 plays a
critical role at the binding site. F200 could be situated in a location that was not
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accessible to the large MTSEA-biotin reagent used in the SCAM study, but is still
accessible to the smaller GABA molecule. Alternatively, F200 could be inaccessible to
both and mediate GABA binding indirectly.
A cation-π interaction could also occur between F200 and a positively charged
residue in the GABA binding pocket. Analysis of two potential candidates (R67 and
R207) only revealed a strong coupling energy between F200 and R207. The mutantcycle analysis result from the two alanine mutations of these residues cannot distinguish
if coupling arises from a direct or indirect interaction. The use of a side-chain swap was
able to substantiate a direct interaction. The constructs F200R, and F200R/R207F were
generated as part of this investigation, but were later fully analyzed during a separate
project in the Wagner lab. Not only are the effects of F200R/R207F non-additive, but the
double mutant partially rescues the effects of either single swap (P. Tran, unpublished
data). This result may represent a restoration of a direct interaction between the residues
at position 200 and 207. The significance of the R207-F200 interaction could be
necessary to position F200 in the optimal position to stabilize GABA. Considering that
the single F200A mutant is even more disruptive than R207A, F200 is likely located in
closer proximity to the site of GABA binding. F200 may participate with the previously
identified Y97 to stabilize the amino group of GABA.
The structural significance for F200, and its interaction with R207, may
alternately be rooted in its location and influence on Loop C. This dynamic loop is
expected to move during GABA binding. Comparison of crystal structures of AChBP
bound with ligand or bound with HEPES indicated that loop C contracts around the
ligand (Celie et al., 2004). In the GABAA receptor, movement of Loop C during receptor
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activation was demonstrated using SCAM experiments (Wagner and Czajkowski, 2001).
Furthermore, the mobility of loop C appears to be greater in the resting state of the
GABAA receptor than in the activated state. Experiments using a pair of cysteine
mutations at K196 of Loop C and the closely situated E153 found that disulfide formation
was restricted in the presence of GABA or pentobarbital (Venkatachalan and Czajkowski,
2008). The flexibility of Loop C when the GABAA receptor is unbound may allow the
ligand access to the binding pocket, and the closure of Loop C during ligand binding may
stabilize the ligand-receptor complex as well as be integral to receptor activation. The
mutation of F200 could disrupt Loop C’s mobility and interfere with the region’s ability
to facilitate binding. The results here clearly demonstrate that F200A leaves the binding
pocket in a non-ideal conformation that not only decreases the ability of GABA to bind,
but also allows GABA to fall off more easily. Whether F200 directly interacts with
GABA or supports the local architecture of the binding site, the dramatic effects F200A
have on GABA kinetics suggest it is close to a critical position that mediates GABA
binding.
F200 stabilizes the bound state for SR-95531
The changes in SR-95531 affinity also bear significance because the structure of
SR-95531 contains a GABA-like region and binds in the GABA binding pocket. F200A
predominantly altered KD-SR by increasing the koff-SR. The significant increase in the koff
(while kon is relatively unchanged) suggests that aromatic side-chain is necessary for
stabilizing the SR-95531-receptor complex, but does not contribute a direct interaction
that facilitates binding. Conceivably, F200 provides stability via hydrophobic
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interactions between the aromatic ring of F200 and the ring structure of SR-95531. This
of course would require that the F200 side-chain contribute to the binding pocket.
Mutation of F200 to alanine specifically alters GABA binding and unbinding
processes, without affecting desensitization. Furthermore it significantly alters the free
energy of the bound state of the receptor with SR-95531, indicating F200 is in the
binding pocket. The precise role of F200 is not yet clear, but these results make it a
candidate for one of the primary residues that directly mediate GABA binding.
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VII. IDENTIFICATION OF AMINO ACID RESIDUES
THAT DICTATE SELECTIVE ASSEMBLY OF
GABAA RECEPTOR SUBUNITS
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Introduction
Depending on their subunit composition, GABAA receptors exhibit distinct
pharmacological and electrophysiological properties; however, the extent of receptor
diversity in vivo is unknown. Although nineteen GABAA receptor subunits have been
identified, providing the potential to form a vast number of distinct receptors, only a
limited number of combinations (approximately 25) are thought to exist in vivo
(Mizielinska et al., 2006). Considering the fact that multiple subunits from different
classes (i.e. α, β, γ, δ) and within the same class (i.e. α1, α2, α3) can be expressed at the
same time in a single neuron, additional mechanisms must exist to control receptor
biogenesis (Whiting, 2003). In order to have a clear picture of receptor diversity and the
subsequent pharmacology, it is important to understand the processes that dictate subunit
assembly.
The determinants for assembly of α, β, and γ subunits have been explored most
frequently because receptors containing α, β, and γ subunits are the most common in the
brain (Mohler, 2006). Several independent studies have established these subunits are
capable of forming receptors composed of two α, two β, and one γ subunit, or two α and
three β subunits (Tretter et al., 1997, Farrar et al., 1999, Bauman et al., 2001; Bauman et
al., 2002). In addition, these studies have suggested the specific subunit arrangements of
these receptors are βαβαγ or βαβαβ, forming five inter-subunit interfaces: β(+)/α(-),
α(+)/β(-), β(+)/α(-), α(+)/γ or β(-), and γ or β(+)/β(-) (Figure 7.1).
The key to understanding receptor diversity is the identification of the assembly
signals that govern which subunits prefer to be positioned next to each other. This has
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Figure 7.1 GABAA receptor subunit arrangement. Depicted is a GABAA receptor composed
of 2α1, 2β2, and a fifth subunit that is either γ2 or β2. The (+) and (-)) face of each subunit is
labeled. These subunits have been shown to assemble with a counter
counter-clockwise
clockwise orientation of β,
α, β, α, and γ/β.. The GABA binding si
sites, at the β/α interfaces, are indicated by black triangles,
and the location of the mutations studied here are denoted by a star.

been studied using fluorescent microscopy to follow surface expression of epitope tagged
subunits, as well as with co-immun
immunoprecipitation experiments and western blots. The
determinants of specific oligomerization patterns have been exploited using these
techniques along with the comparison
omparison of vvarious
arious subunit isoforms, construction of
chimeric isoforms, and site-directed
directed mutagenesis. A region required for assembly of all
GABAA receptor subunits was identified in the cytoplasmic loop between transmembrane
domains 3 and 4 (Lo et al., 2008)
2008);; however, the majority of assembly signals have been
found in the N-terminal
terminal extracellular domain. Many of these signals lie at or near
predicted subunit interfaces..
At the α(+)/γ(-) inter--subunit interface the sequences α1(80-100) and γ2(91-104)
have been shown to mediate assembly of these subunits, and a direct interaction
eraction has been
demonstrated between these specific regions (Klausberger et al., 2000; Klausberger et al.,
2001). On the other face of the γ2 subunit, residues 83-90 have been shown to mediate
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assembly of γ2 with β3 subunits (Klausberger et al., 2000). At the equivalent interface in
receptors containing β2, the epilepsy mutation γ2R43Q has been shown to disrupt
assembly of functional receptors (Hales et al., 2005). Residues 58-67 on α1 are important
for assembly with a β subunit at the GABA binding site interface (Taylor et al., 2000;
Bollan et al., 2003). At the α(+)/β(-) inter-subunit interface (non-GABA binding) β3(7689) and α1A108 are critical for assembly of functional receptors (Ehya et al., 2003; SartoJackson et al., 2006).
The assembly signals for β2 have not been as well studied. Several mutations on
β2 at the GABA binding site abolish GABAA receptor function (Amin and Weiss, 1993),
suggesting a role for such residues in assembly of the β(+)/α(-) inter-subunit interface;
however it has not been verified if these mutations alter translation of the subunit, the
subunits fail to completely oligomerize, fully assembled receptors are not properly
transported to the cell surface, or if non-functional receptors reach the cell surface.
Therefore it is not known if such β2 residues dictate assembly with specific subunits.
The scanning alanine mutagenesis study presented in Chapter III identified three
mutations of the β2 subunit (Y97A, Y157A, and D163A) that lead to interesting
expression profiles and may play an important role in assembly of GABAA receptors.
Mutation of these residues allowed the assembly of functional receptors when expressed
with α1 and γ2, but not when expressed with α1 only. αβ receptors are believed to contain
three β subunits, while αβγ receptors only contain two (the third being replaced by γ).
Because of this a β(+)/β(-) interface exists in αβ receptors, but a γ(+)/β(-) interface exists
in αβγ receptors. Our result suggests these residues are required in assembly of the
β(+)/β(-) interface, critical for GABAA receptors composed of βαβαβ subunits, but not
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βαβαγ subunits. Here we show that the lack of functional expression for these mutants is
the consequence of reduced surface expression. Furthermore, the corresponding residues
on the γ2 subunit were mutated and characterized. The results suggest that β2Y97 is a
general determinant of assembly for multiple classes of GABAA receptor subunits, while
β2Y157 has a specific role in assembly of the β(+)/β(-) interface.
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Results
Electrophysiological expression profiles are altered by mutations at the (+) face of β2
The residues Y97, Y157, and D163 of the β2 subunit were mutated to alanine, and
the mutant constructs were separately transfected with the α1 construct in HEK-293 cells.
GABA application (10-100 mM) to outside-out patches pulled from these cells rarely
evoked currents (Table 7.1, Figure 7.2). Propofol (100 µM – 300 µM) also failed to
evoke current with patches pulled from these cells (Figure 7.3). Interestingly, when these
mutants were expressed with α1 and γ2, GABA application consistently evoked a current
response (Table 7.1, Figure 7.2). However, the average maximum current amplitude
during GABA application to each patch was diminished for all of the mutants. These
results indicate that the three β mutations do not prevent oligomerization of the β(+)/α(-)
interface, which is the site of GABA binding. These mutations may be interfering with
assembly of a β(+)/β(-) interface, but are not relevant to a γ(+)/β(-) interface.
Table 7.1 Electrophysiology characterization of the expression of β2 mutants
Receptor Type

Total patches

Patches with GABA
current*

% Patches with
current

α1β2
α1β2D163A
α1β2Y97A
α1β2Y157A
α1β2γ2
α1β2D163Aγ2
α1β2Y97Aγ2
α1β2Y157Aγ2

5
13
8
16
12
10
9
12

5
2
0
3
12
9
8
12

100
15
0
19
100
90
89
100

Average
Maximum
Amplitude (pA)†
88
6
0
11
580
164
39
175

* Only responses >5 pA were counted. † Measured as the peak current response of a single
pulse of GABA (10 – 100 mM). Average includes only patches with current.
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Figure 7.2
GABA
responses from αβ and
αβγ receptors containing
mutant
β2
subunits.
Currents evoked from 500
ms application of GABA
(black bar) to patches
pulled from HEK-293
HEK
cells
expressing control and
mutant receptor types.
GABA
concentrations
between 30 mM and 100
mM
were
used
as
indicated.

Figure 7.3
Propofol
responses from αβ and
αβγ receptors containing
con
mutant
β2
subunits.
Currents evoked from 500
ms application of 300 µM
propofol (black bar) to
patches pulled from HEKHEK
293
cells
expressing
control
and
mutant
receptor types.
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Surface Expression of α1β2-Halo receptors and α1β2-Haloγ2 receptors
In order to clarify the impact each mutation has on GABAA receptor biogenesis
and function, the cell surface expression of receptors was assessed. This was
accomplished using a Halotag® (Promega), which has been commercially designed with
various fluorescent ligands that are highly specific and are either cell permeable or cell
impermeable. A Halotag®-β2 fusion protein was generated, placing the Halotag®
between the 4th and 5th amino acids of the mature protein sequence. Although the
Halotag® is a large domain (400 amino acids), it has previously been shown that the
Halotag® is well tolerated and does not interfere with assembly, cell surface trafficking,
or GABAA receptor pharmacology or function when incorporated into the γ2 subunit (Los
and Wood, 2007). Whether the Halotag® influences receptor function when placed on
the β2 subunit was not known; therefore, electrophysiological expression experiments
were repeated for each receptor type. Responses of outside-out patches with α1β2-Haloγ2
receptors to GABA application were indistinguishable from α1β2γ2 receptors when
comparing current amplitude and EC50-GABA. The Halotag® did not alter the expression
profile of β2-HaloY97A or β2-HaloY157A; however, β2-HaloD163A could no longer respond
to GABA when expressed with α1 and γ2. This prevented further characterization of the
effects of D163A on receptor assembly.
Labeling and fluorescent microscopy was performed using HEK-293 cells that
had been plated onto poly-lysine coated glass coverslips and incubated in 24-well plates.
40-50 hours post-transfection, the cells were labeled first with the cell-impermeant
AlexaFluor 488 ligand (494ex/517em). This ligand bound the receptors on the cell
surface. This was followed by labeling with the cell-permeant TMR ligand
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(555ex/585em), which labeled the intracellular Halo-tagged subunits. The surface and
intracellular labels were simultaneously observed using confocal microscopy and laser
excitation at 494 (for the Alexafluor ligand) and 555 (for the TMR ligand). α1β2-Halo and
α1β2-Haloγ2 receptors exhibited pronounced surface labeling (Figure 7.4). Expression of
β2-Halo alone exhibited no surface labeling. This is in agreement with previous reports of
the β2 subunit not being able to reach the cell surface without being assembled into a
pentamer with α subunits and/or other isoforms (Connolly et al., 1996).
In agreement with the electrophysiology results, both β2-HaloY97A and β2HaloY157A

exhibited only intracellular labeling when expressed with α1 (Figure 7.4A).

These results were quantitatively assessed by comparing the percent surface label for
individual cells. Both α1β2-HaloY97A and α1β2-HaloY157A demonstrated significantly
reduced surface expression compared to wild-type α1β2-Halo, and were indistinguishable
from the negative control (Figure 7.4C). The reduction in surface expression confirmed
that the lack of electrophysiological responses for αβ receptors with these mutations was
the consequence of disrupted assembly or trafficking.
When expressed with α1 and γ2, β2-HaloY157A demonstrated visible surface
expression (Figure 7.4B). Quantitatively, the percent surface expression was not
different from the positive control (Figure 7.4D). β2-HaloY97A, however, exhibited
reduced surface labeling when expressed with α1 and γ2 (Figure 7.4B). Quantitatively,
the percent surface expression for α1β2-HaloY97Aγ2 was significantly reduced compared to
wild-type receptors, but was still greater than the negative control (Figure 7.4D).
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Figure 7.4 Surface expression of α1β2-Halo receptors and α1β2-Haloγ2 receptors. (A and B)
Expression of Halo-tagged
tagged subunits was determined by labeling with a cell-impermeable
cell
Alexafluor 488 ligand, followed by labeling with a cell
cell-permeable
permeable TMR ligand 60 hours after
transfection, and images were collected by confocal microscopy. The scale bars represent 40 µm.
A) Combinations of α1 and mutant β2-Halo subunits were examined. Rows labeled Y97A and
Y157A represent expression of α1β2-HaloY97A and α1β2-HaloY157A receptors, respectively. B)
Combination of α1, mutant β22-Halo, and γ2 subunits were examined. Rows labeled Y97A’ and
Y157A’ represent expression of α1β2-HaloY97Aγ2 and α1β2-HaloY157Aγ2 receptors, respectively.
(C and D) The percent of surface expression was quantified by measuring the mean intensity of
the AlexaFluor 488 label relative to the total of AlexaFluor 488 label plus TMR label mean
intensity of individual cells. The percent surface expression is normalized to C) the wild-type
wild
α1β2-Halo receptor or D) the wild
wild-type α1β2-Haloγ2 receptor. * Denotes significant difference
di
when
compared to the wild-type
type receptor and † denotes significant difference when compared to the
negative control (β2-Halo only), Student’s tt-test
test (p < 0.05). Panels B, C, and D continued on next
page.

116

117
Mutation and expression of conserved residues on the γ2 subunit
Both β2Y97 and β2Y157 are highly conserved across cys-loop LGIC subunits, and
the corresponding residues on the γ2 subunit were also investigated to determine if the
same signals that are important to assembly of the β(+)/β(-) inter-subunit interface are
also important for the γ(+)/β(-) inter-subunit interface. β2Y97 aligns with γ2F112, and
β2Y157 aligns with γ2Y172. A Halotag®-γ2 fusion protein was generated in order to
specifically assess the incorporation of this subunit when the corresponding mutations are
added. Expression of either γ2-HaloF112A or γ2-HaloY172A with α1 and β2 yielded GABA
evoked currents that appear to be the result of receptors containing α, β, and γ subunits,
not αβ receptors (Figure 7.5). These currents demonstrated a peak response to 100 µM
GABA that was 60% of the peak response to 100 mM GABA, similar to α1β2γ2 receptors
which have an EC50-GABA of 70 µM and also demonstrate a 60% response of 100 µM to
100 mM GABA. This suggests the γ2-Halo subunit is being incorporated into these
receptors because receptors composed of α1β2, which have an EC50-GABA of 6 µM, show a
90% response with 100 µM GABA compared to 100 mM GABA. Also, the average
maximum current amplitude was 200 pA for α1β2γ2-Halo receptors, which is much larger
than normally seen for α1β2 receptors. Both characteristics support that these responses
are from γ2 containing receptors. When these mutants were combined with the
corresponding mutation of the β2 residue, neither α1β2Y97Aγ2-HaloF112A nor
α1β2Y157Aγ2-HaloY172A exhibit current response to GABA.
To test whether the γ2 mutations reduced the surface expression of receptors,
labeling and fluorescence microscopy was performed. α1β2γ2-HaloY172A demonstrated
substantial γ2-Halo localization at the cell surface (Figure 7.6A). The percent surface
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expression for α1β2γ2-HaloY172A was equivalent to the wild-type α1β2γ2-Halo receptors
(Figure 7.6B). α1β2γ2-HaloF112A exhibited only 75% surface expression compared to
wild-type receptors (Figure 7.6A and B). Combination of the γ2-HaloF112A subunit with
β2Y97A completely abolished surface expression, whereas combination of γ2-Halo
Y172A
2
and β2Y157A still exhibited the equivalent surface expression as wild
wild-type
type receptors.
The corresponding
esponding residues γ2F112 and β2Y97 appear to both play a role in assembly,
where as β2Y157 plays a unique role in assembly of the β(+)/β(-) interface compared to
the corresponding residue γ2Y172 at the γ(+)/β(-) interface.

Figure 7.5 GABA concentration responses for α1β2γ2-Halo mutant receptors. Currents evoked
by applications of 100 mM GABA (black trace) and 100 µM
M GABA (red trace) to the same patch
are overlaid for each receptor type. A prolonged pulse of GABA was applied in all cases (black
bar). Example responses are ensemble averages of 10
10-30 traces.
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Figure 7.6 Surface expression of α1β2γ2-Halo receptors. A) Expression of Halo-tagged
tagged subunits
was determined by labeling with a cell
cell-impermeable
impermeable Alexafluor 488 ligand, followed by labeling
with a cell-permeable
permeable TMR ligand 60 hours after transfection, and images were collected by
confocal microscopy. Row labe
label F112A represents expression of α1β2γ2-HaloF112A, Y97A/F112A
represents α1β2Y97Aγ2-HaloF112A, Y172A represents α1β2γ2-HaloY172A, and Y157A/Y172A
represents α1β2Y157Aγ2-HaloY172A receptors. B) The percent of surface expression was
quantified by measuring the mean intensity of the AlexaFluor 488 label relative to the total of
AlexaFluor 488 label plus TMR label mean intensity of individual cells. The percent surface
expression is normalized to the wild
wild-type α1β2-Halo receptor. * Denotes significant difference
differ
when compared to the wild-type
type receptor and † denotes significant difference between α1β2γ2F112A and α1β2Y97Aγ2-HaloF112A, Student’s tt-test
test (p < 0.05). Panel B continued on next
Halo
page.

120

121

Discussion
Specific assembly signals between subunits exist that are critical for accurate
receptor biogenesis. Three residues on the β2 subunit (Y97, Y157, and D163) that may
serve as assembly signals were investigated. When each of these residues was mutated to
alanine, the β2 mutant subunit was unable to form functional receptors with α1. However,
when the β2 mutants were expressed with α1 and γ2, robust GABA evoked currents were
observed. This implies that these residues are not obligatory for cell-surface expression
of GABAA receptors, but influence specific receptor stoichiometries. These mutations
allow the successful assembly of the β(+)/α(-) interface (as it is necessary for GABA
binding) and likely interfere with the assembly of a third β subunit, which forms the
β(+)/β(-) interface (Figure 7.1).
Y97 and Y157 have distinct influences over surface expression of αβ and αβγ receptors
The absence of surface labeling when β2Y97A or β2Y157A is expressed with α1
verifies that the lack of current responses to GABA or propofol is the result of disrupted
assembly or trafficking of the receptor. The disruption of assembly by these residues
would likely manifest at the β(+)/α(-) interface (the GABA-binding site) or the β(+)/β(-)
interface, where they are present. A β(+)/β(-) interface only exists when expressing α and
β, not when expressing α, β, and γ (Tretter et al., 1997, Farrar et al., 1999, Bauman et al.,
2001; Bauman et al., 2002). Therefore, if such residues mediate assembly specifically of
the β(+)/β(-) interface, cell-surface expression would be impaired when expressing α and
β, but not when expressing α, β, and γ. This is exactly what we observed.
When β2Y97A or β2Y157A is expressed with α1 and γ2, both allow the functional
expression of receptors that can elicit GABA-evoked currents. Also, both demonstrate a
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reduction in the average current amplitude relative to wild-type receptors. Based on
surface labeling results, the current reduction associated with β2Y97A when expressed
with α1 and γ2 is in part the consequence of decreased receptors at the cell membrane.
The sensitivity of assembly to mutation at β2Y97 suggests that the residue plays a general
role in assembly of receptors. While it is absolutely disruptive to formation of αβ
receptors, it partially disrupts the formation αβγ receptors. Therefore, β2Y97 is not only
important for assembly of a β(+)/β(-) interface, because no β(+)/β(-) interface exists in
the αβγ receptor. The complete failure of assembly for αβ receptors may not be due
solely to disruption of a β(+)/β(-) interface, but may arise due to an accumulation of
disturbances at three interfaces, the β(+)/β(-) interface and both β(+)/α(-) interfaces. Such
disturbances of inter-subunit interactions could lead to an altered quaternary subunit
positioning, making incorporation of the last subunit more fragile.
There is no reduction in surface labeling when β2Y157A is expressed with α1 and
γ2, suggesting the observed reduction in current amplitude is attributable to a change in
receptor function. The large shift in the concentration-response curve, with an EC50-GABA
greater than 30 mM, supports that this is the result of decreased GABA affinity. The
normal expression of α1β2-HaloY157Aγ2 indicates that β2Y157 is specifically important for
the assembly of a β(+)/β(-) interface, not a γ(+)/β(-) interface. β2Y157 is located at the
(+) face of the β2 subunit and not expected to directly influence the γ(+)/β(-) interface.
β2Y157 is also at the β(+)/α(-), but the results here suggests that it is not a major
assembly determinant of this interface.
Although the electrophysiological expression profile for β2D163A containing
receptors was similar to the other mutations, changes in surface expression could not be
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verified because β2D163A does not tolerate the Halotag®. The reduction in average
maximum current amplitude for α1β2D163Aγ2 receptors compared to α1β2γ2 receptors
may reflect a partial disruption of assembly, even in the presence of γ2. Unlike β2Y157A,
β2D163A caused only a mild 2-fold shift in the EC50-GABA (Chapter III). Also, β2D163A
does not change the single channel conductance of αβγ receptors when on a β2-GKER
background (Chapter V). Therefore the reduced current amplitude is more likely
because of fewer receptors being present at the cell surface. In this regard, β2D163A
appears more similar to β2Y97A than β2Y157A.
Conserved residues do not always have completely conserved roles
These residues are highly conserved amongst human GABAA receptor subunits:
α1(F100, Y160), β2(Y97, Y157), and γ2(F112, Y172) (Chapter I, Figure 1.7) . Whether
either residue serves as an assembly signal for the γ2 subunit at the γ(+)/β(-) interface was
investigated with the mutations γ2F112A and γ2Y172A. Although a GABA-evoked
response was observed when expressing γ2-HaloF112A with β2 and α1, reduced surface
labeling indicates incorporation of γ2 was hindered. The observed current reduction may
result from only αβ receptors, which have a lower single channel conductance than αβγ
receptors (Fisher and Macdonald, 1997; Jahn et al., 1997), being properly assembled and
trafficked to the cell surface, or may be the result of a reduced number of αβγ receptors at
the cell surface. It therefore appears β2Y97 and γ2F112 have a conserved role in
assembly. The reduced surface expression of β2Y97A in αβ receptors and γ2F112A in
αβγ receptors suggest this residue is required for oligomerization of a β(+)/β(-) interface,
as well as a γ(+)/β(-) interface. The lack of surface labeling when α1β2Y97Aγ2-HaloF112A
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is expressed further suggests a compounding effect when the mutation is present at three
interfaces.
Uniquely, β2Y157A only disrupts the assembly of the β(+)/β(-) interface.
Mutation of the corresponding residue γ2Y172 does not alter surface expression. When
γ2-HaloY172A is expressed with β2 and α1 or with β2Y157A and α1, γ2-HaloY172A reaches
the cell membrane as robustly as wild-type γ2-Halo. γ2 does not reach the cell membrane
by itself when expressed with α and β subunits (Connolly et al., 1999; Los and Woods,
2007); therefore, it is assumed that surface expression of γ2 represents intact receptors at
the cell surface. γ2Y172A is able to restore the surface expression of receptors with
β2Y157A, suggesting γ2Y172 does not play the same role in assembly as β2Y157.
The absence of GABA current when expressing β2Y157A, γ2-HaloY172A, and α1
subunits further demonstrates the significance of this tyrosine for GABA mediated
events. Additionally, the receptor function of the β2Y157A/γ2Y172A could be explored
using alternative receptor agonists, such as propofol. Although it was a very small sample
size, the lack of current may suggest a severe disruption of GABA binding site, or
receptor activation overall.
Residues at the subunit interface influence assembly
Residues that are positioned on a subunit so they face an inter-subunit interface
are in an ideal location to mediate protein-protein interactions. SCAM experiments
demonstrated that β2Y97, β2Y157, and β2D163 face the aqueous environment at the
GABA binding pocket (Boileau et al., 1999; Newell et al., 2004).

These residues may

mediate assembly via direct interaction with residues on the opposing subunit. There
could be an electrostatic interaction for D163 (perhaps with R120 or another positive
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residue during the oligomerization process). The aromatics may provide stabilization at
an inter-subunit interface by stacking with other aromatic side-chains in a π-π interaction,
or by participating in a cation-π interaction with a basic residue (Burley and Petsko,
1985). Also, the hydrophobic nature of the aromatic side-chains could influence
assembly because covering them with the adjacent subunit will minimize the number of
hydrophobic side-chains exposed to water and stabilize the protein conformation.
A final word on GABAA receptor stoichiometry
The ability of γ2 to rescue (at least to some extent) the mutations of β2D163,
β2Y97, and β2Y157 adds strong support to the stoichiometry of αβ receptors consisting of
two α and three β subunits. The stoichiometry of αβ receptors is particularly relevant to
the work of our lab, which has relied heavily on the expression of αβ receptors. Although
several studies have concluded this same ratio, there still exists debate about whether a
third α might actually complete the pentamer. This originates from studies expressing αβ concatenated subunits that found only the addition of a single α subunit could result in
GABA activated channels (Im et al., 1995; Boileau et al., 2005). This expression may be
a consequence of the tandem construct, which relied on 10x-glutamine linkers between
the two subunits. The positioning between the tandem subunits may not represent the
normal orientation, and allow for unnatural receptor combinations to form that are
otherwise unfavorable. It is clear that two α and two β subunits are required to form the
GABA binding sites, but it is not intuitively obvious what the fifth subunit must be. The
ability of γ to replace the fifth subunit and rescue assembly of these mutants is much
more plausible if the fifth subunit is β. In this scenario, the γ containing receptor now has
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only two mutated β subunits instead of three. Considering the dosage-like dependence of
β2Y97A expression, two α and three β is most likely the correct stoichiometry.
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VIII. Conclusion
The studies performed in this dissertation were designed to refine our knowledge
about the architecture of the GABA binding pocket of the GABAA receptor. A clear
description of the structure, including inter-subunit interactions, intra-subunit interactions
and interactions with GABA that exist in the binding pocket, is necessary to build a
complete biophysical description of receptor function. This was not an entirely novel
endeavor. For decades researchers have been trying to elucidate the structures of LGICs
and identify the locations of binding for various ligands. A variety of site-directed
mutagenesis studies and photoaffinity labeling studies had firmly placed the GABA
binding pocket at the inter-subunit interfaces between β and α subunits. A picture of the
GABA binding pocket started to evolve with the help of secondary structure prediction
from the protein sequence. Homology modeling of the GABAA receptor has provided a
putative three-dimensional framework of the binding pocket. Also, SCAM studies have
surveyed the six discontinuous loops surrounding the binding pocket. The SCAM studies
have indicated specific residues that face the binding pocket, the secondary structure of
each loop, and the mobility of each loop.
Despite these advances, the specific interactions that mediate GABA binding are
unknown. Using the earlier evidence as a guide and starting point, our lab set out to
identify important structural components of the binding pocket. A multitude of results
from this dissertation provide evidence of specific side-chain interactions, and they
suggest certain residues that are most likely to contribute to the binding of GABA and
stabilization of the bound state.
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Homing in on the location of GABA in the binding pocket
SCAM results suggested which residues were likely to face the aqueous space that
exists at the inter-subunit
subunit interface and represents the GABA binding pocket (Figure
8.1A) (Boileau
Boileau et al., 1999; Wagner et al., 2001; Boileau et al., 2002
2002; Newell et al.,
2003;Newell et al., 2004; Kloda et al., 22007).. These results provided major evidence of
the potential players in the binding pocket, but offered little indication of the precise
location of GABA when bound. More discerning SCAM experiments, conducted as part
of the same studies, identified seve
several
ral residues that were protected from MTS reaction by
GABA and SR-95531
95531 compounds (Figure 8.1B). Protection may result from steric block
of the MTS reagent by the ligand or from a conformational rearrangement induced by the
ligand, but these two compounds are not expected to induce the same conformational
changes. The residues that are protected by both compounds begin to paint a clearer
picture of the sub-region
region of the pocket that facilitates binding. The residues are

Figure 8.1 SCAM experiments provi
provided
ded an outline of the GABA binding pocket. A) The
residues on each of the six discontinuous loops of the binding pocket that were found to face the
aqueous environment are shown with space
space-filled
filled van der Waals surfaces. B) The residues that
are protected from MTS reaction by both GABA and SR
SR-95531
95531 are depicted and are clustered
closer to the center of the binding pocket. C) Two residues ((α1R120 and α1D63) were not
protected by GABA, but were protected by the larger SR
SR-95531
95531 compound, suggesting their
positions
sitions are removed from the site of a bound GABA compound.
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concentrated "behind" Loop C, and mainly include contributions from Loop A, Loop B,
Loop C, and Loop E. This sub-region was a primary focus of the studies here, and it is
interesting to consider how mutations of these residues have diverse effects on receptor
kinetics.
Mutational studies have examined most of these residues previously in a variety
of expression systems, with various subunit combinations, and with various side-chain
substitutions. This dissertation presented a methodical characterization of these residues
and included a detailed analysis of macroscopic kinetics of the deactivation and
desensitization phases. Additionally, β2R207, α1R132 and α1R67 were analyzed in a
parallel study performed in the Wagner lab. The most dramatic shifts in the EC50 were
observed for β2Y97A, β2F200A, β2T202A, β2Y205A, β2R207A, α1R67A (Figure 8.2A).
The large shifts were consistent with previous concentration-response studies (Amin and
Weiss, 1993; Boileau et al., 2002; Wagner and Czajkowski, 2001; Holden and
Czajkowski, 2002). A dramatic change in EC50 does not imply a direct interaction with
GABA; furthermore, it may not even be the result of changes in GABA affinity, as
decreases in efficacy can also shift the concentration-response curve rightward. In order
to separate residues that mediate GABA affinity from those that may provide a link in the
transduction mechanism of the receptor, it was necessary to characterize how each
residue impacts specific aspects of receptor function (binding, unbinding, desensitization,
or channel opening).
At minimum, examination of the effect each mutation had on the macroscopic
kinetics of the GABAA receptor was able to identify residues that influence macroscopic
desensitization and/or deactivation kinetics. In cases where macroscopic desensitization
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was unaltered, but macroscopic deactivation was affected, we can infer changes in the
unbinding rate of GABA. In figure 8.2B, mutations that cause the most sign
significant
ificant
acceleration of the macroscopic deactivation phase are shown. It is not possible to make
a distinction from a residue that directly interacts with GABA or one that indirectly
influences the stability of a bound GABA compound. However, it is expec
expected
ted that
mutation of a residue that directly interacts with GABA will adversely affect the stability
of the ligand-receptor
receptor complex. Therefore, these residues are all plausible candidates for
mediating GABA binding.
Mutation of a residue that directly interacts with GABA is also expected to
decrease the GABA binding rate. Although fewer residues have been examined, the two
residues with the most dramatic reduction in GABA binding when mutated to alanine are
β2F200 and α1R67 (Figure 8.2C). Both residues are located in the middle of the binding
pocket, where the majority of the residues that severely impact EC50-GABA and
deactivation are also found.

Figure 8.2 Alanine mutation of only a few residues caused dramatic shifts in EC50-GABA, the
rate of deactivation, and the microscopic GABA binding rate. Therefore the bound GABA
compound is most likely located at this precise region of the binding pocket. A) The largest
increases in EC50-GABA were observed for α1R67A, β2Y97A, β2Y157A, β2F200A, and β2R207A.
B) The most significant accelerations of the deactivation rate were observed for α1R67A,
α1R120A, β2Y157A, β2F200A, and β2R207A. C) The most significant decreases in kon-GABA were
observed for α1R67A and β2F200A.
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The mechanisms of desensitization are also poorly understood. Although all
evidence suggests desensitization primarily occurs only when GABA is bound (Burkat et
al., 2001), no direct connection between a binding pocket residue and desensitization had
been identified previously. Here, two residues (α1R120 and α1L128) altered the
desensitization phase when mutated to alanine. Both are located on Loop E, which may
represent a structural element that is critical to desensitization.
It is difficult with the methodology employed by our lab to confirm direct
interactions between binding pocket residues and a ligand. However, supporting
information is beginning to accumulate, and the array of effects observed when each
residue is mutated allows us to distinguish the residues that have a critical role in the
binding or stabilization of GABA from those residues that are less influential. The subregion of the binding pocket containing β2F200 and α1R67 offers the most plausible
location for GABA. Several residues in the vicinity of β2F200 and α1R67 have similar
and significant effects on EC50 and deactivation, plus they were protected by GABA
during SCAM experiments.
Residues that demonstrate a mild effect on EC50 and deactivation when mutated to
alanine, are less likely to mediate GABA binding. For example, α1R120A shifts EC50
and deactivation, but to a lesser extent than β2F200A or α1R67. α1R120 is not expected
to directly interact with GABA and appropriately it is found in a more distal region of
the binding pocket. Residues such as α1R120 and α1D63 were not protected by GABA
during SCAM experiments, further indicating they are removed the site of the bound
GABA compound (Figure 8.1C). Remember, these interpretations are being made in the
context of the current homology model, which itself is not certain. It is reasonable to
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believe that the position of each loop represents a close approximation (Cromer et al.,
2002), but we must acknowledge that our interpretations are not yet definitive.
Model for GABA binding
GABA has a zwitter-ion chemistry with a positive amino end and a negative
carboxy end. Its binding is likely to be mediated via electrostatic interactions at each
end. I hypothesize that GABA forms direct interactions with β2F200 and α1R67 (Figure
8.3). These two residues show the largest reductions in binding rate and the largest
increases in the deactivation rate or unbinding rate. The hypothesized binding of GABA
entails β2F200 forming a cation-π bond with the amino end of GABA and α1R67 forming
an electrostatic interaction with the negative carboxy end. β2Y97 may also contribute to
the stabilization of the amino end of GABA. Detailed analysis of the chemistry of β2Y97
using unnatural amino-acid substitution demonstrated that it participates in a cation-π
bond (Padgett et al., 2007). Here we observed that mutation of β2Y97 to alanine
caused an increase in EC50-GABA, accelerated deactivation, and decreased the GABA
binding rate (recently measured in our lab: P. Tran, unpublished data). Although these
effects are similar to the effects caused by β2F200A or α1R67, the effects of β2Y97A are
not as severe. Therefore the working model places GABA closest to β2F200 and α1R67.
The arginine at position 104 of the GABA ρ1 subunit, which aligns with α1R67,
was proposed to stabilize the carboxylate group of GABA in homomeric GABAA
receptors (Harrison and Lummis, 2006). They observed greater than a 10,000-fold shift
in EC50 values ρ1R104 was mutated to alanine or to glutamic acid. Also, docking
simulations indicated that the carboxylate group of GABA was located close to ρ1R104
(Harrison and Lummis, 2006).
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Figure 8.3 Putative GABA binding interactions
interactions.. The evidence presented in this dissertation
suggests the positively charged amino group of GABA interacts with the electronegative center of
the aromatic F200 side-chain.
chain. The negatively charged carboxy group of GABA likely interacts
with a positively charged side--chain in the GABA binding
ing pocket. R67 is the most plausible
candidate. Additional residues may stabilize the bound GABA compound, for instance Y97 may
participate with F200 to stabilize the amino group of GABA.

β2F200 is one of several aromatic residues that form the aroma
aromatic
tic box located at
the heart of the binding pocket. This structural motif is conserved in all cys
cys--loop
receptors and aromatic residues have been shown to stabilize binding of the ligand via
cation-π interactions in nACh receptors ((Grutter and Changeux, 2001; Celie et al., 2004),
glycine receptors (Pless et al., 2008), and 55-HT3A receptors (Beene et al., 2002). In
GABAA receptors, potential cation
cation-π interactions involving β2Y97, β2Y157, or β2Y205
have been examined, and of these, oonly β2Y97 was found to participate in a cation-π
cation
interaction (Padgett et al., 2007). Analysis of a cation
cation-π interaction with β2F200 is
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necessary to strengthen our interpretation that the amino end of GABA and β2F200
directly interact.
This model suggests a mechanism for the conformational changes that will induce
receptor activation. By binding to regions on both subunits, structural elements from
both sides will be pulled slightly closer together than the unbound conformation. GABA
binding requires energy to overcome the activation barrier (Jones et al., 1998) and the
energy required for binding may be because of such movements. In turn these
movements will propagate through the receptor and induce activation. Countless studies
have detailed ligand-induced structural rearrangements at the binding pocket of cys-loop
receptors and the GABAA receptor specifically. Comparison of crystallized AChBP
unbound and bound to nicotinic agonists (Celie et al., 2004; Hansen et al., 2005), as well
as changes in the pattern of fluorescence for site-specific labels in the GABAA receptor
binding pocket support a general closure of the pocket during binding (Muroi et al.,
2006). Agonist binding in our model is expected to displace Loops C and D as β2F200
and α1R67, respectively, interact with GABA. Loop A may also contract towards GABA
if β2Y97 favorably interacts with the amino group of GABA.
The presumed movement of Loop C has a variety of experimental evidence. In
crystallized AChBP structures, the agonist induced a rigid body motion of Loop C,
closing over the binding site cavity (Hansen et al., 2005). Using a chimera that contained
the AChBP fused to the transmembrane domain of a 5-HT3A receptor, these structural
changes in the AChBP were shown experimentally to be linked with receptor activation
(Bouzat et al., 2004). Indeed this chimera was functionally gated by acetylcholine,
demonstrating that the agonist-induced changes in the AChBP can promote receptor
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activation. In the GABAA receptor, movement of Loop C during receptor activation was
demonstrated using SCAM experiments (Wagner et al., 2001). Furthermore, the mobility
of loop C appears to be greater in the resting state of the GABAA receptor than in the
activated state (Venkatachalan and Czajkowski, 2008).
The transmission mechanism of the conformational changes, which occur at the
binding site and are propagated over 50 Å to the channel pore where gating occurs, has
not been elucidated. The movements of Loop C and D, which would accompany GABA
binding with β2F200 and α1R67, are likely to move the β-sheets towards the binding
pocket or cause them to twist. Movement of the β-sheets, which make up a large portion
of the extracellular domain, may provide transduction of the binding signal to the
interface of the extracellular and transmembrane domains, where electrostatic interactions
between extracellular loops and the linker region of the second and third transmembrane
have been identified as a critical structural element for the activation process (Kash et al.,
2003). Also, these motions may be transmitted through the pre-M1 linker, which
connects the extracellular and transmembrane domains (Lee and Sine, 2005).
Additionally, a change in the quaternary subunit positioning may occur as GABA
binds in a location that bridges the β and α subunits. Rotation of the extracellular
domains of each subunit would also allow transmission to the transmembrane domains
(Unwin, 2005). The importance of the quaternary subunit positioning of each interface
was supported by the destabilizing effect of α1R120A and β2D163A. Presumably these
mutations disrupt an inter-subunit salt-bridge interaction, and thereby alter the subunit
positioning at the inter-subunit interface. Both mutations destabilize the ligand-receptor
complex and decrease the rate of macroscopic receptor activation. Furthermore,
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disrupting an inter-subunit interaction at the γ(+)/β(-) was also shown to have effects that
propagate to the GABA binding site (Goldschen-Ohm et al., 2010). A change in the
quaternary subunit positioning around the pentameric ion channel could explain how
mutational effects are propagated to other interfaces.
Subunit composition influences the GABA binding pocket
During the course of these studies several surprising differences between αβ
receptors and αβγ receptors were observed. The αβ receptor consists of two α’s and three
β’s , while the αβγ receptor replaces one of the β’s with a γ, consisting of two α’s, two
β’s, and one γ subunit. There is no doubt that αβ and αβγ receptors exhibit distinct
kinetics. Differences in EC50, single channel conductance, deactivation rates, and
desensitization have been well documented (Haas and Macdonald, 1999; Boileau et al.,
2003). Still, little work has focused on the potential structural differences at the
β(+)/α(-) inter-subunit interfaces between αβ receptors and αβγ receptors.
When α1R120 was mutated to alanine and expressed in αβ receptors, a 10-fold
EC50 increase, 10-fold deactivation increase, and only a subtle decrease in the GABA
binding rate was observed. However, when in αβγ receptors, α1R120A caused a 10-fold
decrease in the binding rate in addition to increasing the EC50 and the rate of deactivation.
Why does α1R120A cause a nearly equal and opposite effect on unbinding and binding in
αβγ receptors, but disproportionately alters unbinding in αβ receptors? The five subunits
are arranged pseudosymmetrically around the ion pore, and it is likely that the subunit
positioning is not identical when γ versus β is incorporated. Not only does this
incorporation affect the γ(+)/β(-) or β(+)/β(-) interface, but it also manifests at the other
interfaces. The effect that the γ(+)/β(-) or β(+)/β(-) interface can have at distant
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interfaces has been observed previously. For example, a site-specific fluorescent study
found different fluorescent patterns in the GABA binding pocket during receptor
activation when examining αβ and αβγ receptors (Muroi et al., 2006). Also, mutations at
the γ(+)/β(-) interface have been shown to alter receptor properties directly associated
with the β(+)/α(-) interface, such the GABA unbinding rate (Goldschen-Ohm et al.,
2010). Differences between αβ receptors and αβγ receptors that occur at the GABA
binding pocket will need to be defined as more detailed structural descriptions of the
GABA binding pocket develop. Certain side-chain interactions may be present in one
receptor type, but not in another receptor type.
The mutations that disrupted assembly also had unique characteristics in αβ
receptors versus αβγ receptors. The data were consistent with a gradual disruption by
β2Y97A and γ2F112A, and a specific β(+)/β(-) interface disruption by β2Y157A.
Considering that incorporation of a γ2 subunit can influence the β(+)/α(-) interface,
alternative interpretations may exist. In αβ receptors, β2Y157A may disrupt the β(+)/α(-)
interface as well as the β(+)/β(-) interface. However, incorporation of a γ2 subunit may
alter the quaternary subunit positioning at the β(+)/α(-) interface, and mask any effect that
β2Y157A had on assembly of the β(+)/α(-) interface in αβ receptors. It raises questions
about whether the results are contingent on the differences at β(+)/α(-) interface with αβ
and αβγ receptors. In any study, the subtle indirect effects of subunit composition can
influence results and must be considered.
Continued study of the GABA binding pocket
The strength of the rapid-ligand application and electrophysiological techniques
utilized in this dissertation lie in their ability to precisely characterize the effect each
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mutation has on specific receptor functions (i.e. ligand binding, ligand unbinding,
desensitization, or gating). In order to establish the role a given residue plays in receptor
function it is necessary to distinguish the various processes. The techniques also allowed
a detailed comparison of two residues, which made it possible to establish those that
participate in similar receptor processes and made it possible to determine if two sidechains are functionally coupled. The GABA binding pocket has not been completely
characterized and it would be beneficial to continue this work. Complete microscopic
kinetics for all of the residues that lie in the sub-region of the binding pocket near β2F200
and α1R67 are needed to clarify which residues influence GABA binding the most. Many
alanine mutations investigated here proved too disruptive to complete the kinetic
analysis. More conservative mutations for β2Y157, β2T202, β2Y205 may be required to
perform all of the electrophysiological experiments. Additionally, the continued use of
these techniques to explore interactions between pairs of side-chains will aid refinement
of the binding pocket structure.
Although a plethora of new information has been garnered by examining
mutational effects on receptor kinetics, there are limitations to how accurately we can
relate structure to function. One concern is that the structural consequence of a given
mutation is not always predictable. Structural changes are not necessarily limited to just
the side-chain being mutated, and if a mutation produces a larger disruption of an entire
structural element or introduces new interactions, our interpretations will be confounded.
Another challenge when relying on electrophysiology to study the GABA binding pocket
is the inability to experimentally confirm direct interactions with a ligand. At best we are

139
able to identify residues that fit a set of characteristics that would occur for a direct
interaction, but unfortunately this will not rule out an indirect interaction.
A number of alternative strategies could be employed in conjunction with our
current methods for characterizing receptor kinetics that would further clarify how each
residue of the binding pocket contributes to the overall structure. In order to explore
side-chain chemistry, unnatural amino acid substitution could be used. In particular this
should be used to complete analysis of β2F200 and verify if it participates in a cation-π
interaction. Unnatural residue substitution can also be used to explore interactions with
the peptide backbone. Unnatural substitution with hydroxy acids produces an ester
backbone linkage that does not contain a hydrogen bond donating amide group
(Gleitsman et al., 2008).
In order to exploit how agonists interact in the GABA binding pocket it may also
be prudent to compare various GABA analogues that have variations in length and charge
distribution. Whether mutations that disrupt GABA binding differentially affect related
analogues could be insightful. Lastly, mutational studies could be guided by considering
different subunit isoforms that have varying binding properties. The use of chimeric
subunits, which have small segments of the binding pocket replaced with the sequence of
another isoform, could help identify the regions that contribute to differences in binding
properties between two subunit isoforms. A similar strategy was used by Schmeiden et
al. (1993) to identify a specific sequence that varies in glycine receptors and GABAA
receptors and is critical for distinguishing glycine and GABA agonists. Continued use of
such experiments could help identify the specific residues that are required for GABA
binding.
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Outside of the electrophysiology realm, the biggest breakthroughs in GABAA
receptor structure are likely to come from crystallization experiments that actually offer
atomic level resolution of the binding pocket architecture. Recently, bacterial pentameric
ligand gated ion channels were discovered and the structures of two channels were
determined at better than 3.3 Å resolution (Hilf and Dutzler, 2008; Bocquet et al., 2009;
Hilf and Dutzler, 2009). Although the prokaryotic receptors have extensive sequence
divergence from the eukaryotic LGICs, they share a conserved extracellular ligand
binding domain and four transmembrane domains (Tasneem et al., 2005). The two
prokaryotic receptors represent the first complete pentameric channel complexes ever
crystallized, a step forward from the crystallization of the soluble AChBP (Brejc et al.,
2001), or a single nACh receptor subunit (Dellisanti et al., 2007). The newly determined
structures confirm many of the conserved features identified in the AChBP and the single
nACh receptor subunit, such as the extracellular domain β-sheets and the orientation of
the transmembrane domains. These bacterial homologues, however, are not activated by
the same ligands as the cys-loop receptors. Without crystallization of a GABAA receptor
bound to GABA it will be difficult to confirm all of the interpretations spawned by
electrophysiological studies.
Our description of the architecture of the GABA binding pocket is continually
improving. By distinguishing residues that potentially mediate GABA binding from
those that influence gating, and identifying the residues with the strongest influence on
GABA binding we move closer to understanding how the GABAA receptor interacts with
the agonist. Additional structural studies in the field will hopefully provide comparison
for our interpretations, and the structural model will be refined as information about the
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binding pocket accumulates. These advances shed some light onto the biomolecular
function of the receptor, which is able to transduce the binding of a neurotransmitter to
the gating of an ion channel.

142

BIBLIOGRAPHY
Abramson SN, Li Y, Culver P and Taylor P (1989) An analog of lophotoxin reacts
covalently with Tyr190 in the alpha-subunit of the nicotinic acetylcholine receptor. J Biol
Chem 264:12666-12672.
Amin J (1999) A single hydrophobic residue confers barbiturate sensitivity to gammaaminobutyric acid type C receptor. Mol Pharmacol 55:411-23.
Amin J and Weiss DS (1993) GABAA receptor needs two homologous domains of the ßsubunit for activation by GABA but not by pentobarbital. Nature 366:565-569.
Bali M and Akabas MH (2004) Defining the propofol binding site location on the
GABAA receptor. Mol Pharmacol 65:68-76.
Barberis A, Mozrzymas JW, Ortinski PI and Vicini S (2007) Desensitization and binding
properties determine distinct alpha1beta2gamma2 and alpha3beta2gamma2 GABA(A)
receptor-channel kinetic behavior. Eur J Neurosci 25:2726-2740.
Baumann SW, Baur R and Sigel E (2002) Forced subunit assembly in
alpha1beta2gamma2 GABAA receptors. Insight into the absolute arrangement. J Biol
Chem 277:46020-5.
Baumann SW, Baur R and Sigel E (2001) Subunit arrangement of gamma-aminobutyric
acid type A receptors. J Biol Chem 276:36275-80.
Beene DL, Brandt GS, Zhong W, Zacharias NM, Lester HA and Dougherty DA (2002)
Cation-pi interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic
acetylcholine receptors: the anomalous binding properties of nicotine. Biochemistry
41:10262-10269.
Benke D, Fritschy JM, Trzeciak A, Bannwarth W and Mohler H (1994) Distribution,
prevalence, and drug binding profile of gamma-aminobutyric acid type A receptor
subtypes differing in the beta-subunit variant. J Biol Chem 269:27100-27107.
Bianchi MT and Macdonald RL (2002) Slow phases of GABA(A) receptor
desensitization: structural determinants and possible relevance for synaptic function. J
Physiol (Lond ) 544:3-18.
Bocquet N, Nury H, Baaden M, Le Poupon C, Changeux JP, Delarue M and Corringer PJ
(2009) X-ray structure of a pentameric ligand-gated ion channel in an apparently open
conformation. Nature 457:111-114.
Boileau AJ, Evers AR, Davis AF and Czajkowski C (1999) Mapping the agonist binding
site of the GABAA receptor: evidence for a ß-strand. Journal of Neuroscience 19:48744854.

143
Boileau AJ, Kucken AM, Evers AR and Czajkowski C (1998) Molecular dissection of
benzodiazepine binding and allosteric coupling using chimeric gamma-aminobutyric
acidA receptor subunits. Mol Pharmacol 53:295-303.
Boileau AJ, Li T, Benkwitz C, Czajkowski C and Pearce RA (2003) Effects of gamma2S
subunit incorporation on GABAA receptor macroscopic kinetics. Neuropharmacology
44:1003-1012.
Boileau AJ, Newell JG and Czajkowski C (2002) GABA(A) receptor beta 2 Tyr97 and
Leu99 line the GABA-binding site. Insights into mechanisms of agonist and antagonist
actions. J Biol Chem 277:2931-7.
Boileau AJ, Pearce RA and Czajkowski C (2005) Tandem subunits effectively constrain
GABAA receptor stoichiometry and recapitulate receptor kinetics but are insensitive to
GABAA receptor-associated protein. J Neurosci 25:11219-11230.
Boileau AJ, Pearce RA and Czajkowski C (2005) Tandem subunits effectively constrain
GABAA receptor stoichiometry and recapitulate receptor kinetics but are insensitive to
GABAA receptor-associated protein. J Neurosci 25:11219-11230.
Bollan K, King D, Robertson LA, Brown K, Taylor PM, Moss SJ and Connolly CN
(2003) GABA(A) receptor composition is determined by distinct assembly signals within
alpha and beta subunits. J Biol Chem 278:4747-55.
Borders CL,Jr, Broadwater JA, Bekeny PA, Salmon JE, Lee AS, Eldridge AM and Pett
VB (1994) A structural role for arginine in proteins: multiple hydrogen bonds to
backbone carbonyl oxygens. Protein Sci 3:541-548.
Bormann J and Clapham DE (1985) gamma-Aminobutyric acid receptor channels in
adrenal chromaffin cells: a patch-clamp study. Proc Natl Acad Sci U S A 82:2168-2172.
Bouzat C, Gumilar F, Spitzmaul G, Wang HL, Rayes D, Hansen SB, Taylor P and Sine
SM (2004) Coupling of agonist binding to channel gating in an ACh-binding protein
linked to an ion channel. Nature 430:896-900.
Bracamontes JR and Steinbach JH (2008) Multiple modes for conferring surface
expression of homomeric beta1 GABAA receptors. J Biol Chem 283:26128-26136.
Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB and
Sixma TK (2001) Crystal structure of an ACh-binding protein reveals the ligand-binding
domain of nicotinic receptors. Nature 411:269-76.
Burkat PM, Yang J and Gingrich KJ (2001) Dominant gating governing transient
GABA(A) receptor activity: a first latency and Po/o analysis. J Neurosci 21:7026-36.

144
Burley SK and Petsko GA (1985) Aromatic-aromatic interaction: a mechanism of protein
structure stabilization. Science 229:23-28.
Casalotti SO, Stephenson FA and Barnard EA (1986) Separate subunits for agonist and
benzodiazepine binding in the gamma-aminobutyric acidA receptor oligomer. J Biol
Chem 261:15013-15016.
Celie PH, van Rossum-Fikkert SE, van Dijk WJ, Brejc K, Smit AB and Sixma TK (2004)
Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in
AChBP crystal structures. Neuron 41:907-914.
Chang Y, Wang R, Barot S and Weiss DS (1996) Stoichiometry of a recombinant
GABAA receptor. J Neurosci 16:5415-5424.
Colquhoun D (1998) Binding, gating, affinity and efficacy: the interpretation of structureactivity relationships for agonists and of the effects of mutating receptors. Br J
Pharmacol 125:924-47.
Colquhoun D and Hawkes AG (1995) The principles of the stochastic interpretation of
ion-channel mechanisms. in Single-channel recording (B. Sakmann and E. Neher eds) pp
397-482, Plenum, New York.
Colquhoun D and Hawkes AG (1995) A Q-matrix cookbook. How to write only one
program to calculate the single-channel and macroscopic predictions for any kinetic
mechanism. in Single-channel recording (B. Sakmann and E. Neher eds) pp 589-633,
Plenum, New York.
Connolly CN, Krishek BJ, McDonald BJ, Smart TG and Moss SJ (1996) Assembly and
cell surface expression of heteromeric and homomeric gamma-aminobutyric acid type A
receptors. J Biol Chem 271:89-96.
Connolly CN, Uren JM, Thomas P, Gorrie GH, Gibson A, Smart TG and Moss SJ (1999)
Subcellular localization and endocytosis of homomeric gamma2 subunit splice variants of
gamma-aminobutyric acid type A receptors. Mol Cell Neurosci 13:259-71.
Connolly CN and Wafford KA (2004) The Cys-loop superfamily of ligand-gated ion
channels: the impact of receptor structure on function. Biochem Soc Trans 32:529-534.
Cromer BA, Morton CJ and Parker MW (2002) Anxiety over GABA(A) receptor
structure relieved by AChBP. Trends Biochem Sci 27:280-7.
Dellisanti CD, Yao Y, Stroud JC, Wang ZZ and Chen L (2007) Crystal structure of the
extracellular domain of nAChR alpha1 bound to alpha-bungarotoxin at 1.94 A resolution.
Nat Neurosci 10:953-962.

145
Deng L, Ransom RW and Olsen RW (1986) 3H]muscimol photolabels the gammaaminobutyric acid receptor binding site on a peptide subunit distinct from that labeled
with benzodiazepines. Biochem Biophys Res Commun 138:1308-1314.
Dennis M, Giraudat J, Kotzyba-Hibert F, Goeldner M, Hirth C, Chang JY, Lazure C,
Chretien M and Changeux JP (1988) Amino acids of the Torpedo marmorata
acetylcholine receptor alpha subunit labeled by a photoaffinity ligand for the
acetylcholine binding site. Biochemistry 27:2346-2357.
Ehya N, Sarto I, Wabnegger L and Sieghart W (2003) Identification of an amino acid
sequence within GABA(A) receptor beta3 subunits that is important for receptor
assembly. J Neurochem 84:127-135.
Enna SJ and Mohler H (2007) The GABA Receptors. Humana Press, Totowa, New
Jersey.
Enz R and Cutting GR (1998) Molecular composition of GABAC receptors. Vision Res
38:1431-1441.
Farrar SJ, Whiting PJ, Bonnert TP and McKernan RM (1999) Stoichiometry of a ligandgated ion channel determined by fluorescence energy transfer. J Biol Chem 274:1010010104.
Gleitsman KR, Kedrowski SM, Lester HA and Dougherty DA (2008) An intersubunit
hydrogen bond in the nicotinic acetylcholine receptor that contributes to channel gating. J
Biol Chem 283:35638-35643.
Goldschen-Ohm MP, Wagner DA and Jones MV (2010) The roles of arginines in the
binding pocket of the GABA(A) receptor. Manuscript in preparation.
Goldschen-Ohm MP, Wagner DA, Petrou S and Jones MV (2010) An epilepsy-related
region in the GABA(A) receptor mediates long-distance effects on GABA and
benzodiazepine binding sites. Mol Pharmacol 77:35-45.
Griffon N, Buttner C, Nicke A, Kuhse J, Schmalzing G and Betz H (1999) Molecular
determinants of glycine receptor subunit assembly. EMBO J 18:4711-4721.
Grutter T and Changeux JP (2001) Nicotinic receptors in wonderland. Trends Biochem
Sci 26:459-463.
Grutter T, Ehret-Sabatier L, Kotzyba-Hibert F and Goeldner M (2000) Photoaffinity
labeling of Torpedo nicotinic receptor with the agonist [3H]DCTA: identification of
amino acid residues which contribute to the binding of the ester moiety of acetylcholine.
Biochemistry 39:3034-3043.

146
Haas KF and Macdonald RL (1999) GABAA receptor subunit gamma2 and delta
subtypes confer unique kinetic properties on recombinant GABAA receptor currents in
mouse fibroblasts. J Physiol 514 ( Pt 1):27-45.
Hales TG, Tang H, Bollan KA, Johnson SJ, King DP, McDonald NA, Cheng A and
Connolly CN (2005) The epilepsy mutation, gamma2(R43Q) disrupts a highly conserved
inter-subunit contact site, perturbing the biogenesis of GABAA receptors. Mol Cell
Neurosci 29:120-127.
Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Taylor P and Bourne Y (2005)
Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal
distinctive binding interfaces and conformations. EMBO J 24:3635-3646.
Harrison NJ and Lummis SC (2006) Locating the carboxylate group of GABA in the
homomeric rho GABA(A) receptor ligand-binding pocket. J Biol Chem 281:2445524461.
Hartvig L, Lukensmejer B, Liljefors T and Dekermendjian K (2000) Two conserved
arginines in the extracellular N-terminal domain of the GABA(A) receptor alpha(5)
subunit are crucial for receptor function. J Neurochem 75:1746-53.
Hidalgo P and MacKinnon R (1995) Revealing the architecture of a K+ channel pore
through mutant cycles with a peptide inhibitor. Science 268:307-10.
Hilf RJ and Dutzler R (2009) Structure of a potentially open state of a proton-activated
pentameric ligand-gated ion channel. Nature 457:115-118.
Hilf RJ and Dutzler R (2008) X-ray structure of a prokaryotic pentameric ligand-gated
ion channel. Nature 452:375-379.
Holden JH and Czajkowski C (2002) Different residues in the GABA(A) receptor alpha
1T60-alpha 1K70 region mediate GABA and SR-95531 actions. J Biol Chem 277:1878592.
Horovitz A (1996) Double-mutant cycles: a powerful tool for analyzing protein structure
and function. Fold Des 1:R121-6.
Horovitz A, Serrano L, Avron B, Bycroft M and Fersht AR (1990) Strength and cooperativity of contributions of surface salt bridges to protein stability. J Mol Biol
216:1031-1044.
Hosie AM, Dunne EL, Harvey RJ and Smart TG (2003) Zinc-mediated inhibition of
GABA(A) receptors: discrete binding sites underlie subtype specificity. Nat Neurosci
6:362-9.

147
Hosie AM, Wilkins ME, da Silva HM and Smart TG (2006) Endogenous neurosteroids
regulate GABAA receptors through two discrete transmembrane sites. Nature 444:486489.
Im WB, Pregenzer JF, Binder JA, Dillon GH and Alberts GL (1995) Chloride channel
expression with the tandem construct of alpha 6-beta 2 GABAA receptor subunit requires
a monomeric subunit of alpha 6 or gamma 2. J Biol Chem 270:26063-26066.
Jahn K, Hertle I, Bufler J, Adelsberger H, Pestel E, Zieglgansberger W, Dudel J and
Franke C (1997) Activation kinetics and single channel properties of recombinant
alpha1beta2gamma2L GABA(A) receptor channels. Neuroreport 8:3443-6.
Johnston GA (2005) GABA(A) receptor channel pharmacology. Curr Pharm Des
11:1867-1885.
Jones MV, Goldschen-Ohm MP, Fangmann JK, Moodie LJ and Wagner DA. Two
arginines that stabilize the agonist-bound state of the GABA(A) receptor. Program No.
261.2. 2005 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience,
2005. Online.
Jones MV, Jonas P, Sahara Y and Westbrook GL (2001) Microscopic kinetics and
energetics distinguish GABA(A) receptor agonists from antagonists. Biophys J 81:266070.
Jones MV, Sahara Y, Dzubay JA and Westbrook GL (1998) Defining affinity with the
GABAA receptor. J Neurosci 18:8590-8604.
Jones MV and Westbrook GL (1995) Desensitized states prolong GABAA channel
responses to brief agonist pulses. Neuron 15:181-191.
Kash TL, Jenkins A, Kelley JC, Trudell JR and Harrison NL (2003) Coupling of agonist
binding to channel gating in the GABA(A) receptor. Nature 421:272-5.
Kash TL, Trudell JR and Harrison NL (2004) Structural elements involved in activation
of the gamma-aminobutyric acid type A (GABAA) receptor. Biochem Soc Trans 32:540546.
Klausberger T, Ehya N, Fuchs K, Fuchs T, Ebert V, Sarto I and Sieghart W (2001)
Detection and binding properties of GABA(A) receptor assembly intermediates. J Biol
Chem 276:16024-16032.
Klausberger T, Fuchs K, Mayer B, Ehya N and Sieghart W (2000) GABA(A) receptor
assembly. Identification and structure of gamma(2) sequences forming the intersubunit
contacts with alpha(1) and beta(3) subunits. J Biol Chem 275:8921-8928.

148
Klausberger T, Sarto I, Ehya N, Fuchs K, Furtmuller R, Mayer B, Huck S and Sieghart W
(2001) Alternate use of distinct intersubunit contacts controls GABAA receptor assembly
and stoichiometry. J Neurosci 21:9124-9133.
Kloda JH and Czajkowski C (2007) Agonist-, antagonist-, and benzodiazepine-induced
structural changes in the alpha1 Met113-Leu132 region of the GABAA receptor. Mol
Pharmacol 71:483-493.
Law RJ and Lightstone FC (2009) Modeling neuronal nicotinic and GABA receptors:
important interface salt-links and protein dynamics. Biophys J 97:1586-1594.
Lee WY and Sine SM (2005) Principal pathway coupling agonist binding to channel
gating in nicotinic receptors. Nature 438:243-247.
Levitan ES, Schofield PR, Burt DR, Rhee LM, Wisden W, Kohler M, Fujita N,
Rodriguez HF, Stephenson A, Darlison MG, Barnard EA and Seeburg PH (1988)
Structural and functional basis for GABAA receptor heterogeneity. Nature 335:76-79.
Lo WY, Botzolakis EJ, Tang X and Macdonald RL (2008) A conserved Cys-loop
receptor aspartate residue in the M3-M4 cytoplasmic loop is required for GABAA
receptor assembly. J Biol Chem 283:29740-29752.
Los GV and Wood K (2007) The HaloTag: a novel technology for cell imaging and
protein analysis. Methods Mol Biol 356:195-208.
Lummis SC, L Beene D, Harrison NJ, Lester HA and Dougherty DA (2005) A cation-pi
binding interaction with a tyrosine in the binding site of the GABAC receptor. Chem Biol
12:993-997.
Macdonald RL, Kang JQ and Gallagher MJ (2010) Mutations in GABAA receptor
subunits associated with genetic epilepsies. J Physiol 588:1861-1869.
Macdonald RL and Olsen RW (1994) GABAA receptor channels. Annu Rev Neurosci
17:569-602.
Macdonald RL, Rogers CJ and Twyman RE (1989) Kinetic properties of the GABAA
receptor main conductance state of mouse spinal neurones in culture. J Physiol (Lond )
410:479-499.
Makhatadze GI, Loladze VV, Ermolenko DN, Chen X and Thomas ST (2003)
Contribution of surface salt bridges to protein stability: guidelines for protein
engineering. J Mol Biol 327:1135-1148.
McKernan RM and Whiting PJ (1996) Which GABAA-receptor subtypes really occur in
the brain? Trends Neurosci 19:139-43.

149
Mihic SJ, Ye Q, Wick MJ, Koltchine VV, Krasowski MD, Finn SE, Mascia MP,
Valenzuela CF, Hanson KK, Greenblatt EP, Harris RA and Harrison NL (1997) Sites of
alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature
389:385-9.
Miyazawa A, Fujiyoshi Y, Stowell M and Unwin N (1999) Nicotinic acetylcholine
receptor at 4.6 A resolution: transverse tunnels in the channel wall. J Mol Biol 288:76586.
Mizielinska S, Greenwood S and Connolly CN (2006) The role of GABAA receptor
biogenesis, structure and function in epilepsy. Biochem Soc Trans 34:863-867.
Muroi Y, Czajkowski C and Jackson MB (2006) Local and global ligand-induced
changes in the structure of the GABA(A) receptor. Biochemistry 45:7013-7022.
Newell JG and Czajkowski C (2003) The GABAA Receptor alpha 1 Subunit Pro174Asp191 Segment Is Involved in GABA Binding and Channel Gating. J Biol Chem
278:13166-72.
Newell JG, McDevitt RA and Czajkowski C (2004) Mutation of glutamate 155 of the
GABAA receptor beta2 subunit produces a spontaneously open channel: a trigger for
channel activation. J Neurosci 24:11226-11235.
Niesler B, Weiss B, Fischer C, Nothen MM, Propping P, Bondy B, Rietschel M, Maier
W, Albus M, Franzek E and Rappold GA (2001) Serotonin receptor gene HTR3A
variants in schizophrenic and bipolar affective patients. Pharmacogenetics 11:21-27.
Noda M, Takahashi H, Tanabe T, Toyosato M, Kikyotani S, Furutani Y, Hirose T,
Takashima H, Inayama S, Miyata T and Numa S (1983) Structural homology of Torpedo
californica acetylcholine receptor subunits. Nature 302:528-532.
O'Mara M, Cromer B, Parker M and Chung SH (2005) Homology model of the GABAA
receptor examined using Brownian dynamics. Biophys J 88:3286-3299.
Padgett CL, Hanek AP, Lester HA, Dougherty DA and Lummis SC (2007) Unnatural
amino acid mutagenesis of the GABA(A) receptor binding site residues reveals a novel
cation-pi interaction between GABA and beta 2Tyr97. J Neurosci 27:886-892.
Pless SA, Millen KS, Hanek AP, Lynch JW, Lester HA, Lummis SC and Dougherty DA
(2008) A cation-pi interaction in the binding site of the glycine receptor is mediated by a
phenylalanine residue. J Neurosci 28:10937-10942.
Price KL, Millen KS and Lummis SC (2007) Transducing agonist binding to channel
gating involves different interactions in 5-HT3 and GABAC receptors. J Biol Chem
282:25623-25630.

150
Pritchett DB, Sontheimer H, Shivers BD, Ymer S, Kettenmann H, Schofield PR and
Seeburg PH (1989) Importance of a novel GABAA receptor subunit for benzodiazepine
pharmacology. Nature 338:582-585.
Ranganathan R, Lewis JH and MacKinnon R (1996) Spatial localization of the K+
channel selectivity filter by mutant cycle-based structure analysis. Neuron 16:131-139.
Sarto I, Klausberger T, Ehya N, Mayer B, Fuchs K and Sieghart W (2002) A novel site
on gamma 3 subunits important for assembly of GABA(A) receptors. J Biol Chem
277:30656-30664.
Sarto-Jackson I, Ramerstorfer J, Ernst M and Sieghart W (2006) Identification of amino
acid residues important for assembly of GABA receptor alpha1 and gamma2 subunits. J
Neurochem 96:983-995.
Schmieden V, Kuhse J and Betz H (1993) Mutation of glycine receptor subunit creates ßalanine receptor responsive to GABA. Science 262:256-258.
Schofield PR, Darlison MG, Fujita N, Burt DR, Stephenson FA, Rodriguez H, Rhee LM,
Ramachandran J, Reale V, Glencorse TA, Seeburg PH and Barnard EA (1987) Sequence
and functional expression of the GABAA receptor shows a ligand-gated receptor
superfamily. Nature 328:221-227.
Serafini R, Bracamontes J and Steinbach JH (2000) Structural domains of the human
GABAA receptor 3 subunit involved in the actions of pentobarbital. J Physiol (Lond )
524 Pt 3:649-76.
Shen XM, Ohno K, Sine SM and Engel AG (2005) Subunit-specific contribution to
agonist binding and channel gating revealed by inherited mutation in muscle
acetylcholine receptor M3-M4 linker. Brain 128:345-355.
Sieghart W and Sperk G (2002) Subunit composition, distribution and function of
GABA(A) receptor subtypes. Curr Top Med Chem 2:795-816.
Sigel E, Baur R, Kellenberger S and Malherbe P (1992) Point mutations affecting
antagonist affinity and agonist dependent gating of GABAA receptor channels. EMBO J
11:2017-23.
Sigel E and Buhr A (1997) The benzodiazepine binding site of GABAA receptors.
Trends Pharmacol Sci 18:425-9.
Sigworth FJ (1980) The variance of sodium current fluctuations at the node of Ranvier. J
Physiol (Lond ) 307:97-129.
Simon J, Wakimoto H, Fujita N, Lalande M and Barnard EA (2004) Analysis of the set
of GABA(A) receptor genes in the human genome. J Biol Chem 279:41422-41435.

151
Smith GB and Olsen RW (1995) Functional domains of GABAA receptors. Trends
Pharmacol Sci 16:162-168.
Smith GB and Olsen RW (1994) Identification of a [3H]muscimol photoaffinity substrate
in the bovine gamma-aminobutyric acidA receptor alpha subunit. J Biol Chem
269:20380-7.
Srinivasan S, Nichols CJ, Lawless GM, Olsen RW and Tobin AJ (1999) Two invariant
tryptophans on the alpha1 subunit define domains necessary for GABA(A) receptor
assembly. J Biol Chem 274:26633-26638.
Tasneem A, Iyer LM, Jakobsson E and Aravind L (2005) Identification of the prokaryotic
ligand-gated ion channels and their implications for the mechanisms and origins of
animal Cys-loop ion channels. Genome Biol 6:R4.
Taylor PM, Connolly CN, Kittler JT, Gorrie GH, Hosie A, Smart TG and Moss SJ (2000)
Identification of residues within GABA(A) receptor alpha subunits that mediate specific
assembly with receptor beta subunits. J Neurosci 20:1297-306.
Taylor PM, Thomas P, Gorrie GH, Connolly CN, Smart TG and Moss SJ (1999)
Identification of amino acid residues within GABA(A) receptor beta subunits that
mediate both homomeric and heteromeric receptor expression. J Neurosci 19:6360-71.
Tretter V, Ehya N, Fuchs K and Sieghart W (1997) Stoichiometry and assembly of a
recombinant GABAA receptor subtype. J Neurosci 17:2728-2737.
Unwin N (2005) Refined structure of the nicotinic acetylcholine receptor at 4A
resolution. J Mol Biol 346:967-989.
Unwin N (1995) Acetylcholine receptor channel imaged in the open state. Nature
373:37-43.
Venkatachalan SP and Czajkowski C (2008) A conserved salt bridge critical for
GABA(A) receptor function and loop C dynamics. Proc Natl Acad Sci U S A 105:1360413609.
Wagner DA and Czajkowski C (2001) Structure and dynamics of the GABA binding
pocket: A narrowing cleft that constricts during activation. J Neurosci 21:67-74.
Wagner DA, Czajkowski C and Jones MV (2004) An arginine involved in GABA
binding and unbinding but not gating of the GABA(A) receptor. J Neurosci 24:2733-41.
Westh-Hansen SE, Rasmussen PB, Hastrup S, Nabekura J, Noguchi K, Akaike N, Witt
MR and Nielsen M (1997) Decreased agonist sensitivity of human GABA(A) receptors
by an amino acid variant, isoleucine to valine, in the alpha1 subunit. Eur J Pharmacol
329:253-7.

152
Westh-Hansen SE, Witt MR, Dekermendjian K, Liljefors T, Rasmussen PB and Nielsen
M (1999) Arginine residue 120 of the human GABAA receptor alpha 1, subunit is
essential for GABA binding and chloride ion current gating. Neuroreport 10:2417-21.
Whiting PJ (2003) GABA-A receptor subtypes in the brain: a paradigm for CNS drug
discovery? Drug Discov Today 8:445-450.
Whittington MA, Traub RD and Jefferys JG (1995) Synchronized oscillations in
interneuron networks driven by metabotropic glutamate receptor activation. Nature
373:612-5.
Whittington MA, Traub RD, Kopell N, Ermentrout B and Buhl EH (2000) Inhibitionbased rhythms: experimental and mathematical observations on network dynamics. Int J
Psychophysiol 38:315-36.
Xu M, Covey DF and Akabas MH (1995) Interaction of picrotoxin with GABAA
receptor channel-lining residues probed in cysteine mutants. Biophys J 69:1858-67.
Zhong W, Gallivan JP, Zhang Y, Li L, Lester HA and Dougherty DA (1998) From ab
initio quantum mechanics to molecular neurobiology: a cation-pi binding site in the
nicotinic receptor. Proc Natl Acad Sci U S A 95:12088-12093.

